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1.1 Patterning the hindbrain 
 
The development of the vertebrate central nervous system (CNS) is one of the most 
daunting tasks that has to be performed during embryogenesis. Over a thousand different 
neuronal cell types are generated from a single neural progenitor cell lineage to form the 
functional entity that is the CNS. Characteristic of the development of the vertebrate CNS 
is the sequential partitioning of the neural tube, whereby a compartmentalised adult central 
nervous system is formed with fore-, mid-, hindbrain, and spinal cord. Each of these areas 
harbours neuronal cell populations that are specified at set temporal and spatial positions 
during development. The partitioning of the CNS is directed in two orientations: dorso-
ventral (DV) and antero-posterior (AP). DV patterning will be addressed only briefly, 
while a detailed account will be given of genes that are involved in the AP patterning of the 
CNS. The focus will be on the hindbrain, as defects in this region are thought to underlie 
the main aspects of the etiology of the syndromes investigated in this thesis. 
 DV patterning regulates the differentiation of neural cell populations perpendicular to 
the body axis, and the most prominent proteins involved in this are Sonic-hedgehog (Shh), 
and members of the TGF-ß superfamily (e.g. BMPs). Shh, expressed initially in the 
notochord, and later also from the floorplate of the neural tube, regionalises the ventral 
neural tube by activating distinct homeodomain transcription factors along the dorsoventral 
axis, among which are members of the Gli protein family (1;2). Additionally, Shh is one of 
the necessary factors in the generation of dopaminergic and serotonergic neurons in the 
mid- and hindbrain (3;4), and regulates the proliferation and survival of several neuronal 
and non-neuronal cell types (5).  
 Key regulators of dorsal neuraxis patterning are members of the transforming growth 
factor-ß (TGF-ß) family, in particular the bone morphogenetic proteins (BMPs) (6;7). 
BMPs are initially expressed at the boundary of neural and non-neural ectoderm, and later 
from the roofplate of the neural tube. It has been shown that the opposing gradients of 
ventral Shh and dorsal BMPs, combined with the action of ventrally produced BMP 
inhibitors (e.g. noggin, follistatin, chordin) establish dorsoventral domains that generate 
distinct populations of neurons (8-10). Additionally, Bmps and Shh have shown to be 
involved in several other neural and non-neural processes, including cell fate 
determination, oligodendrocyte maturation, and limb formation (11;12). 
 
Organisation of the hindbrain 
 
The adult hindbrain is made up of the medulla oblongata, the pons and the cerebellum. 
Among others, the cerebellum functions in coordinate movement, transmitting signals from 
the body to the motor cortex. Together with the posterior midbrain, the pons and medulla 
are part of what is known as the brainstem (figure1).  
 The brainstem harbours a collection of nuclei called the reticular formation, involved 
in respiration, circulation, mood regulation, modulation of pain sensation, and locomotor 
control. The hindbrain is also the birthplace of 8 of the 12 pairs of cranial nerves, from the 
trigeminal (V) to the hypoglossal (XII). These cranial nerves are important for relaying 
both motor and sensory information to and from the brain, and they innervate the 
musculature associated with the pharyngeal/branchial arches (13). During development the 
cranial nerves are born in well defined metameric units along the antero-posterior axis, 
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called rhombomeres (14). Rhombomeres (R) are morphologically and genetically distinct 
regions in the hindbrain that each generate a specific set of neuronal cell types (14-16).  
A total of 7 or 8 rhombomeres are formed in the hindbrain, depending on the organism, 
and are visible as bulges along the AP axis (figure 2).  
 
 
Figure 1. a. A schematic diagram, showing a ventral view of the adult mouse brainstem, and the overal 
organization of the cranial nerves. b. Schematic diagram of the position of afferent fibres of cranial sensory 
ganglia (left) and the positions of the nuclei of the different motor nerves (right). Reprinted with permission of 
Nature Reviews Neuroscience, (17)).Color figure available in appendix. 
 
  
 
 
figure 2. Lateral hindbrain view of a 18 hours postfertilization zebrafish. Individual rhombomeres are transiently 
visible as bulges along the AP axis of the hindbrain. R2–R6: rhombomeres 2 to 6, ov : otic vesicle.  Adapted from 
(18). 
 
 In this fashion, the adult neuroanatomy is set up to correspond exactly with the 
morphological segmentation of the hindbrain (14;19). Gene defects that disrupt the 
segmentation during development lead to disruption of the segmental organization of 
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neural populations in the adult hindbrain, underscoring the importance of the rhombomeres 
during development (reviewed in (17)). The mechanisms that govern the segmentation of 
the hindbrain will be discussed below. During gastrulation neural inducing factors and 
modifiers are produced by tissues underlying the future neural plate (Spemann-Mangold 
organiser), which induce the neural ectoderm and produce the first crude AP pattern of the 
neural tube (for reviews see (20;21)). After gastrulation is completed, this pattern is 
progressively refined. The first segmentation takes place in the region of the future 
hindbrain, the evolutionary most ancient part of the vertebrate brain (22).  
 
The function of the Isthmus in hindbrain development 
 
At its rostral limit, the hindbrain is separated from the midbrain by the mid-hindbrain 
boundary (MHB) or Isthmus. The Isthmus is an important signalling center for the 
development of the midbrain, and anterior hindbrain (23;24). The position of this boundary 
is physically marked by a constriction in the neural tube and genetically matched by the 
complementary expression of Otx2 (midbrain) and Gbx2 (hindbrain) (25;26). This pattern 
is initiated at late gastrulation, when Otx2 is expressed from the anterior tip of the neural 
plate, up to the presumptive MHB, and Gbx2 is expressed in the posterior embryo. 
Establishment of the Isthmus during gastrulation requires the spiel ohne grenzen/pou2 gene 
(27-29). Pou2 is a homeodomain transcription factor, expressed in the mid-hindbrain 
boundary primordium, and in the anterior hindbrain during gastrulation (27;28). Later in 
development it is also expressed in the R2 and R4 territories of the hindbrain. It has been 
postulated that Pou2 acts as a regional competence factor for fibroblast growth factor (Fgf) 
signalling in the hindbrain primordium, and in specific rhombomeres during later 
development (30). 
 At the Isthmus several signalling pathways are active. The genes of these pathways 
are initially expressed in broad domains, but during early somite stages expression is 
progressively restricted to narrower domains (31). Wnt1 is initially expressed in a broad 
domain at the Otx+ side of the Isthmus, while Fgf8 is expressed in a similar domain at the 
Gbx+ side, up to rhombomere 2. The homeobox genes Engrailed-1 and -2, and the paired 
domain transcription factors Pax-2 and -5, are initially expressed across the MHB, 
overlapping with wnt and fgf expression (31). As development continues, the broad 
expression domains become more restricted, and the definitive Isthmic expression pattern 
for these genes is attained (figure 3). The effects of members of the wnt and fgf gene 
families in AP patterning of the hindbrain are discussed below. 
 
 
Wnt signalling in development of the anterior hindbrain 
 
Wnt genes encode a large family of cysteine rich secreted glycoproteins, several of which 
are expressed during brain development. Most notably, wnt1, wnt3, wnt8, and wnt10b have 
been shown to function in AP subdivision of the neural plate, formation of the MHB, and 
formation of the anterior hindbrain (32;33).  
 Wnt8 was shown to be one of the initial posteriorising signals during early 
gastrulation, setting up a regional AP pattern in the neurectoderm (34;35). Wnt8 was 
hypothesized to function in stimulation of expression of posteriorising neural genes by 
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alleviating the repression of these genes by headless, a wnt inhibitor involved in specifying 
anterior neural fates (35). Wnt1 was essential for the formation of a part of the midbrain 
and anterior hindbrain, including the MHB and cerebellum. Mouse embryos lacking wnt1 
function showed severe reductions in both the mid- and hindbrain, and failed to form a 
MHB (36-38). The lack of a phenotype in the dorsal neural tube in the trunk and tail of the 
wnt1-/- mouse were due to the overlap in expression and functional redundancy of wnt1 
and wnt3a, as wnt1/wnt3a double knockout mutants showed a more severe phenotype 
including deficiency of dorsal spinal cord derivatives (39;40). 
 
 
 
Figure 3. Gene expression patterns at the murine MHB, from E7.5 to E9.5. At E9.5 the final Isthmic expression 
pattern has matured, and the Isthmus functions as a regional organizer for midbrain and anterior hindbrain 
development.  Mes: mesenchephalon, Met: Metencheplalon, D: Diencephalon, T: Telenchepalon, r2-4 : 
rhombomeres 2-4. Reprinted with permission from Current opinion in Cell Biology, from (31)). Color figure  
available in appendix.. 
 
 These results from mice do not completely overlap with results obtained in zebrafish. 
In zebrafish, wnt1 in combination with wnt10b, was not essential in MHB and cerebellum 
formation, but regulated expression of ventral MHB genes. These do not include  MHB / 
cerebellum formation genes (e.g. fgf8, en3, wnt8b, and wnt3a) (33). However, the 
simultaneous ablation of wnt3a and wnt1/wnt10b function, both separately dispensable for 
MHB and cerebellum formation (33;41), led to a large decrease in the size of the midbrain 
and cerebellum similar to that seen in mice, showing the evolutionary conservation of wnt 
signalling for brain patterning and development in vertebrates (41). The decrease in tissue 
size was shown to be a consequence of extensive apoptosis, and not respecification of cell 
fate as was seen in the acerebellar (fgf8) and no isthmus (pax2.1) mutants (41), implying a 
function for wnt signals in proliferation or cell survival at the MHB.  
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 Additional to wnt expression which specifies posterior fates, expression of wnt 
inhibitors in the anterior neural tube is essential to induce forebrain and head formation. 
Several wnt signalling inhibitor genes have been identified (e.g. Cerebrus, Frzb1, 
Dickkopf, and Headless), and functional studies have confirmed that they encode proteins 
that promote anterior fates in the developing head (42-46). The antagonistic action of 
posteriorly expressed wnts, and anterior expression of wnt-inhibitors in the neural tube thus 
aids in the formation of an AP axis. 
 
Fgfs in patterning of the hindbrain 
 
Fgf signalling from the Isthmus is particularly important for maintenance of the MHB and 
the formation of the cerebellum, as knocking out fgf8 function in the zebrafish acerebellar 
(ace) mutant led to a failure to maintain the MHB, and to form the cerebellum from R1 
(47). Isthmus derived fgf also functions in setting up the anterior expression limit of Hox 
genes to the R1-R2 border (48;49). Injection of Fgf3 mRNA in zebrafish embryos leads to 
a supression of anterior neural markers (cyp26, otx2), and expansion of posterior markers 
(hoxb1b). Conversely, blocking Fgf function by a dominant-negative Fgf-receptor led to an 
expansion of cyp26 and otx2 domains, and the reduction of hoxb1b positive territory, 
showing the importance of fgf signalling in defining the expression limit of these anterior 
and posterior genes (48).  
 In addition to its early role in anterior hindbrain development fgf’s also play a role in 
more caudal regions of the hindbrain during segmentation stages. General induction of fgf 
signalling was shown to initiate the expression of several caudally expressed hindbrain 
genes (e.g. hoxb1b, caudal, and nlz) in zebrafish (50). The authors identified direct 
regulation of expression of nlz by fgf signalling, whereas the induction of hoxb1b and 
caudal expression appeared to be indirectly regulated. A part of the indirect actions of fgf’s 
in regulating this expression could be brought about by influencing the retinoic acid 
pathway, which will be discussed below. Blocking of fgf signalling led to downregulation 
of expression of several key components of this pathway (RA-receptors, retinoic acid 
synthesis and degredation proteins) (51), suggesting that the retinoic acid pathway is a 
downstream target of fgf signalling. Surprisingly, the expression of several of these 
caudally expressed genes recovered at later stages of development, indicating that other fgf 
independent compensatory mechanisms (some of which are retinoic acid dependent) are 
present (50). Several members of the Fgf gene family, expressed in the R2-R6 region, 
function in patterning the caudal hindbrain by modulating the expression of the early 
segmentation genes Krox-20 and Kreisler/Valentino (52-55). This function is dependent on 
the expression of the transcription factor vhnf1, that supplies regional cellular competence 
to respond to fgf signals in the hindbrain (56;57). 
 
The role of retinoic acid signalling in hindbrain patterning 
 
Retinoic acid (RA), is an important signal for the initiation of Hox gene expression, and 
thereby for posterior patterning of the hindbrain (58;59). RA, the active derivative of 
vitamin A, has been shown to function as an overall mediator or modulator of Hox gene 
expression, and hindbrain development (60-64). Several of the Hox gene regulatory 
sequences contain Retinoic Acid Response Elements (RARE’s), to which heterodimers of 
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Retinoic Acid Receptors (RAR) and Retinoid X Receptors (RXR) can bind to activate 
expression (62;63;65-67). Three RAR’s (RAR  , RAR , RAR ), and three RXR’s (RXR  , 
RXR

, RXR ) have been identified (68), and part of the control of Hox gene expression 
and hindbrain patterning resides in the different affinities for RARE’s by different receptor 
heterodimers (69-72). The response to RA is not only dependent on the differential binding 
of RAR/RXR heterodimers to RARE’s, RA is also thought to posteriorize the hindbrain by 
a graded response (58;59;63). It has been shown that the most 3   genes from the Hox 
clusters are sensitive to relatively low levels of RA, whereas the more caudally expressed 
5   Hox genes require increasingly higher doses of RA to be transcribed (73). It has been 
common belief for a long time that a passively generated gradient of RA existed. More 
recently it was shown that active RA metabolism is more likely to generate the graded 
response along the AP axis (48;74;75).  Retinoic acid is formed by proteins of the RALDH 
family (RALDH1, 2, 3). These enzymes catalyse the final step in the production of retinoic 
acid from Vitamin A. RALDH2 is the only source of RA in the hindbrain, where it is 
expressed in the paraxial mesoderm (76-79). The proteins regulating degradation of RA in 
the hindbrain are the cytochrome p450 proteins belonging to the CYP26 family. These 
proteins convert RA in more polar metabolites that are non-functional in hindbrain 
patterning. Detailed expression analysis of the CYP26 genes has revealed that they are 
expressed in specific rhombomeres, and in tissue surrounding the hindbrain. Early in 
development (E8.5-9.0) CYP6A1 is expressed in R2, CYP26B1 is expressed in 
rhombomeres 2 to 6, while CYP26C1 is expressed in rhombomeres 2 and 4.  
 
 
 
Figure 4. An example of opposing expression of RA synthesizing and RA metabolising genes. RALDH2 is 
expressed in the paraxial mesoderm up to the level of the posterior hindbrain, CYP26A1 is expressed in R2. The 
diffusion of RA, produced by RALDH2, into the hindbrain is counteracted in R2 by the degredation of RA by 
CYP26A1, generating a region of low RA concentration. Adapted from (75)). 
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A little later (E9.5) both CYP26B1 and Cyp26C1 are also expressed in the cervical 
mesenchyme around R3 (78;80;81). These enzymes probably function in a source/sink 
mechanism, enhancing the RA gradient along the AP axis, and facilitating differential 
expression of target genes along this axis (figure 4) (48;75).  
 Once the Hox expression territories are established, auto- and cross-regulatory Hox-
responsive elements are involved in modulating the expression of Hox genes during later 
hindbrain development (82-84). 
 
The early segmentation genes Krox-20 and Kreisler 
 
In addition to the large scale processes of early segmentation in the hindbrain discussed 
above, two individual genes, that have already been mentioned, have essential functions in 
segmentation of distinct rhombomeres in the hindbrain: Krox-20, and Kreisler/Valentino.  
 Krox-20 is a zinc-finger transcription factor with hindbrain expression restricted to 
R3 and R5 (85). It is essential for maintenance of R3 and R5 (86-88), and for specification 
of neuronal identity of these rhombomeres, by regulating Hox gene expression (89-91). 
Krox-20 has also been shown to directly drive the transcription of the EphA4 in R3 and R5, 
thereby playing a role in rhombomere boundary formation ((92), see below). Kreisler (kr), 
the mouse homologue of zebrafish valentino (val), is expressed exclusively in R5 and R6 
of the hindbrain, and is required cell-autonomously for the development of R5 and R6 
(93;94), and for the acquisition of segmental neuronal identity by regulating Hox gene 
expression (95). Kr/val, like krox-20 also plays a role in boundary formation, as it was 
found to be an upstream activator of Eph signalling (96). Expression of krox-20 and kr/val 
is regulated by fgf3 and fgf8 (52-55), synergising with vhnf1, which probably supplies 
regional competence to respond to these fgf’s (56). 
 
Sharpening rhombomere borders and restricting cell movement 
 
When the crude AP pattern is established, at least 2 mechanisms refine it to produce the 
clear rhombomeric division of the hindbrain: cell sorting and cell plasticity (figure 5).  
 The initially loosely defined boundaries between rhombomeres are sharpened by the 
interactions of Eph tyrosine kinase receptors and their ligands, ephrins (reviewed in (97)). 
Also activation of the Notch signalling pathway appears to be involved in this process 
(98;99). Eph receptors and ephrin ligands are expressed in evolutionary conserved patterns 
in the hindbrain, alternating in odd and even numbered rhombomeres (figure 6) (100-105). 
 The alternating expression of Eph end ephrins is largely dependent on the activities of 
Krox-20 and kreisler, already mentioned above (92;96). Bidirectional signalling between 
cells expressing Eph or ephrin regulates cell sorting, and establishes strict cell boundaries 
between adjacent rhombomeres that prohibit intermingling (97;106). Cells that have 
inadvertently remained in the “wrong” rhombomere will change the expression of 
rhombomere specific genes to match that of the rhombomere they are “stuck in” ((97) and 
refs therein). These two processes combined assure that each single rhombomere is made 
up of morphologically and genetically identical cells, and that no intermingling of cells 
from adjacent compartments occurs. Recently the notch signalling pathway was also 
implicated in boundary formation in the hindbrain, by a similar cell sorting mechanism as 
is already known for Eph/ephrin. In mouse and zebrafish, interfaces between cells 
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expressing high and low levels of fringe, a modulator of notch signalling (107;108), where 
shown to prefigure rhombomere boundaries (109;110). Moreover, the R5/6 segmentation 
gene kreisler/valentino, which acts upstream of Eph signalling (96), functions also in notch 
signalling, as val mutants have lost the interfaces between high and low levels of fringe 
expression, correlating with the loss of boundaries (110).  
 
 
 
 
Figure 5. Cell sorting and cell plasticity in sharpening borders of rhombomeres. Cells that are incorrectly 
positioned (b) can either move to the correct compartment (c, cell sorting), or they can adopt a new identity, 
corresponding to the cells of the compartment in which they reside (d, cell plasticity). Both mechanisms can 
contribute to the formation of sharp interfaces between adjacent rhombomeres (e). Adapted from (97). 
 
 
 
Figure 6. Alternating expression of Eph receptors and ephrin ligands in the hindbrain. Black bars indicate strong 
rhombomere specific expression, grey bars indicate intermediate levels. Adapted from (104). 
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The role of Hox genes in segmentation and neuronal identity 
 
A major component of the hindbrain segmentation machinery are the homeodomain 
transcription factors of the Hox gene family. The Hox genes are organised into four 
clusters, Hoxa –Hoxd (95;111). The genes in these clusters can be divided into 13 
paralogous groups on the basis of sequence similarity. The order of the genes in the 
clusters is conserved throughout vertebrates, as is the expression pattern of Hox genes. In 
general Hox genes are colinearly expressed, meaning that the more 3   a gene is in the 
cluster, the more rostral its anterior limits of expression will be (reviewed in (112)). As a 
consequence, the most 3   genes of the Hox a, b, and d complexes are expressed in the 
hindbrain, with generally a two rhombomere shift in rostral expression limits between 
members of the same complex (figure 7) (113;114).  
 
 
 
Figure 7. Hox gene expression in the hindbrain. With the exception of the Hox paralouge group 1 genes Hoxa-1 
and –b1, Hox gene expression shows a two rhombomere periodicity in the hindbrain. Dark bars indicate high 
levels of expression, lighter shading indicates lower levels of gene expression. Adapted from (115). 
 
 The combinatorial effect of the expression of the individual Hox genes in a given 
rhombomere is thought to specify regional identity in the hindbrain (reviewed in (116)). 
An example of such a combinatorial effect is the synergistic function of Hoxa1 and Hoxb1 
in patterning the region of R4-R6 (117). When the function of either of these genes was 
disrupted, only relatively mild phenotypes were observed. Functional inactivation of 
Hoxa1 leads to the (near) complete deletion of R5, and a slight reduction of R4 (118-121). 
In Hoxb1 null mutants only the cells in R4 were misspecified, leading to abnormalities in 
the VIIth cranial nerve (Facial nerve, (122)). However, when Hoxa1/Hoxb1 double null 
mutants were produced, a patterning defect of the entire R4-R6 territory was shown, and 
consequently the patterning of the VIIth to XIth cranial nerve was disturbed (117;123). 
 Additionally, second branchial arch-derived elements were missing, and external and 
middle ear development was disrupted. This type of research shows the necessity for the 
combined expression of sets of Hox genes in each rhombomere, to facilitate correct 
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specification and maintenance of neuronal populations, and development of tissues 
adjacent to the rhombomeres.  
 
Post-transcriptional control of Hox function 
  
Retinoic acid, generated in the hindbrain by direct or indirect mechanisms, is one of the 
main regulators of Hox gene transcription during the segmentation stages (see above). 
Additionally, Hox function is regulated by rhombomere specific posttranslational control. 
Pbx and Meis proteins have been shown to form stable multimeric complexes with Hox 
proteins, promoting hindbrain fates. Four Pbx genes, Pbx1-4 (124-127), and four Meis 
genes, Meis1-4 (128-131), have been identified to date. Pbx and Meis proteins interact with 
Hox proteins to modulate the selectivity and affinity of binding to promoters of Hox 
responsive genes (reviewed  in (132)), and Meis, Pbx, binding sites have been identified in 
several Hox-dependent promoters (133-136). Additionally, the nuclear translocation of 
Pbx/Meis dimers controls the formation of the nuclear complex, as Pbx and Meis 
monomeres are cytoplasmic (figure 8) (137;138).  
 
Figure 8. Posttranscriptional regulation of Hox function by members of the Pbx and Meis/Prep protein families. 
Cytoplasmic Meis and Pbx must interact to be translocated to the nucleus, there a trimeric Hox/Pbx/Meis 
complex is formed that triggers the expression of downstream target genes, containing Hox/Pbx and Meis binding 
sites in the promoter. Nucl: nucleus, Cyto : cytoplasm. 
  
 The importance of Pbx in hindbrain development was underscored by the defects 
generated by eliminating Pbx function in zebrafish (139). Eliminating Pbx4 and Pbx2 
function affected the expression of a number of hindbrain segmentation genes, including 
Val, Krox-20, vhnf1, fgf3, and fgf8, and segmentation of R2-R6 was impeded (139). The 
importance of Pbx and Meis for proper segmentation of R2-R6 was also demonstrated in a 
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recent study by Choe and Sagerstrom, showing that the repression of R4 fate in R5 and R6 
by vhnf1 was dependent on the binding of Meis proteins to group 1 Hox paralogs (140). 
 Another  gene that is regulated by Hox/Pbx/Meis complexes is Phox2b (141). A 
proximal enhancer region mediating rhombomere restricted expression of Phox2b contains 
separate Pbx-Hox and Meis binding sites, and was found to be directly regulated by Hoxb1 
and b2 in rhombomere 4 (141). In addition to activating the expression of downstream 
targets, auto- and cross-regulatory processes performed by Hox family members maintain 
the correct spatial and temporal Hox expression patterns seen in the hindbrain (82-84). 
 
A model for hindbrain segmentation, and neuronal cell fate 
 
The data above can be combined to form a two step genetic model in which primary 
hindbrain segmentation is the first step (A), followed by segmentation refinement and the 
specification of neuronal identity in idividual rhombomeres (B) (figure 9). 
 
 
Figure 9 : Two step model for hindbrain segmentation and neural specification. A) Fgf signalling in the anterior 
hindbrain, combined with the expression of the fgf facilitator gene vnhf1, activates the expression of genes 
regulating the early segmentation of the hindbrain (e.g. Krox-20, kreisler). The opposing actions of wnts and wnt 
inhibitors at the rostral side of the MHB specifies anterior fates, and functions in the development of the midbrain 
and forebrain. Retinoic acid produced by the paraxial mesoderm diffuses into the posterior hindbrain, and high 
levels of RA in the caudal neural tube leads to posterior fates, and the development of the spinal cord. Genes of 
the CYP26 family, involved in RA metabolism, are being expressed in the region of R2-R6, and a gradient of RA 
across the hindbrain is formed. B) In the second step, the early segmentation genes Krox-20 and kreisler activate 
Eph- and Notch–signalling in the hindbrain. By cell sorting and cell plasticity mechanisms rhombomere borders 
are sharpened, and cells movement across rhombomere borders is prevented. The gradient of RA across the AP 
axis of the hindbrain drives the differential expression of Hox genes, specifying the identity of neuronal 
subpopulations of individual rhombomeres. Low levels of RA at the anterior hindbrain leads to the expression of 
the 3’ genes of the Hox clusters, caudally increasing RA concentrations lead to the expression of more 5’ Hox 
genes.  
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Figure 9. 
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 1.2 Development of cranial nerves 
 
After segmentation and neural specification are completed each rhombomere contains a 
characteristic, segmentally reiterated set of neurons, from which, among others, the cranial 
nerves will develop (reviewed in (116)). As was mentioned above, the hindbrain gives rise 
to cranial nerves V to XII, that  innervate a large number of muscles in the head and body, 
and relay various types of sensory information (Table 1, reviewed in (17)). The adult 
orientation of the cranial nerves reflects the sequential pattern in which their neural cell 
populations are positioned during hindbrain development. A general pattern of 
rhombomere development is assumed for vertebrate hindbrain development, but there are 
some subtle differences in the neuronal architecture between vertebrates (142-144). For 
example, the trigeminal (V) nerve of mice gets contributions from R1-R3,  whereas in 
chick and zebrafish only the neuronal cell bodies in R2 and R3 contribute to the trigeminal 
(V) nerve. Similarly, glossopharyngeal motor neurons form in R6 in mice, R7 in zebrafish, 
and R6 and R7 in the chick. Once cell fate specification has determined the identity of a 
neuron in the hindbrain, development of the cranial nerves has to take place, and 
connections to appropriate targets have to be made. Two important processes in this are 
cell migration and axonal guidance.  
 
Table 1. Innervation by cranial motor nerves and sensory ganglia. Adapted from (17). 
 
Cranial nerve Target tissue / organs 
Motor nerves 
Trochlear (IV) Extraocular muscles 
Trigeminal (V) Muscles of mastication 
Aducens (VI) Extraocular muscles 
Facial (VII) Muscles of facial expression, tear glands,  
salivary glands 
Glossopharyngeal (IX) Muscles of jaw and neck for swallowing, parotid gland 
Vagus (X) Muscles of pharynx and larynx (speech control), heart, blood 
vessels, trachea, bronchi, oesophagus, stomach, and intestine 
Spinal accesory (XI) Trapezius and sternocleidomastoid muscles 
Hypoglossal (XII) Tongue muscles 
Sensory nerves 
Trigeminal (V) Sensation and proprioception from the skin, muscles and joints  
in face and mouth, sensory innervation of teeth. 
Facial (VII) Sensation of skin of external ear, visceral sensation of external 
ear and anterior two-thirds of the tongue, taste from anterior 
two-thirds of the tongue 
Acoustic (VIII) Hearing and balance 
Glossopharyngeal (IX) Sensations from skin of face and throat,visceral sensation from 
palate and posterior third of the tongue, taste from posterior third 
of the tongue 
Vagus (X) Sensation from skin of throat and abdomen, visceral sensation 
from pharynx, larynx, thorax and abdomen, taste from the 
epiglottus. 
CHAPTER 1 
 26 
Neuronal cell migration during hindbrain development 
 
All newborn neurons must migrate out of the germinal zone (145), a process that mostly 
involves movement along radial glia (146;147). However, a large number of neurons also 
undergo nonradial or tangential migrations, and these play an essential role in proper 
positioning of neurons in the brain (148). The migration process is best studied for 
branchiomotor neurons, in particular those of the facial nerve, that can easily be traced by 
retrograde labelling. Branchiomotor neurons are a subpopulation of cranial nerve neurons 
that innervate derivatives of the branchial arches, and undergo tangential migration in all 
species to aquire their distinct dorsolateral locations (149-152). The branchiomotor neurons 
of the facial (VII) nerve migrate rostrocaudally over a distance of several cell body 
diameters to reach their final position (82;122;153). The facial branchiomotor neurons are 
born in R4, and migrate along the floorplate, through R5 and R6. Shortly after they have 
reached R6, radial migration to the pial surface of the hindbrain starts, where the facial 
nucleus is formed. Several genes that are expressed in the facial branchiomotor neurons at 
their birth place function in their migration. Mice lacking Hoxb1 showed abnormal facial 
neuron migation (122), and mutations in Hoxb2 or GATA3 both have a detrimental effect 
on migration of facial branchiomotor neurons, but do not affect their survival (154).  
 Processes that are less well known are the mechanisms that regulate neuronal 
migration. Ebf1 and Nkx6.1 knockout mice showed that the transient expression of genes 
encoding axon guidance and cell adhesion molecules in migrating neurons play an 
important role in migration (152;155). Ebf1 regulated the expression of TAG-1, cadherin 8 
and Ret during migration, and mutant mice showed defects that correlate with the aberrant 
expression of these genes (152). Nkx6.1 mutant mice showed a similar result, where the 
expression of Unc5h3 and Ret were disrupted, and facial neurons failed to migrate out of 
R4 (155). Very recently, expression of neuropilin-1 in migrating facial branchiomotor 
neurons was shown to be important during facial nerve migration. Neuropilin proteins have 
long been known to funtion in semaphorin mediated axonal guidance, which will be 
discussed below. Mice lacking the neuropilin-1 gene where shown to have defects in the 
migration of facial branchiomotor neurons, implying a role for neuropilin-1 in cell body 
movement (156). 
 Several lines of evidence imply an additional regulatory function for extracellular 
cues in facial neuron migration. The Strabismus protein, encoded by the gene mutated in 
the trilobite zebrafish mutant (157;158), was shown to be involved in migration of facial 
nerve neurons from R4 (159). Strabismus, expressed ubiquitously in the hindbrain, is a key 
component of the noncanonical Wingless/Wnt signalling pathway, that is involved in 
planar cell polarity (PCP) in Drosophila, and gastrulation-associated cell movement in 
vertebrates (reviewed in (160-162)). The facial nerve neurons in the trilobite mutant have 
retained the capacity to migrate in a wildtype environment, but seem to have lost the ability 
to generate or maintain polar protrusion by the absence of Strabismus function (163). 
Knockdown of zebrafish prickle, a LIM-domain protein component of the Wnt/PCP 
pathway, also led to defects in tangential migration of facial neurons (164), implying that 
the Wnt/PCP pathway modulates environmental cues necessary for the initiation or 
maintanance of facial neuron migration.  
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Axon pathfinding during cranial nerve development 
 
 The general process of axon growth is an interplay between positive and negative 
cues originating in the extracellular space, combined with guidance cues that direct the 
advance of a growing axon. The cues for neurite development can be presented by the 
extracellular matrix, on the surface of adjacent cells, or it can be delivered by diffusable 
secreted factors. General neurite development has been reviewed in detail (165;166). In 
this part the focus will be on genes that are specifically linked to the development of 
cranial nerves, although some of them also serve a more general purpose in axon growth in 
other parts of the embryo.  
 Axon guidance of cranial nerves in the hindbrain can be divided into two phases 
(144). In the initial phase axons grow within the neural tube, away from the midline 
towards their exit points. These exit points are positioned dorsally in the neural tube of the 
even numbered rhombomeres for the branchiomotor (V, VII, IX, X, and XI), visceromotor 
(III, VII, IX, and X), and otic / lateral line (VIII) nerves, and in the ventral neural tube for 
somatomotor (III, IV, VI, and XII) nerves. In the second phase, the axons exit the neural 
tube, and grow towards their distal targets. The migration of cranial nerve axons in the 
hindbrain, and the periphery is the result of opposing chemo-repulsive (inhibitory) and 
chemo-attractive (permissive) cues, for which few players are known to date.  
 One class of proteins, the secreted semaphorins, regulate axon migration and 
fasciculation in the hindbrain of invertebrates (D. melanogaster, C. elegans) and 
vertebrates (mice). Semaphorins signal through multimeric receptor complexes including 
neuropilin and plexin proteins, and primarily act as repulsive/inhibitory cues (reviewed in 
(167;168)). Mutations in sema3d, or in its receptors neuropilin-1, or neuropilin-2 cause 
defasciculation and inappropriate migration of axons in the hindbrain of mice (169;170). In 
keeping with these findings, rat hindbrain transplants show a reduction in branchiomotor 
neuron axon outgrowth in the presence of the rat sema3A homologue, SemD (171). A role 
for other members of the semaphorin family in axon guidance in the hindbrain can not be 
excluded, but has yet to be described. Another class of proteins in axon guidance are the 
Netrins. Netrin-mediated signalling (reviewed in (172)) could be involved in cranial nerve 
axon repulsion from the midline, as netrin-1 expressing cells are able to repell mouse 
trochlear (IV) axons (173). Additionally, branchiomotor axon outgrowth from rat hindbrain 
explants are reduced in the presence of netrin-1 (171). A receptor for netrins (UNC5H1) is 
expressed in rat cranial motor neurons shortly after the onset of axon outgrowth (174). A 
role for the homologues of the midline repellent slit, and the slit receptors (robo) in cranial 
nerve axon guidance was recently shown (Slit signalling is reviewed in (175)). Mutations 
in the ROBO3 gene are causative for horizontal gaze palsy with progressive scoliosis 
(176), a syndrome that belongs to the congenital cranial dysinnervation disorders, a family 
of syndromes resulting from aberrant development of cranial nerves ((177), see below). 
Further investigations into the roles of slit/robo mediated signalling need to be performed 
to elucidate the full extent of their function in axon guidance. ErbB4, a cell surface 
receptor expressed in R3 and R5, appears to act as a barrier molecule, routing cranial 
sensory ganglia to the correct rhombomeric entry points, thus connecting the peripheral 
and the central nervous system (178). Chemoattractive cues that direct axon growth 
towards the exit points have been proposed to be another mechanism by which axons 
sprout in the hindbrain, but exit point chemoattractants have yet to be identified (144).  
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 Guidance of specific cranial nerves in the periphery is even less well understood, and 
only a handfull of region- or nerve-specific factors have been identified. Some 
chemoattractive and repellent cues expressed in the branchial arches and neuronal plexus 
are known to mediate axonal migration of motor neurons to their targets (179-181). Eph 
receptors and ephrins have been implicated in axon outgrowth. In chick, EphA was found 
to be expressed in a subset of branchiomotor neurons, and ephrins are expressed in specific 
branchial arches (182). Peripheral cranial nerve axon outgrowth is also stimulated by the 
action of several trophic factors. Brain-derived neurotrophic factor (BDNF), ciliary-derived 
neurotrophic factor, and cardiotropin are involved in motor neuron axon outgrowth (183), 
and a factor derived from the maxillary process acts as a chemoattractant for developing 
trigeminal sensory axons (184). One specific receptor-ligand pair that is known to function 
in peripheral axon guidance is hepatocyte growth factor, and its receptor, the Met tyrosine 
kinase receptor, which are essential for the guiding the hypoglossal (XII) nerve to its 
posterior targets (180;181).  
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1.3 Congenital cranial dysinnervation disorders 
 
As discussed above, the mechanisms that regulate the development of the hindbrain, and 
the cranial nerves, are very elaborate and intricate. Defects in the embryonic development 
of the rhombencephalon can therefore lead to a wide variety of clinical phenotypes. 
Recently, a number of different neuromuscular diseases with congenital, nonprogressive, 
isolated or familial, developmental abnormalities of the cranial nerves, or their nuclei, have 
been classified as congenital cranial dysinnervation disorders (CCDDs) (177). CCDDs are 
characterised by abnormal motility of the eye, the eyelid, and/or facial muscles. In the past, 
disorders linked to this group were referred to as the ‘congenital fibrosis syndromes’ 
(185;186), but the current name more accurately captures the syndromes with 
developmental cranial nerve defects leading to dysinnervation in the ocular and facial 
muscles. The CCDD family of diseases currently consists of congenital fibrosis of the 
extraocular muscles (CFEOM), Duane syndrome, horizontal gaze palsy, congenital ptosis, 
Möbius syndrome, and congenital facial palsy. A subclassification within the CCDDs can 
be made when the probable underlying defects are reviewed. Abnormalities of the 
oculomotor and trochlear nerves, or nerve nuclei, most likely result in the predominantly 
vertical disorders of ocular motility seen in the CFEOM variants and congenital ptosis. 
Dysfunction or maldevelopment of the abducens nerves, or nuclei, is suggested to result in 
the horizontal ocular motility defects seen in Duane syndrome and horizontal gaze palsy. 
Möbius syndrome and congenital facial weakness, disorders with a facial motility defect, 
are thought to result from developmental defects in the facial nerves, or nuclei, in Möbius 
syndrome combined with ocular motor abnormalities. The work in this thesis focusses on 
the latter two disorders, and they will be discussed in more detail below than disorders of 
the former two subclasses. 
 
Syndromes with vertical ocular motility defects 
 
The first subclass of the CCDDs contains the CFEOM variants and congenital ptosis. 
CFEOM has three phenotypical variants, and to date four loci have been described. A 
dysinnervation of the oculomotor and/or trochlear nerve is believed to be the primary cause 
of CFEOM. For congenital ptosis two loci are known, and it has been proposed that defects 
of the unpaired caudal central oculomotor subnucleus is causal for this disorder. 
 
 CFEOM1 (MIM135700), at chromosome 12p11.2-q12 (FEOM1), is the most 
common  CFEOM variant, and is characterised by autosomal dominantly inherited 
congenital bilateral ptosis and bilateral ocular motility defects with full penetrance (187-
189). In 2003 causative mutations in the kinesin motor protein gene KIF21A were 
identified in CFEOM1 patients (190). The KIF21A protein is known to homodimerize, and 
the majority of the mutations identified appear to interfere with this dimerization. It should 
be noted that in rare occasions, families that fullfil the criteria for CFEOM1 are linked to 
the locus for CFEOM3 (186).  
 CFEOM2 (MIM602078), at chromosome 11q13.2 (FEOM2), is a rare autosomal 
recessive form of CFEOM. Patients are born with bilateral ptosis and restrictive 
ophthalmoplegia with the globes "frozen" in extreme abduction (191). In 2001 causative 
mutations in the ARIX (PHOX2A) gene were identified in 3 CFEOM2 pedigrees (192). The 
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ARIX gene encodes a homeodomain transcription factor protein required for nIII/nIV 
development. ARIX was the first gene for which a causal relation was identified with one 
of the CCDDs. PHOX2B, expressed in a rhombomere specific fashion in the hindbrain, and 
regulated by Hox genes (see above), is a relative of PHOX2A. This gene may be a very 
plausible candidate gene for involvement in CCDDs. However, to this date no linkage for 
CCDDs to 4p13, the chromosomal location for PHOX2B, has been reported. 
 CFEOM3 (MIM600638), at chromosome 16q24.4-q24.3 (FEOM3), is an autosomal 
dominantly inherited disorder with incomplete penetrance. Patients show a variable 
phenotype within one pedigree with at least 1 patient not meeting the criteria for CFEOM1 
(193), and present with absent or unilateral ptosis, ortho- or hypertropia in primary gaze, 
and near to normal elevation of the globe. In rare cases families that meet the criteria for 
CFEOM3 are linked to the CFEOM1 locus (194), and mutations in the KIF21A gene have 
been idenitifed in these (195). Additionally, one CFEOM3 family was mentioned with a 
chromosomal translocation co-inherited in an autosomal dominant pattern (177), this 
variant has been designated FEOM4, and fine mapping of the breakpoint is in progress. 
The true causal gene for CFEOM3 is still unknown.  
 PTOS1 (MIM178300), at chromosome 1p32-p34.1, consists of unilateral or bilateral 
ptosis, with varying degrees of severity (196). This dirorder is inherited in an autosomal 
dominant pattern, with penetrance estimated at 90 %.  
 PTOS2 (MIM300245), at chromosome Xq24-27.1, is characterised by severe 
congenital bilateral symmetrical ptosis, without amblyopia (197). Patients show a 
characteristic chin-up head posture, and frontal muscle overactivity. The disease is 
inherited in a X-linked pattern, with both sexes equally affected. 
 
Syndromes with horizontal ocular motility defects 
 
The second subclass in the CCDD family consists of the disorders with primarily a 
horizontal ocular motility defect. These include Duane (retraction) syndrome (DURS) and 
the horizontal gaze palsies. Duane syndrome is characterised by restriction or absence of 
abduction, restricted adduction, and narrowing of the palpebral fissure and globe retraction 
on attempted adduction. Duane syndrome most likely arises by a reduction in or absence of 
the abducens motor neurons, with sparing of the abducens interneurons. Like CFEOM, 
Duane syndrome is heterogeneous, as at least 3 loci have been identified in a familial 
background, and 2 more are inferred from isolated cases. In horizontal gaze palsy the 
phenotype manifests itself by agenesis of the abducens nuclei including both alpha motor 
neurons and interneurons, one locus has been identified. 
 DURS1 (MIM126800), deletion at chromosome 8q13, is bilateral in most cases, and 
can be accompanied by other clinical features including mental retardation, branchio-oto-
renal syndrome, genital tract anomalies, and other somatic malformations based on the size 
of the deletion (198-200). Pizzuti et al. showed that the CPAH gene in the DURS1 locus, 
coding for a carboxypeptidase, is disrupted by a balanced translocation in a Duane 
syndrome patient, making this gene the most prominent candidate for involvement in 
DURS1 (201). 
 DURS2 (MIM604356), at chromosome 2q31, can be bilateral and unilateral, and is 
inherited in an autosomal dominant pattern. Patients can show additional features including 
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a variety of vertical deviations, decreased abduction with or without decrease adduction, 
and often amblyopia (202-204). 
 DRRS (MIM607323), at chromosome 20q13, also known as Okihiro syndrome, is 
autosomal dominantly inherited. Patients show unilateral or bilateral Duane syndrome, 
including decreased abduction with or without decreased adduction, accompanied by 
unilateral or bilateral radial dysplasia (most commonly thumb hypoplasia), deafness, and 
somatic malformations (205;206). Truncating mutations have been identified in DRRS 
patients in a gene encoding a putative zinc finger transcription finger, SALL4 (207-209). 
SALL4 is a member of the spalt-like family of proteins, showing homology to the D. 
melanogaster spalt (sal), an important developmental regulator. 
 Inferred DRS loci: A locus at chromosome 22pter-q11.2 has been inferred on the 
basis of three reports in isolated Duane syndrome patients showing asscociation with the 
region or chromosomal abberations (210-212). A fifth locus is inferred at chromosome 
4q27-q31, based on a deletion in an isolated patient (213), and Duane syndrome in 
conjunction with Rieger syndrome (214). 
 HGPPS (MIM607313), at chromosome 11q23-q25, horizontal gaze palsy with 
progressive scoliosis. Patients are born with complete absence of conjugate horizontal 
gaze, and suffer from progressive scoliosis with onset in childhood. Occasionally patients 
show nystagmus, esotropia, and/or retraction of the globe on adduction. The inheritance 
pattern for HGPPS is autosomal recessive. Recently, mutations in the ROBO3 gene, 
located at chromosome 11q24.2, were shown to cause HGPPS (176). ROBO3 is one of the 
vertebrate homologues of the Drosophila Roundabout receptor, and is involved in midline 
crossing of commissural and precerebellar neurons and axons (215;216). In concordance 
with this function, patients with HGPPS were shown to have a defect in midline crossing 
of some brainstem neuronal pathways (217). 
 
Syndromes with facial motility defects 
 
The third subclass of the CCDD family contains the disorders with abnormalities of facial 
motility, these include congenital facial palsy and Möbius syndrome.  
 Hereditary congenital facial palsy (HCFP), also referred to as hereditary facial nerve 
palsy (HFNP), is characterised by the isolated unilateral or bilateral dysfunction of the 
facial nerves or facial nerve nuclei. The palsy is often asymmetrical, and unequal 
involvement of the branches of the facial nerve means that the upper facial muscles are 
mostly affected, with relative sparing of the lower facial muscles. In some occasions 
patients suffer from hearing loss, and in rare instances congenital deafness is observed 
(218). In the past we proposed congenital facial palsy to be a phenotypical subclass of 
Möbius syndrome (218;219), but recently we showed that on the basis of pathological 
differences these syndromes should be treated as two seperate entities (220). Linkage 
analysis in two large Dutch HCFP pedigrees with autosomal dominant inheritance with 
reduced penetrance identified two distinct loci, showing heterogeneity for the disorder.  
 Patients from the first pedigree presented with asymmetric facial weakness, with 
unequal involvement of the three branches of the facial nerve. Figure 10 shows a patient 
from this pedigree, asked to perform several tasks. A locus for HCFP in this pedigree was 
initially defined at chromosome 3q21-q25, spanning about 10 cM (HCFP1, formerly 
known as MBS2, MIM601471) (221). Linkage analysis in additional family members from 
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the pedigree (figure 11) reduced the critical interval to 3q21-q22, a region of 4.9 cM 
between the markers D3S1589 and ACPP (Figure 12, 13) (222). A penetrance of 95% was 
observed for HCFP1 in this family. 
 
 
Figure 10. A patient from the HCFP1 pedigree, with unilateral left side facial palsy. Panel A shows the patient 
raising his eyebrows, the left eyebrow is not responding. In panel B the patient is asked to close his eyes, closure 
is incomplete at the left side (compare the width of the eyelids). In panel C the patient is pouting his lips, non-
responsiveness of the corner of the mouth can easily be identified at the left side of the face. 
 
 
 
Figure 11. Pedigree of the family used in the linkage analysis for HCFP1. The arrows indicate the HCFP1 
patients with the original demarcating recombinations described in 1996 (221). The arrowheads indicate the new 
family members carrying a novel limiting recombination (222).  
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Figure 12. Haplotypes for the linkage region of HCFP1 at chromosmome 3q21-q22. II.6, III.14, IV.4 and IV.6 
were analysed in the initial linkage analysis in 1996 (Kremer1996), 2002a,b, and c are additional patients used to 
refine the locus. Patient II.6 shows the co-segregating haplotype. Arrows in the haplotype of patients III.14 and 
IV.6 indicate the borders of the approximately 10 cM linkage interval defined in 1996, the arrowhead in the 
haplotype of patient 2002a indicates the new distal border, defining the refined interval to the region between 
D3S1589 and ACPP (222). 
 
 
 
 
Figure 13. HCFP1 locus on the long arm of chromosome 3. The vertical arrow indicates the 4.9 cM HCFP1 
critical region between markers D3S1589 and ACPP. 
 
A second locus (HCFP2, formerly known as MBS3, MIM604185), was identified at 
chromosome 10q21-q22 in an unrelated pedigree presenting with uni- and bilateral facial 
weakness, in some patients combined with hearing loss (figure 14) (218). The critical 
region spans 3.7 cM between the markers D10S581 and D10S502, at chromosome 10q21.3 
(UCSC Genome Browser, July 2003 assembly, figure 15, 16). In this HCFP2 pedigree the 
penetrance of only 60% was significantly lower than for HCFP1.  
 Besides these two pedigrees, OMIM lists several other familial cases of congenital 
facial palsy (MIM134100, 134200), but linkage analysis has not been performed or 
reported in these pedigrees (223-228). To increase the knowledge of the genetic defects 
CHAPTER 1 
 34 
involved in congenital facial palsy, it would be very helpful to analyse these and additional 
families, to refine existing loci, or identify new ones. More recently, a case report by Punal 
et al. (229) suggested the involvement of chromosome 22q11 in some cases of congenital 
facial palsy. The authors identified deletions of this chromosome band in three unrelated 
isolated patients with unilateral facial palsy. It should be noted that the facial palsy in these 
three patients is part of a broader phenotype, including congenital heart defects in all three 
patients, and brain malformations of the cerebellum and cerebrum, and involvement of 
other cranial nerves in separate instances. In light of this, at least one of these patients 
would probably better fit the diagnosis Möbius syndrome, having involvement of the 6th 
and 7th cranial nerve (see below). 
 
 
 
Figure 14. Partial pedigree of the family used in the linkage analysis for HCFP2. The arrows indicate the HCFP2 
patients with the proximal demarcating recombination, the arrowhead indicates the patient with the distal 
demarcating recombination, described in 1999 (218). 
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Figure 15. Haplotypes for the linkage region of HCFP2 at chromosome 10q221.3-q22.1. Patient IV.2 shows the 
co-segregating haplotyope. Arrows in the haplotypes for patients V.13 and V.20 indicate the proximal border, and 
the arrowhead in the haplotype of patient V.7 indicates the distal border of the HCFP2 critical region, defining 
the interval to a 3.7 cM region between D10S581 and D10S502 (218). 
 
 
Figure 16. The HCFP2 locus on the long arm of chromosome 10. The vertical arrow indicates the 3.7 cM HCFP2 
critical region between markers D10S581 and D10S502. 
 
Möbius syndrome (MBS, MIM157900) is characterised by the combined dysfunction of 
the abducens and the facial nerve, and we recently defined it as a syndrome of 
rhombencephalic maldevelpoment (230). In addition to dysfunction of the abducens and 
facial nerve, dysfunction of other cranial nerves, limb malformations, musculoskeletal 
defects and orofacial malformations are part of the MBS spectrum. Upper limb 
malformations varying from brachy-, clino-, campto-, syn-, and ectrodactyly to lowset 
thumbs, hypoplasia of the phalanges, aplasia and hypoplasia of metacarpalia, nail 
deformities, and clenched hands are seen. The lower limb defects include pes planus or 
valgus, femur and hip defects, hypoplasia of the lower legs, anisomelia, arthrogryposis 
multiplex, and uni- or bilateral talipes equinovarus. Several MBS patients present a 
musculoskeletal malformation phenotypes well, in which the MBS phenotype is combined 
with a Poland sequence (MIM173800, Poland-Möbius syndrome MIM173750). Poland 
sequence is characterised by unilateral absence or hypoplasia of the pectoralis muscle, 
most frequently involving the sternocostal portion of the pectoralis major muscle, and a 
variable degree of ipsilateral hand and digit anomalies (231). Figure 17 shows some of the 
additional clinical features of MBS. The orofacial malformations in MBS are mostly 
limited to the palate and pharynx, leading to difficulties in swallowing and feeding, and 
later on in life in some patients to a delay in language development. 
 The bulk of MBS patients are isolated cases, indicating a very low recurrence risk for 
siblings. However, several reports on the familial recurrence of MBS suggest a genetic 
cause for the disorder. Pedigrees with autosomal dominant, autosomal recessive, and X-
linked inheritance have been described (see table in Chapter 2, (230)). Already, two 
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chromosomal loci have been cytogenetically defined for MBS, indicating heterogeneity for 
the disorder, as for HCFP. 
 MBS1 (MIM157900), at chromosome 13q12.2-q13, was defined by a three 
generation pedigree with seven affected members, all carrying an apparently balanced 
translocation between  chromosomes 1 and 13 t(1;13)(p34;q13) (232), and a report of an 
isolated patient with a deletion of chromosome 13q12.2 (233).  
 MBS4 (included in MIM157900), at chromosome 1p22, is based on de novo 
translocations in two isolated MBS patients. In a case report by Donahue et al. a 
t(1;11)(p22;p13) translocation was identified in a broad-spectrum MBS patient (234), 
suggesting a gene for MBS should be located at chromosome 1p22 or 11p13. Several years 
later a second unrelated MBS patient was reported with a translocation between 
chromosomes 1 and 2 t(1;2)(p22;q21.1) (235). These two reports combined render the 
locus on 1p22 the most likely to harbour a gene for MBS. A summary of the genetic loci 
and causal genes involved in CCDDs is given in  the following table. 
 
 
 
 
Figure 17. Additional clinical features in Möbius syndrome. Figure A shows an example of a patient with 
brachydactyly. Figure B show a patients hand with complete absence of digits. In figure C a patient with Poland 
anomaly is shown, the right side pectoral muscle is missing, as a consequence the nipple is displaced. Figure D 
shows a patient with talipes equinovarus (230). 
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Table 2. Chromosomal loci and identified causal genes for CCDDs. AD: autosomal 
dominant, AR: autosomal recessive, XR: X-linked, n.i. : not identified. 
 
Syndrome Locus Inheritance Causal gene 
    
CFEOM1 12p11.2-q12 AD KIF21A 
CFEOM2 11q13.2 AR PHOX2A 
CFEOM3 16q24.4-q24.3 AD n.i. 
PTOS1 1p32-p34.1 AD n.i. 
PTOS2 Xp24-p27.1 XR n.i. 
    
DURS1 8q13 Translocations  CPAH ? (breakpoint 
gene) 
DURS2 2q31 AD n.i. 
DRRS 20q13 AD SALL4 
DURSinf 22pter-q11.2 Deletions  n.i. 
DURSinf 4q27-q31 Deletions n.i. 
HGPPS 11q23-q25 AR ROBO3 
    
HCFP1 3q21.3-q22.1 AD n.i. 
HCFP2 10q21.3 AD n.i. 
HCFP3?? 22q11 Deletions  n.i. 
MBS1 13q12.2-q13 Translocation / deletion  n.i.  
MBS4 1p22 Translocations  n.i  
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1.4 Aim and outline of this thesis 
 
 
The identification of disease genes has been highly beneficial to clinical geneticists, 
providing a powerful diagnostic tool for counseling. Linkage analysis has identified 
numerous disease loci, and many of the causal genes in these regions are now known. 
Where the focus in the early years has been on the clear monogenic disorders, focus is 
shifting more and more to the polygenic and even multifactorial diseases. Finding the 
genetic defects that underlie polygenic diseases will not only give insight into the 
pathology of a certain phenotype. From a fundamental scientific point of view, finding the 
causal genes in such disorders will directly show the in vivo interactions between the 
genes, and provide information of the cascades that are involved in development of 
associated organs. This is also true for monogenic disorders presenting with genetic 
heterogeneity. It can be envisaged, and in fact has already been demonstrated, that the 
causative genes are involved in the same cellular / biological processes. Two chromosomal 
loci have been identified for hereditary congenital facial paresis, and to date three loci are 
known for Möbius syndrome, making these diseases genetically heterogeneous. The aim of 
the work presented in this thesis has been to identify the genes involved in the pathogenesis 
of HCFP and MBS. Identification of causal genes for these disorders will give clinicians 
the opportunity to improve diagnostics, and it will give researchers a direction to follow for 
the identification of other genes involved in these and similar syndromes. Additionally, the 
combined knowledge of these genes should identify the genetic and biological pathways 
that are activated in the early development of the rhombencephalon. 
 
 This Chapter 1 of this thesis serves as a general introduction to show recent 
advances in the genetic knowledge on rhombencephalic and cranial nerve development, 
and summarises the phenotypes of a number of syndromes that result from defective 
development of these tissues. In Chapter 2 the phenotype of Möbius syndrome is 
redefined to one of rhombencephalic maldevelopment, on the basis of a study in a large 
number of MBS patients. Chapter 3 describes the histo-pathological comparison of the 
hindbrain of patients suffering from HCFP and MBS, and concludes that these two 
disorders, though overlapping in phenotype, should be treated as two separate disease 
entities. In Chapter 4 we exclude 3 genes (GATA2, PGT, and EGR2) identified in a 
traditional positional cloning approach as candidate genes for HCFP and MBS, and report 
the reduction of the HCFP1 critical region at chromosome 3q21-q22. In Chapter 5 we 
introduce a new and potentially powerful approach to select new candidate genes, RNA in 
situ hybridisation. By investigating the expression patterns, during mouse embryogenesis, 
of a large number of genes from the critical region of HCFP1 (3q21-q22), we eliminate 
most of these genes as candidates, and end up with a limited number of genes on which to 
perform a genetic analysis. In Chapter 6 the detailed expression analysis of plexin-D1 
during mouse embryogenesis is given, suggesting a role for this gene in the development of 
the facial nerve. Succesively, Chapter 7 reports the mutation analysis on basis of which 
we excluded plexin-D1 as the causal gene for HCFP. In Chapter 8, we performed a similar 
analysis for a relative of plexin-D1, also present in the HCFP1 locus: plexin-A1. The 
expression of plexin-A1 during hindbrain development was investigated, and suggested a 
role for plexin-A1 in facial nerve or facial nerve nucleus development. Mutation analysis of 
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the plexin-A1 gene was performed, but no causal mutations were identified, excluding this 
gene for involvement in the pathology of HCFP. Finally, in Chapter 9 we discuss the 
results and issues raised in the previous chapters, and outline the horizon for future 
research. 
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Abstract  
 
Objective: To investigate the variable clinical picture of Möbius syndrome (MIM no. 
157900) and to further understand the pathogenesis of the disorder. Methods: A 
standardized questionnaire was submitted to 37 Dutch patients with Möbius syndrome. All 
underwent standardized neurologic examination with special attention to cranial nerve 
functions, motor skills, and facial and limb anomalies. Results: Of 37 patients with facial 
paresis, 97% had bilateral and 3% had unilateral ocular abduction weakness. Further 
analysis showed isolated abducens nerve palsy in 9%, a conjugated horizontal gaze paresis 
in 48%, features of Duane’s retraction syndrome in 34%, and congenital fibrosis of the 
extraocular muscles in 9%. Other signs included lingual involvement (77%), dysfunction 
of palate and pharynx (56%), general motor disability (88%), poor coordination (83%), and 
respiratory abnormalities (19%). Conclusion: Möbius syndrome is more than a cranial 
nerve or nuclear developmental disorder. It is a syndrome of rhombencephalic 
maldevelopment involving predominantly motor nuclei and axons, as well as traversing 
long tracts. The authors also noted gaze palsies, Duane retraction syndrome, feeding and 
respiratory problems, and poor motor development, suggesting a regional developmental 
disorder.  
  
Introduction  
 
Congenital facial and abducens palsy was originally described by Von Graefe in 1880 
(236), followed by other reports (237). In 1888, Möbius drew attention to patients with 
congenital nonprogressive bilateral facial and abducens palsy. The eponym Möbius 
syndrome has since been used for this condition (238). A variety of criteria have been 
applied when diagnosing the syndrome, varying from congenital facial palsy without 
abducens palsy to congenital facial palsy with abducens palsy, and with or without 
craniofacial dysmorphisms and congenital abnormalities of the extremities (239).  
 Etiology and pathogenesis of the syndrome are unclear (239), but two explanations 
have been proposed: a primary genetic (240;241) and a primary ischemic cause (242-244). 
Teratogenicity is suggested as an important etiological factor in both (245). The postulated 
etiological mechanisms are based on limited pathologic observations, which include 
agenesis or hypoplasia of cranial nerve nuclei, atrophy of cranial nerve nuclei secondary to 
peripheral nerve involvement, and primary muscle involvement without abnormalities in 
the brainstem or cranial nerves (246).  
 Nontraumatic congenital facial weakness without ocular muscle weakness has been 
reported frequently as an autosomal dominant trait (table 1), for which two loci have been 
defined (218;221). Facial weakness plus abducens weakness or the extended phenotype is 
most frequently described as a sporadic condition. However, rare instances of autosomal 
dominant, autosomal recessive, and even X-linked recessive inheritance have been 
described (table 1). Cytogenetic studies have suggested two loci: 1p22 (234;235) and 
13q12.2-13 (232;233). The delineation of the syndrome has been hampered by a large 
number of reports on a relatively small number of patients mostly examined at a young 
age. To determine the variability of the Möbius condition, we studied a number of cases of 
various age and obtained a homogeneous clinical picture, diverse both in extent of 
structures involved and in severity of involvement. This suggested a developmental 
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disorder of the entire lower brainstem with variable severity rather than absence of cranial 
nerve nuclei. For the current study, we have defined the Möbius syndrome as a congenital 
facial weakness with impairment of ocular abduction. 
Methods 
 
Subjects  
Thirty-seven Dutch patients with Möbius syndrome were included in a nationwide survey. 
Ten of them were obtained through a request for participation by the Dutch Möbius 
association and 14 on referral by neurologists, pediatricians, ophthalmologists, genetic 
counselors, ears-nose-throat specialists, or plastic surgeons. An additional 13 patients were 
referred by both the Möbius association and medical specialists. We defined Möbius 
syndrome as a congenital facial weakness with impairment of ocular abduction. All 
patients who satisfied both criteria were included. Dysfunction of other cranial nerves, 
orofacial and limb malformations, musculoskeletal defects, and mental retardation 
commonly occur as associated features.  
 
Questionnaire  
A questionnaire on pregnancy, delivery, post-partum vital functions, clinical symptoms, 
psychomotor development, and family history was given to the patients.  
 
Physical examination 
A standardized neurologic examination, using a specific checklist paying special attention 
to cranial nerve functions, motor skills, and facial and limb dysmorphisms, was performed 
by the same clinician (H.T.F.M.V.). The medical records of all patients were reanalyzed 
once consent had been obtained.  
 
Results 
 
The study resulted in a well-defined clinical picture. Tables 2 through 5 contain a summary 
of the clinical findings in 17 female and 20 male with Möbius syndrome, ages ranging 
from 6 months to 53 years.  
 
Pregnancy and delivery 
Twenty-five of 35 patients (71%) were delivered after an uncomplicated pregnancy. 
Pregnancy information was not available for two patients. Of the remaining 8 cases, one 
mother (Case 14) had diabetes, one mother (Case 3) used Trinordiol and alcohol, three 
mothers (Cases 12, 19, 20) had influenza early in pregnancy, one mother (Case 4) had 
sinusitis, and one mother (Case 33) had gastro-enteritis. Two mothers (Cases 12, 26) had 
vaginal blood loss in pregnancy. Nine children (Cases 2, 5, 6, 18, 20, 23, 26, 27, 33) were 
hypotonic at birth: one child (Case 3) was hypertonic. 
 
Post-partum vital functions 
Seven patients (19%) exhibited respiratory difficulties. In two patients (Cases 29, 33), a 
severe primary respiratory dysfunction was present at birth. These patients died soon after 
deferring artificial ventilation, as a result of the conclusion that the lack of respiratory drive 
was part of the syndrome. In five patients, problems included breath-holding spells up to 
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the age of 1 year (Cases 2, 19), apnea and bradycardias up to the age of 12 weeks (Cases 3, 
5), and acute respiratory arrests in Case 5 at 1 year and in Case 12 at 13 years of age. All 
five patients survived. 
 
Family history 
In one case, there was a family history of cranial nerve palsy. Both mother and son (Cases 
35, 36) had a congenital bilateral facial palsy of mainly the upper face and bilateral ocular 
abduction paresis. 
 
Facial paresis (table 2) 
Thirty-four of the patients (92%) had bilateral and 3 (8%) had unilateral facial weakness. 
In the two subjects who died, the extent of bilateral facial weakness could not beaccurately 
reconstructed. Facial diplegia was complete in 11 out of 32 patients (34%); in 20 patients 
(62%) there was a palsy of the upper face with a relative sparing of the lower half of the 
face, including the perioral muscles and platysma (figure 1). In one patient the upper and 
the lower face was paralyzed to the same extent (Case 16). Three patients had unilateral 
weakness: one (Case 6) complete and two (Cases 19, 37) partial.  
 
Abnormal ocular motility (table 2) 
Esotropia at birth was present bilaterally in 19 patients (54%), and unilaterally in four 
patients (11%; Cases 13, 19, 21, 37). Three patients (9%; Cases 30, 35, 36) demonstrated 
exotropia of both eyes, and two patients (6%; Cases 1, 7) of one eye. On convergence, the 
pupils constricted normally in all cases.Thirty-three patients, excluding the four patients 
with exotropia, were unable to abduct the eyes beyond the midline, 32 patients (97%) 
bilaterally and 1 patient (Case 37) unilaterally. Information on eye movements was 
incomplete in the two deceased patients (Cases 29, 33). Abducens nerve palsy was present 
in 3 of 35 patients (9%; Cases 18, 31, 37). Seventeen patients (48%) had conjugated 
horizontal gaze palsies (figure 2). Twelve patients (34%) demonstrated features of Duane 
retraction syndrome, consisting of limitation of abduction as well as a variable degree of 
limited adduction, and  retraction of the eye on attempted adduction with narrowing of the 
palpebral fissure, caused by an aberrant innervation of the lateral rectus muscle by fibers of 
the oculomotor nerve (see figure 2) (247). In this study, five patients had type I Duane 
retraction syndrome characterized by marked limitation of abduction with minimally 
defective or normal adduction and retraction of the adducting eye, and seven patients had 
type III Duane retraction syndrome for which combined limitation or absence of both 
abduction and adduction are specific features next to retraction of the eye on attempted 
adduction. Three patients (9%; Cases 1, 30, 35) with prominent facial paresis showed 
features of congenital fibrosis of the extraocular muscles, consisting of restrictive external 
ophthalmoplegia, ptosis, and eyes fixed in an abnormal position, resulting from a 
developmental anomaly of all or portions of the oculomotor or trochlear nuclei (248;249). 
In this study, one patient had type I or classic congenital fibrosis of the extraocular muscles 
(CFEOM) characterized by ptosis and a restrictive infraductive external ophthalmoplegia 
with on attempted abduction, elevation, and depression retraction of the eyelid, and two 
patients had type II CFEOM with ptosis and a restrictive exotropic external 
ophthalmoplegia. Nine patients (Cases 2, 5, 11, 23, 24, 26, 28, 34, 36) had undergone 
strabismus surgery.  
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Lingual features (table 2) 
There was insufficient information concerning the tongue in the two deceased patients. 
Twenty-seven patients (77%) had a hypoplastic tongue that could not be protruded beyond 
the lips (figure 3). Thirteen patients (37%) showed an asymmetry in size of the tongue (see 
figure 3). In 8 patients (23%; Cases 2, 7, 9, 10, 12, 15, 26, 34) we observed a groove over 
the midline of the tongue with elevations on both sides (see figure 3). In the majority of 
cases, function of the affected tongues was normal, but the range of motion was limited. 
Three patients (9%; Cases 4, 8, 23) demonstrated a unilateral paresis of the tongue (see 
figure 3). In 8 patients (23%) the tongue had a normal appearance and function. 
 
Palate and pharynx (tables 2 and 3) 
Feeding problems at birth due to insufficient sucking, swallowing, palatal weakness, or 
regurgitation were present in 32 patients (86%). In 21 of these, tube feeding was necessary 
throughout the first weeks and, in some cases, even during the first months of life. Two 
patients (Cases 5, 18) underwent gastrostomy. Three patients (Cases 5, 6, 27) could not be 
assessed properly because of limited cooperation, and there was no information available 
on the two deceased patients (Cases 29, 33). Nasal dysarthria was evident in 22 of 29 
speaking patients (76%). A delay in language development occurred in 16 out of 29 
patients (55%). Information is lacking in eight patients because of premature death (Cases 
29, 33), young age (Cases 3, 4, 6, 20, 31), and foreign language problems (Case 32). 
 
Trigeminal paresis 
Six patients (16%) demonstrated masticatory difficulties due to a weak bite (Cases 10, 11, 
16, 25) and the absence of jaw rotation during chewing (Cases 17, 24, 25). Four patients 
(11%; Cases 6, 12, 19, 24) showed a loss of sensation of the lip, the cheek, the forehead, 
and the cornea, suggesting a partial defect of the sensory root of the trigeminal nerve.  
 
Vision 
The frequencies of mild hypermetropia, myopia, astigmatism, and amblyopia did not differ 
from the normal population. Severe visual disability occurred in one patient. Case 30 had 
bilateral optic nerve hypoplasia and retinal detachment. 
Hearing loss 
Of 35 patients, 10 (29%; Cases 1, 6, 7, 9, 11, 14, 17, 20, 23, 25) complained of some 
degree of hearing loss, but no examinations were performed to confirm this. One of these 
patients (Case 19) was congenitally deaf in both ears.  
 
Smell and taste 
Our assessment did not reveal indications of olfactory loss. There were no complaints 
about taste.   
 
Craniofacial malformations (tables 2 and 4) 
Epicanthic folds (89%), flattened nasal bridge (81%), micrognathia (64%), high arch palate 
(61%), external ear defects (47%), teeth defects (33%), and hypertelorism (25%) were the 
most frequent features present in the group under study. Other malformations are listed in 
table 4. 
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Figure 1. Facial paresis. Incomplete (1) and complete (2) facial palsy. Raising eyebrows (A), smiling (B). 
 
 
 
 
Figure 2.  Abnormal ocular motility. Horizontal gaze palsy (1) and Duane retraction syndrome type I (2). 
Looking to the right (A), looking to the left (B). 
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Figure 3. Lingual features. Hypoplastic and asymmetric, dysplastic tongue (1), hypoplastic and asymmetric, 
dysplastic tongue that could not be protruded beyond the lips and unilateral paresis of the tongue (2), hypoplastic 
tongue and a groove over the midline of the tongue with elevations on both sides (dysplasia)(3).  
 
Mental deficiency 
Examination of mental status was not done, so there is no detailed information on IQ-
levels. All schoolgoing patients, with the exception of two autistic patients (Cases 5, 11), 
had attended elementary school, with Iqs of at least 80. Of these patients, 6 were attending 
elementary school, 11 had finished elementary school and one or more grades of high 
school, and 12 were attending special education for physically affected children.  
 
Extremity malformations (tables 2 and 5) 
Thirty-one (86%) had malformed extremities with variable degrees of severity. Hand 
deformities were evident in 22 patients (61%), ranging from brachydactyly, clinodactyly, 
camptodactyly, syndactyly, and ectrodactyly to low set thumbs, hypoplasia of the 
phalanxes, aplasia and hypoplasia of the metacarpals, nail deformities, and clenched hands 
(figure 4). Twenty-five patients (69%) showed deformities of the legs, varying from pes 
planus or valgus, femur and hip defects to hypoplasia of the lower legs (see figure 4). 
Anisomelia was observed in one patient. Two patients (6%) exhibited arthrogryposis 
multiplex, 16 (44%) had talipes equinovarus; in 11 of these cases both feet were affected.  
 
Other malformations (Tables 2 and 5) 
Poland syndrome, diagnosed by unilateral absence or hypoplasia of the pectoralis muscle, 
most frequently involving the sternocostal portion of the pectoralis major muscle, and a 
variable degree of ipsilateral hand and digit anomalies (231), was present in four patients 
(11%; Cases 2, 19, 24, 32). Cardiovascular malformations occurred in two patients (Cases 
2, 14). Other malformations and their frequency of occurrence are listed in table 5. 
 
Motor dysfunction (Table 2) 
Thirty of 34 patients (88%) demonstrated motor disabilities. There was a lack of 
information in three patients because of early death (Cases 29, 33) and young age (Case 
31). Only four patients (12%; Cases 13, 35, 36, 37) showed no motor problems. In 23 
patients (68%), there was retardation in motor development; they took longer than average 
to master the milestones of major motor skills such as sitting, standing, walking, and, even 
more clearly, of running, jumping, and hopping; the presence of skeletal deformities 
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appeared to have influenced these motor skills only to a small degree. When attempting to 
run, six patients (Cases 9, 12, 18, 19, 23, 26) kicked their legs awkwardly to all sides, 
failing to reach any speed. In time, most of them developed relatively normal walking and 
running abilities. In 20 of the 23 patients, fine motor skills were uniformly awkward; none 
could dance, do gymnastics, or play musical instruments. Eight of 11 patients (Cases 1, 3, 
4, 8, 15, 20, 22, 32) without a history of retarded motor development showed the same 
clumsiness. On examination, 28 of 34 patients (82%) showed clumsy movements, even 
when skeletal deformities were taken into account. Information on two patients is lacking 
because of young age. In 11 patients (31%) a remarkable hypotonia of neck, thorax, and 
extremities occurred up to the age of 4 years. 
 
 
Figure 4. Extremity malformations. Hypoplasia of the lower legs (1), brachydactyly, syndactyly, ectrodactyly and 
camptodactyly (2), arthrogryposis multiplex (3). 
 
 
Coordination dysfunction (table 2) 
Twenty-nine of 35 persons (83%) had poor coordination. Twenty of the 30 patients (67%) 
who could walk  five (Cases 3, 4, 6, 20, 31) were too young  had a disturbed tandem 
gait. Seven patients lurched when riding a bike, and three of them (Cases 23, 25, 30) were 
committed to a tricycle because lurching was getting worse. Of 30 patients who could be 
instructed  five (Cases 3, 4, 6, 20, 31) were too young  19 (63%) demonstrated 
dysdiadochokinesis of the hands. An axial imbalance was present in 12 patients (34%). In 
seven of them (Cases 3, 4, 12, 20, 23, 24, 31), balance improved to normal within 6 months 
to 3 years after birth, and in five patients (Cases 5, 6, 19, 25, 30) imbalance was still 
present at 2, 5, 9, 36, and 53 years of age. Six patients had no problems with coordination; 
two patients had died. 
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Sensory disturbances (table 2) 
One patient (Case 30) suffered from a progressive sensory polyneuropathy of unknown 
origin. In five patients (Cases 15, 19, 26, 27, 34) parents noticed a high tolerance to pain. 
In the other 32 cases there were no disturbances. 
 
Tendon reflexes 
In general, tendon reflexes were normal. Reflexes were diminished only in the patient with 
neuropathy (Case 30). Pathologic reflexes were not observed. 
 
Discussion 
 
All previous reviews on Möbius syndrome are compilations of the literature and focus 
mainly on a particular aspect of the syndrome (237;250-265). To date, the largest number 
of Möbius syndrome patients studied by a single author is 27, and the pertinent report is 
restricted to a retrospective analysis with patients not re-examined at later stages (250). In 
the current study, we analyzed the characteristics of the syndrome in 37 Dutch Möbius 
patients of different age groups, taking all clinical aspects into consideration. The same 
physician (H.T.F.M.V/) studied all patients. The patients referred by medical specialists as 
compared to the number and type of cases obtained from the patients' association suggests 
that we studied a true cross-section of the Dutch population. Because of the overlap of 
patients mentioned, especially of those in the first decade, we are confident that we 
identified almost all of the Dutch patients with Möbius syndrome born in 1996. In this 
year, the prevalence of Möbius syndrome is at least 0.002% of births (4 per 189,000 
newborn). A similar percentage was obtained in 1997 and 1998. The majority of our 
patients are in their first or second decade of life, and in the subsequent decades the 
number of patients declines due to limited filing by specialists and reduced interest of the 
patients (table 2). There is no indication of early death. 
 The aim of the study was to gain more insight into the variability of anomalies 
associated with Möbius syndrome and thereby into the pathogenesis of the syndrome. For 
this study, we defined the syndrome as a congenital facial palsy with impairment of ocular 
abduction. Whereas dysfunction of other cranial nerves, orofacial malformations, limb 
malformations, musculoskeletal system defects, and mental retardation are commonly 
associated features, we considered them unnecessary for the diagnosis. 
 In the majority of patients, we observed a homogeneous clinical picture characterized 
by facial diplegia of the upper and lower facial muscles, bilateral abduction impairment, 
hypoglossia, craniofacial and limb malformations, and symptoms of the long tracts. Two 
patients with unilateral facial palsy and bilateral abduction palsy also showed this well-
defined extensive clinical picture. Two patients, mother and son, with upper facial diplegia 
and bilateral abduction weakness and one patient with unilateral facial and abducens nerve 
palsy lacked craniofacial and limb malformations and symptoms of the long tracts, and 
could therefore be considered as a subset of the Möbius syndrome. Furthermore, we found 
no indication that a specific type of ocular finding, oral dysfunction, craniofacial and 
extremity involvement, or motor dysfunction is accompanied by specific associated 
findings. The distribution of the facial palsy in the Möbius syndrome cases, with more 
severe involvement of the upper facial muscles and a relative sparing of the lower facial 
muscles, contrasts considerably with that found in the common supranuclear and 
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infranuclear types of facial palsy. This distribution appears to be characteristic for Möbius 
syndrome and, in the absence of the accompanying features, may be of diagnostic value 
(237;239;266). 
 We observed that the inability to abduct the eye beyond the midline  usually bilateral 
and complete  constitutes, by definition, a highly characteristic feature of the syndrome. 
In contrast to previous series (237;250;251;253;255;257), we observed an isolated 
abducens nerve palsy in a minority of cases. In many cases we found horizontal gaze 
palsies, suggesting that more than the 6th cranial nerve nucleus is involved. Also, we found 
that Duane retraction syndrome was frequently present and can only conclude that it may 
have been overlooked previously (247;255;257;263). The cases with oculomotor palsies, 
which we diagnosed as CFEOM, suggest that overlap with mesencephalic developmental 
syndromes occurs more frequently than previously thought (248;249). The recent 
identification of a gene for this condition (192;267) might contribute to a better 
understanding of midbrain motor neuron development and give an insight into molecular 
pathways necessary for brainstem development involved in the pathogenesis of Möbius 
syndrome.  
 We observed two types of tongue abnormalities: a global hypoplasia of the tongue 
and an appearance resembling a nonprogressive asymmetric lingual dysplasia. More 
autopsy studies of these phenomena are required. 
 Our findings indicate considerable dysfunction of palate and pharynx with remarkable 
clinical consequences, which has escaped full attention in the literature (237;253-255). In 
accordance with earlier reports (254;267), in a large number of cases (86%), we observed 
feeding problems in the earlier phases of life, probably because of combined facial, lingual, 
and palatal abnormalities, making infants prone to recurrent aspiration and necessitating 
tube feeding. Most patients overcame these problems using a suitable comforter and by the 
development of compensatory mechanisms. Delay in language and speech development, 
observed frequently (55%) in our patients, requires early attention by a speech therapist. 
Difficulties with suckling and feeding should trigger treatment to develop normal 
prespeech activities and maximize the range of motion of the articulators to optimize the 
condition for speech later in life.  
 The weak bite and absence of jaw rotation during chewing may be caused by 
trigeminal motor nerve involvement. However, we observed a striking sparing of the 
masticatory muscles. Occlusion defects because of oromandibular hypoplasia played an 
important role in chewing difficulties. In a small number of cases we found trigeminal 
sensory nerve involvement. 
 Mental retardation has been reported in Möbius syndrome patients (237;258), 
occurring from 10 to 75% of cases (237;251;255;258;268-271). We did not observe a high 
occurrence of mental retardation, but prospective studies using standardized scales to 
evaluate mental capacities are needed. 
 We confirmed that limb malformations, particular of the hands and feet, are 
abnormalities most commonly associated with Möbius syndrome (239). Whereas lower leg 
hypoplasia was frequently seen, a similar hypoplasia of the arms was not. Genes may be 
responsible for the phenotype of brainstem syndromes associated with limb malformations, 
such as recently demonstrated in Okihiro syndrome (207;208). 
 Summarizing the cases of congenital absence of muscles, we noted that the pectoralis 
muscles were most frequently absent, which could be classified as part of the Poland 
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syndrome. In view of the high frequency of Poland-Möbius syndrome (272), it has been 
proposed as a formal genesis syndrome  i.e., it has a pathogenesis that is at least to some 
extent similar or related (258;273). These clinical overlap syndromes might represent 
variable expression of a single gene or might represent a contiguous gene syndrome.  
 Hypotonia at birth is often present and motor development and coordination do not 
reach normal levels at older ages, even when skeletal deformities are taken into account. 
The lack of fine motor skills and the poor coordination and balance performance can be 
best summarized as clumsiness (274). The developmental nature of this condition probably 
preludes recognizable pyramidal or cerebellar signs as indicated by lesions occurring later. 
We suggest, and feel supported by radiologic studies (274), that clumsiness is the 
functional result of hypoplasticity  i.e., maldevelopment of either the corticospinal or 
cortico-bulbocerebellar long tracts. In a minority of cases we saw primary respiratory 
dysfunction, supporting the concept that the caudal part of the brainstem is poorly 
developed. In this sense, Möbius syndrome could be viewed as a syndrome of 
rhombencephalic maldevelopment involving both nuclei and traversing long tracts. In 
extreme cases, the caudal part of the brainstem is so poorly developed that primary 
respiratory dysfunction occurs, which is incompatible with independent life. This 
observation is consistent with reported MRI findings, demonstrating hypoplasia of the 
lower brainstem (275;276). 
 In this survey, personal examination of patients with Möbius syndrome showed 
evidence of possible pharmacologic, hormonal, or toxic effects in only one or two 
instances. Therefore, we could not substantiate the claims that teratogens are a possible 
cause of the syndrome. There were no common obstetric events compatible with a 
causative mechanism. We did not observe geographic clustering of cases; patients were 
scattered all over The Netherlands. 
 The vascular hypothesis for Möbius syndrome supposes ischemic events in the 
median avascular and paramedian watershed zones of the lower brainstem to be the result 
of hypoperfusion or occlusion of the developing primitive subclavian artery (242;244). 
Although this artery supplies a fair part of the rostral embryo, it is doubtful that ischemia of 
part of its supply-zones leads to specific and recognizable syndromes with involvement of 
a limited number of structures, tissues and germ layers such as in Poland or Klippel-Feil 
syndrome. This vascular hypothesis does not explain the frequent occurrence of lower 
extremity involvement (86% in our series) or congenital abnormalities outside the 
subclavian arterial bed. 
 A widely spectrum of severity of Möbius syndrome, as seen in our study, is not 
incompatible with a genetic cause of this disorder. Two reports with abnormal karyotypes 
(233;234)  and one report of identical twins with Möbius syndrome (277) have been 
documented, suggesting a genetic cause for the disorder. Six families with autosomal 
dominant, two with autosomal recessive, and three families with X-linked inherited 
Möbius syndrome have been reported (table 1). In our study, we observed a mother and 
son with Möbius syndrome, suggesting that dominant inheritance is likely. We also 
observed one proband with three healthy children, which does not make autosomal 
dominant inheritance unlikely. The mother and son appeared less severely affected by 
upper facial diplegia and bilateral abduction weakness without craniofacial and limb 
malformations and symptoms of the long tracts, suggesting that they might suffer from a 
subset of the Möbius syndrome, possibly with a unique etiology. One sporadic patient 
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showed comparable although not the same features  i.e., unilateral facial palsy and a 
unilateral abducens nerve palsy without craniofacial and extremity malformations and 
without symptoms of the long tracts. We found no secondary cases in the 54 sibs of 37 
probands, making autosomal recessive inheritance extremely unlikely. The lack of a clear 
hereditary pattern in the vast majority of cases does not rule out genetic causes. The 
observation that the questionnaire did not elicit any significant history of stillbirths or 
spontaneous abortions suggests that the genes involved are not lethal. The lack of affected 
siblings may be because the disorder is polygenetic  i.e., the phenotype only emerges if 
there are coexisting mutations in more than one developmental gene  which has been 
shown for the Bardet-Biedl syndrome (278). Also, genes acting as modifiers may prevent 
or enhance the phenotype, as recently demonstrated in the tubby mice (279). The clinical 
heterogeneity of Möbius syndrome with congenital facial weakness accompanied by 
impairment of ocular abduction as the prime feature may be due to a combination of a 
number of loci involved and different types of mutation at each locus. Also, just as folic 
acid in pregnancy lowers the risk of neural tube defects in humans, and retinoic acid can 
rescue the inner-ear defects of Hoxa1 deficient mice (280), external factors influencing the 
intrauterine environment could play a modifying role in the manifestations of Möbius 
syndrome. Such explanations are in accordance with observations that cocaine and 
prostaglandin abuse is occasionally associated with the occurrence of Möbius syndrome 
(244;281;282). We hypothesize that the spectrum of Möbius syndrome is the sum of 
changes in a number of genes that are functional in the organization and development of 
the lower brainstem at a specific gestational age. In some cases, these changes may also 
interact with environmental factors in a specific time period in the development of the 
lower brainstem.  
 Because Möbius syndrome is a complex developmental disorder of the lower 
brainstem, rather than a congenital absence of certain cranial nerves, it is clear that the 
associated deficiencies of the syndrome require a multidisciplinary approach by 
pediatricians, neurologists, ophthalmologists, genetic counselors, orthopedic, plastic and 
dental surgeons, audiologists, physical therapists, and speech therapists. 
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Table 1. Pattern of inheritance in families with Möbius syndrome and congenital facial 
palsy. 
 
 Autosomal dominant Autosomal 
recessive 
X-linked 
Möbius 
syndrome 
Hicks, 1943(260) 
Hellstrom, 1949(269) 
Kruger von and Friedrich, 
1963(283) 
Legum et al., 1981(240) 
Wishnick et al., 1981(284) 
MacDermot et al., 1991(285) 
Legum et al., 
1981(240) 
Criado and 
Aytes, 1999(286) 
Singh et al., 
1992(287) 
 
 
Thomas, 1898(288) 
Harrison and Parker, 
1960(289) 
Journel et al., 1989(290) 
Congenital 
facial 
palsy 
Thomas, 1898 (288)  
Fry and Kasak, 1919(291) 
Trautman, 1925 (292) 
Fortanier and Speijer, 
1935(293)  
(Verzijl et al., 1999 (218)) 
Wiel van der, 1957(294)  
(Kremer et al., 1996(221)) 
Rosin, 1964(295) 
Skyberg and van der Hagen, 
1965(224) 
Wittig et al., 1967(225) 
Masaki, 1971(296) 
Becker-Christensen and Lund, 
1974(297) 
Steigner et al., 1975(265) 
Ziter et al., 1977(232) 
Anderson et al., 1979(226)  
May et al., 1981(298) 
Collins and Schimke, 1982(299) 
Mitter and Chudley, 1983(300) 
Dotti et al., 1989(301) 
Erro et al., 1989(302) 
Larrandaburu et al., 1999(303) 
Thomas, 
1898(288) 
Beetz, 1913(304) 
Cadwalander, 
1922(305) 
Sprofkin and 
Hillman, 
1956(306) 
Harrison and 
Parker, 
1960(289) 
Stabile et al., 
1984(241) 
Journel et al., 
1989(290) 
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Table 2. Clinical characteristics of Möbius syndrome.  
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1 17 F ++/+  ++/++ +  + ++/+ ++/+ ++/– +/–    
2 7 M ++/++  ++/++  +#  ++/++ ++/++   +/+   
3 F ++/++  ++/++    ++/++ ++/++     + 
4 2 F ++/+  ++/+  +  ++/++ ++/++     + 
5 5 M ++/++  ++/++  + #  ++/++ ++/++     + 
6 2 F ++/++    –  +  ++/++    +/+   
7 18 F ++/+  ++/+ +   ++/++ ++/++   +/+   
8 10 M ++/+  ++/+    ++/++ ++/++     + 
9 17 M ++/+  ++/+  +  ++/++ ++/++   +/+   
10 8 M ++/+  ++/+    ++/++ ++/++     + 
11 7 F ++/++  ++/++  +#  ++/++ ++/++     + 
12 14 F ++/+   ++/+  +  ++/++ ++/++     + 
13 15 F ++/++   ++/–  +  ++/++ ++/++     + 
14 10 M ++/++  ++/++  +  ++/++    +/+   
15 12 M +/+  ++/+    ++/++ +/+   +/+   
16 5 M +/+  +/+    ++/++    +/+   
17 19 M ++/++  ++/++  +  ++/++ +/+   +/+   
18 5 F ++/++  ++/++    +/+     +  
19 6 M –     +/+  +  ++/++ ++/++     + 
20 2 M ++/+  ++/++  +  ++/++    –/+   
21 13 F ++/+  ++/+  +  ++/++ ++/++     + 
22 44 M ++/+  ++/+  +  ++/++ ++/++     + 
23 17 M ++/++  ++/++  +#  ++/++ +/+   +/–   
24 21 F ++/++  ++/++  +#  ++/++ +/+   +/+   
25 53 M ++/++  ++/++  +  ++/++ ++/++     + 
26 8 M ++/+  ++/+  +#  ++/++ ++/++     + 
27 16 F ++/+  ++/++  +#  ++/++ ++/++     + 
28 28 M ++/+  ++/++  +#  ++/++ ++/++     + 
29 † F ++x  ++x x x x +/+x +/+x    x x 
30 35 M ++/+  ++/+ +   ++/+ ++/+ ++/+ +/+    
31 ½ M ++/++  ++/++  +  ++/++     +  
32 3 F ++/++  ++/+    ++/++ ++/++     + 
33 † F ++x  ++x x x x +/+x +/+x    x x 
34 8 M ++/+  +/+  +#  ++/++    +/+   
35 34 F +/–  +/– +   ++/++ ++/++ +/+ +/+    
36 5 M +/–  +/– +#   +/+ +/+     + 
37 31 F ++/+    –  +  +/–     +  
 
++: paralysed, +: paretic or affected, –: not affected, RE: right eye, LE: left eye, unilat.: unilateral. bilat.: bilateral, asymm.: asymmetry, *: eye retraction 
with narrowing of the palpebral fissure on attempted adduction, x or x: no or incomplete information, #: strabismus surgery, †: deceased, ept: elevated 
pain threshold, pnp: polyneuropathy. 
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Table 2. Continued. 
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1 I      + +   +   +   
2   III +   + + +  + + +(1) +    
3   +   + + + +  + +(½) x x +(½)  
4   +   +  + +    + +(1) x x +(1)  
5   +   + + + + + + +(4)   +(5-)  
6    I    + + +  + + +(2) x x +(2-)  
7  III +   + + +  + +  +    
8   +   +   + + + +   +  + +   
9  III +   + + +  + +  + +   
10   +    + + + + + + +  + +   
11   +   + + + + + +  + +   
12   +    + + +   + + +(1) + + +(1)  
13      + + +         
14    I +    + + + + + + +  + +   
15   III +   + + +   +     ept 
16    I +    + + + + + + +      
17   III +   + + + + + +  + +   
18   +   + + +  + + +(1)  +   
19   +    + + + +  + + +(1) + + +(9-) ept 
20    I +    + + + + + + + +(2) x x +(2)  
21   +   + + + + + +   +   
22   +   + +    +  + +   
23   III +   +   + + + + + + + +(1) + + +(3)  
24   III +    + + + + + +  +(1)   +(1)  
25   +    +  + + + + +  + + +(54-)  
26   +    + + + + + + +/+  + +   
27   +    + + + +  + +  + +  ept 
28   +   + + +  +   + +   
29 x   x x  x x + x x  x x x x x x  
30 II     + + +  + +  + + +(36-) pnp 
31   +    + + + + +  x  x x +(½)  
32      + + +   +  + +   
33 x   x x  x   x + + + + x x x x x x ept 
34   I +     + + + + + +  + +  ept 
35 II     +  +         
36                 
37                 
 
++: paralysed, +: paretic or affected, –: not affected, RE: right eye, LE: left eye, unilat.: unilateral. bilat.: bilateral, asymm.: asymmetry, *: eye retraction 
with narrowing of the palpebral fissure on attempted adduction, x or x: no or incomplete information, #: strabismus surgery, †: deceased, ept: elevated 
pain threshold, pnp: polyneuropathy. 
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Table 3. Oral dysfunctions . 
 
Case Feeding 
problems 
Swallowing 
difficulties 
Regurgitation Palatal 
weakness 
Dysarthria Language 
delay 
1       
2 TF +   + + 
3 TF    x x 
4 TF    x x 
5 GS + + x x + 
6 TF + + x x x 
7 TF +  + +  
8 + +  + +  
9 TF + +  + + 
10 TF    + + 
11 + +  + + + 
12 TF +   + + 
13 TF      
14 TF + +  + + 
15 + +   +  
16 TF +   + + 
17 TF +   + + 
18 GS + +  + + 
19 TF + +  + + 
20 TF    x x 
21 TF   + +  
22 + + +  +  
23 TF      
24 +    +  
25     + + 
26 +   Asymmetric 
uvula 
+ + 
27 TF +  x + + 
28 + +  Asymmetric  
uvula 
+  
29 TF + x x x x 
30 TF   + + + 
31 +    x x 
32 +     x 
33 TF + x x x x 
34 TF + + + + + 
35       
36       
37       
 
TF = tube feeding; GS = gastrostomy; + = affected; x = no information. 
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Table 4. Craniofacial malformations. 
 
Case A B C D E F G H I J K L M N O P 
1 + +  +   +          
2 + + + +             
3 + + +  + + +  + +  +     
4 + + + +             
5 + + + +       +   +   
6 + + +  + + +   +  + + +   
7 + + + + +  +  +  + +     
8 + +  +             
9 + + + + +  +  +        
10 + + +  + +   +  + +     
11 + + + +  +    +  +   +  
12 + +  + +            
13 + +   +  +          
14 + + +    + +     +    
15 + +  +    +         
16 + + +    +  +    +    
17 + + +  + + +   +       
18 +  + +        +     
19 + +  + + + + + + +      + 
20 + +  + +            
21 + +  + + +  +         
22 + +  +  +  +         
23 + + + +  +  +         
24 + + + +  +           
25 + + +  +    +  +      
26 + + + + +  + +  + +      
27 + + +  + +       +   + 
28 +   + +   +         
29 x x x x x x x x x x x x x x x x 
30 + + + + +            
31   +              
32 +  +              
33 + + + +          + +  
34 + + + + + + + +         
35                 
36                 
37                 
Total (%) 89 81 64 61 47 33 33 25 19 17 14 14 11 8 8 6 
 
A: epicanthic folds, B: flattened nasal bridge, C: micrognathia, D: high arch palate, E: external ear defects, F: 
dental defects, G: hypertelorism, H: lacrimal duct defects, I: microphthalmia, J: short neck, K: cranium shape 
defect, L: microtia, M: bifid uvula, N: cleft palate, O: trismus, P: hemiatrophia facialis. +: affected, x: no 
information. 
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Table 5. Extremity- and other malformations. 
 
 
Case 
 
A 
 
B 
 
C 
 
D 
 
E 
 
F 
 
G 
 
H 
 
I 
 
J 
 
K 
 
L 
 
M 
 
N 
 
O 
 
P 
 
Q 
 
R 
Talipes 
Ri    Le 
 
Other malformations 
1 + +   +       +         
2     +       +        Agenesis m. pectoralis: Poland anomaly left; 
dextrocardia; cardiac myopathy; rib 
deformities 
3                   +       +  
4                     
5                            +  
6 +     +  + +            
7            +         
8 +                    
9        +  +           
10 + +     +      +      +       +  
11      +             +       +  
12                    Epilepsy 
13 +  +         +         
14                   + Hemivertebra Th 6; ventricle septum 
defect; open Ductus Botalli;  pulmonal 
stenosis 
15            +         
16   +        +  + + +  +  +       +  
17 +  + +    +     +      +       +  
18  +             +     Pyloric stenosis; pectus excavatum 
19 + +           +       Agenesis m. pectoralis: Poland anomaly 
left 
20 + +  +                        + Hemangiomas; cafe au lait spots on the 
thorax 
21 + +  +     +    +      +       +  
22                     
23 +  +    +      +               + Scoliosis; kyphosis; aplasia abdominal 
muscles; vertebra L5 defect; 
Trendelenburg sign 
24    + +  +      +      + Agenesis m. pectoralis: Poland anomaly 
right; mammary hypoplasia; aplasia 
abdominal muscles; adiposity 
25                   +       + Adiposity 
26 +   +         +      +       + Adiposity; hernia umbilicalis; phimosis 
preputium 
27  +    +         + +    Scoliosis; anisomelia; hemangiomas on 
the face 
28 +  + + +        + +   +   Scoliosis; high position right shoulder 
29 x x x x x x x x x x x x x x   x x x         X 
30                  +  Adiposity 
31  +                 +       + Hemangiomas on the face 
32  +                  Agenesis m. pectoralis, agenesis nipple; 
Poland anomaly right 
33                   +       +  
34   +          
 
     +       +  
35            +         
36                     
37                     
Total (%) 33 25 17 17 8 8 8 8 6 3 3 17 28 6 8 3 6 3 44  
A: brachydactyly, B: clinodactyly, C: campylodactyly, D: syndactyly, E: ectrodactyly, F: low set thumbs, G: hypoplasia phalanx, H: nail deformities, I: 
aplasia metacarpalia, J: hypoplasia metacarpalia, K: clenched hands, L: pes planus, M: atrophy distal legs, N: femur defect, O: hip defect, P: pes valgus, 
Q: arthrogryposis multiplex, R: aplasia metatarsalia. +: affected, x: no information, Ri; right, Le: left. 
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Abstract 
 
Objective: To characterize the neuropathology of hereditary congenital facial palsy. 
Methods.  The authors compared brainstem pathology of three members of one family with 
autosomal dominant congenital facial palsy to that in three age-matched controls. The 
neuropathologic findings of the familial patients were compared with those of patients with 
Möbius syndrome. Results: The authors observed a marked decrease in the number of 
neurons in the facial motor nucleus with corresponding small facial nerve remnants. In the 
patients with congenital facial palsy the number of facial motoneurons ranged between 280 
and 1,680 as compared to 5,030 and 8,700 for controls. No signs of neuronal degeneration 
or necrosis with neuronal loss, gliosis, or calcifications were present. There were no other 
abnormalities of the rhombencephalon and its associated structures. The corticospinal 
tracts were fully developed. In contrast, Möbius syndrome is part of a more complex 
congenital anomaly of the posterior fossa with hypoplasia of the entire brainstem, 
including the traversing long tracts, with signs of neuronal degeneration and other 
congenital brain abnormalities. Conclusion: Neuropathologic findings confirm clinical 
observations that hereditary congenital facial palsy and Möbius syndrome are two different 
entities with a different pathogenesis. 
  
Introduction 
 
In 1888, Möbius reported patients with congenital nonprogressive bilateral facial and 
abducens nerve palsy (238). A clear delineation of the Möbius syndrome has been 
hampered by varying definitions. Isolated congenital facial palsy and the extended 
phenotype of congenital facial palsy with ocular muscle weakness, with or without 
craniofacial dysmorphisms and congenital abnormalities of the extremities were criteria for 
the diagnosis of Möbius syndrome (239). Recently, we suggested facial palsy with 
impairment of ocular abduction as the primary criterion for Möbius syndrome (230). While 
dysfunction of other cranial nerves, orofacial malformations, limb malformations, and 
musculoskeletal system defects are associated features, we did not consider them (230). By 
restricting the definition, we excluded congenital facial palsy, and ascertained on clinical 
grounds that congenital facial palsy is a separate entity. 
 While unilateral facial palsy might be caused by an obstetric trauma, facial palsy in 
the absence of trauma, either uni- or bilateral, appears to be a genetic condition for which 
we have found two separate loci on 3q (221) and 10q (218). Moreover, in three unrelated 
patients congenital unilateral facial nerve palsy has been described as part of a wider 
syndrome on chromosome 22q11 (229). The pathogenesis of Möbius syndrome is unclear 
as hereditary cases are rare and most cases are sporadic (230). Two explanations have been 
proposed: a primary genetic (240;241) and a primary ischemic cause (242-244). 
Teratogenicity has been suggested as an important environmental possibly secondary 
factor in both explanations (245). The postulated pathogenetic mechanisms in Möbius 
syndrome are based on limited pathologic observations (246). Previously, we suggested, on 
clinical grounds, that Möbius syndrome is more than a cranial nerve or nuclear 
developmental disorder and that it could be viewed as a rhombencephalic developmental 
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disorder with variable severity, involving motor nuclei and axons, as well as traversing 
long tracts (230).  
 To investigate the hypothesis that hereditary congenital facial palsy and Möbius 
syndrome are two different entities, we studied the brainstem of three members of one 
family with autosomal dominant congenital facial palsy, and compared these findings with 
those of patients with Möbius syndrome. 
 
Methods 
 
In a family with autosomal dominant congenital, nonprogressive facial palsy, either uni- or 
bilateral (221), three affected female members died: two of them, sisters, at the ages of 88 
(Patient 1; II-4 (221)) and 86 years (Patient 2; II-6 (221)), due to no specific cause. The 
third case, a grand-daughter of patient 2, died suddenly because of an undiagnosed acute 
bacterial meningitis, at the age of 41 years (Patient 3; IV-6 (221)). Patients 1 and 2 
demonstrated a bilateral congenital facial paresis; in Patient 1 the left side was more 
affected than the right side and in Patient 2 the right side was more affected than the left 
side. Patient 3 showed a congenital right-sided facial palsy. From our neuropathologic 
archive, we randomly selected three age-matched control subjects who died without 
clinical evidence of brainstem pathology. 
 Furthermore, a sporadic patient with Möbius syndrome, a girl born at 37 weeks after 
an uneventful pregnancy, died at the age of 11 days due to severe primary respiratory 
dysfunction. This patient demonstrated facial diplegia, horizontal gaze palsy, oral 
dysfunction, craniofacial and extremity malformations and severe muscle hypotonia (Case 
33 (230)).  
 The brains of all subjects were fixed in 10% phosphate-buffered formalin for routine 
paraffin sectioning. In addition to routine sampling, the entire brainstem from the 
mesencephalon through the medulla oblongata was blocked into 5 mm thick transverse 
slices for hematoxylin-eosin sectioning. The brainstem was serially cut into 8 µm thick 
sections that were stained with hematoxylin-eosin, Luxol fast blue-hematoxylin-eosin, and 
cresyl violet. The number of cells in each facial nucleus was estimated by counting the 
distinct nucleoli of facial motoneurons present in every tenth section and by multiplying 
the number obtained by 10 (307).   
 
Results 
 
In all familial cases, neither cerebral nor cerebellar hemispheres showed obvious 
pathologic changes, except for evidence of an acute bacterial meningitis in Patient 3. The 
brainstem was macroscopically normal, and no hypoplasia or malformation of the 
rhombencephalon were observed. The corticospinal long tracts were fully developed. In the 
sporadic patient, the cerebral hemispheres and the cerebellum were normal. The brainstem 
(figure 1) was asymmetric and hypoplastic with dysplastic, centrally situated inferior 
olivary nuclei and dysplastic pyramidal tracts which failed to decussate (308).  
 In the familial cases, on sectioning the brainstem, all pairs of cranial nerves were 
identified and appeared, with the exception of the seventh, to be fully developed. 
Microscopic examination of the facial nuclei and nerves revealed the following changes.  
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 Patient 1 (figure 2) showed bilaterally a decrease in number of neurons with 
preservation of a few normal neurons which lay scattered in the region of the seventh 
motor nucleus, the left side being more affected than the right side (table 1: left 520, and 
right 950 motoneurons). Both facial nerves consisted of a few fine fibers only. Patient 2 
(figure 3) demonstrated a decreased number of facial neurons on both sides, the right side 
being more affected than the left side (see table 1: left 960, right 600 motoneurons).  
 
Figure 1. Sporadic patient with 
Möbius syndrome. (A) At the level 
of the upper medulla oblongata 
malformations in the long tracts 
and in other nuclei than the facial 
nuclei are present (LFB-HE-
stain). The inferior olives (IO) on 
both sides meet each other in the 
midline, above the dysplastic 
pyramids with on the left side one 
large pyramid and on the right 
side several bundles. Several 
areas of destruction of tegmental 
nuclei with calcifications are 
present (arrows). (B) Detail in 
box with microcalcifications, 
gliosis and encrusted neurons 
(arrows; hematoxylin-eosinstain).  
Color figure  available in 
Appendix. 
 
 
 
 
 
 
 
 
 
 
The intramedullary fiber tract of both facial nerves was also underdeveloped. In Patient 3 
(figure 4), an evident decrease in the number of neurons in the right facial motor nucleus 
was present (see table 1: 280 motoneurons). Corresponding to the decrease in the number 
of cells in the facial nuclei, the roots of the right facial nerve were only sparsely developed. 
The left seventh motor nucleus and nerve apparently looked normal, but the facial motor 
nucleus contained only 1,680 neurons whereas neuron counts in the three controls varied 
from 5,030 to 8,700 (see table 1) within the range of 4,500 to 9,460 described before.14 In 
the sporadic case, we found neuronal loss, gliosis and microcalcifications in the 
paramedian tegmentum at the junction between the lower pons and the medulla oblongata 
but also more ventrally in the medulla oblongata, affecting the medial reticular nuclei, the 
VIth, VIIth, and XIIth cranial nerve nuclei. Additionally, many other malformations were 
present in this Möbius patient (table 2).  
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Figure 2. (A) Patient 1 with asymmetric, bilateral facial palsy (Luxol fast blue-hematoxylin-eosin stain; LFB-HE). 
(B, C) Detail in boxes with a marked decrease in number of neurons bilaterally in motor facial nucleus, with a 
few normal neurons preserved, the left side (B) being more affected than the right side (cresyl violet stain). Color 
figure  available in Appendix. 
 
 
 
 
Figure 3. (A) Patient 2 with asymmetric, bilateral facial palsy (LFB-HE). (B, C) Detail facial nucleus in boxes 
with a marked decrease in number of neurons in both facial motor nuclei, the right side (C) being more affected 
than the left side (cresyl violet stain). Color figure  available in Appendix. 
 
 
 
 
Figure 4. (A) Patient 3 with right-sided facial palsy (LFB-HE). (B, C) Detail in boxes: on the left side (B) normal 
facial neurons, on the right side (C) a decrease in number of neurons in the facial motor nucleus (cresyl violet 
stain). Color figure  available in Appendix. 
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Table 1. Neuron counts in the VIIth cranial nerve nuclei in three familial patients with 
hereditary congenital facial palsy and three age-matched controls. 
 
VIIth cranial nerve nuclei  Clinical characteristics  
Left Right  
Patients    
1  520 950 Bilateral congenital facial paresis with the left side being more 
affected than the right side 
2 960 600 Bilateral facial paresis from birth, the right side being more 
affected than the left side 
3 1,680 280 Congenital right-sided facial palsy 
Controls    
1  7,320 8,170 No facial nerve palsy 
2  7,090 8,700 No facial nerve palsy 
3  5,030 5,940 No facial nerve palsy 
 
Discussion 
 
To date, this is the first neuropathologic study of hereditary congenital facial palsy in 
several cases from one family; only five neuropathologic studies on sporadic congenital 
facial palsy have been reported (309-313). 
 In the clinical and genetic literature, a long-standing discussion exists about whether 
congenital facial palsy and Möbius syndrome are one and the same entity (314). 
Congenital facial palsy, both with and without ocular muscle weakness, appears in the 
literature as the criterion for the diagnosis of Möbius syndrome (239). Recently, we 
suggested congenital facial palsy with impairment of ocular abduction as the primary 
criterion for Möbius syndrome (230). By restricting the definition, we excluded congenital 
facial palsy.  
 Obviously, Möbius syndrome is unlikely to be a single entity, as in the limited 
pathologic observations in patients classified as having Möbius syndrome rather different 
lesions have been described; four groups of pathology have been categorized (see table 2) 
(246). Group I is characterized by hypoplasia of cranial nerve nuclei and is probably a 
result of rhombomeric maldevelopment. Group II includes neuronal loss and evidence of 
neuronal degeneration possibly secondary to a primary physical defect in the peripheral 
part of the facial nerve. Group III demonstrates, in addition to a decreased number of 
neurons and degeneration, focal necrosis with gliosis and calcifications in the region of the 
tegmentum of the lower pons and medulla where brainstem nuclei are located. These 
findings may be due to vascular insufficiency (242-244). However, calcifications in cases 
with Möbius syndrome equally support the concept of a maldevelopmental pathogenesis, 
as occurs in other developmental disorders (258). No mention is made of descending tract 
degeneration in this group. Group IV consists of primary myopathic changes without 
lesions in the cranial nerve nuclei or nerves.  
 The pathologic findings in our patients with hereditary congenital facial palsy consist 
of hypoplasia of the facial motor nuclei and nerves. No brainstem hypoplasia or 
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maldevelopment of the long tracts, such as the corticospinal tracts were observed, which is 
in line with the absence of clinical signs of involvement of these tracts. In contrast, all our 
cases with Möbius syndrome, forming a spectrum, ranging from the severest affected 
patients with tegmental calcifications whether or not associated with marked brainstem 
hypoplasia, patients with brainstem hypoplasia to cases without brainstem hypoplasia, 
show clumsiness, i.e. lack of fine motor skills, poor coordination, and poor balance 
performance. The degree of clumsiness is greater than could be explained by foot and hand 
deformities, and is probably the result of hypoplasia of of either the corticospinal or 
corticopontocerebellar tracts, or of hypoplasia of the cerebellum (230). Except for two 
reports of Möbius patients and progressive spastic paresis (315;316), no mention is made 
in the literature about involvement of the long tracts in Möbius syndrome. We found 
support for our long tract hypothesis in two cases with Möbius syndrome who have been 
described previously (317), and in the present sporadic case in whom the architecture of 
the entire brainstem, including part of the long tracts, was thoroughly affected by 
dysgenesis, degeneration and necrosis (see figure 1). The corticospinal tracts were 
dysplastic and failed to decussate (308). Recently, in patients with horizontal gaze palsy 
with progressive scoliosis (HGPPS), the gene ROBO3, which encodes an axon-guidance 
protein that is required for hindbrain axon midline crossing, has been identified (176).  
 Our pathologic findings showed conclusively that in hereditary congenital 
nonprogressive facial palsy a central defect is crucial, and that this defect is due to a 
developmental hypoplasia limited to the facial motor nuclei, rather than to a primary 
developmental disorder of the entire lower brainstem including traversing long tracts, or to 
acquired degeneration or atrophy of the cranial nuclei. A primary ischemic process in the 
brainstem, a primary developmental disorder of the facial muscle, and a primary defect in 
the periphery of the facial nerve could be excluded as the primary mechanism of 
pathogenesis. This nuclear maldevelopment may also be the pathogenetic mechanism in 
sporadic patients with uni- or bilateral congenital facial palsy, as demonstrated in the case 
of Richter (312). The great majority of cases of congenital facial palsy, especially 
unilateral, are, however, the consequence of antepartum or intrapartum injury to the facial 
nerve or nucleus (252;318), and might be misnamed in some instances as having Möbius 
syndrome (309-311;313) The neuropathologic observations in our familial cases could be 
compared with the pathologic findings in cases of Group I (246). Obviously, both the 
extent of structures involved and the severity of involvement, which is in accordance with 
the clinical heterogeneity, is far greater in cases with an extended phenotype of congenital 
facial palsy than in cases with isolated congenital facial palsy (see table 2). Much more 
striking is the difference between pathologic findings in our familial cases compared to the 
findings in our present sporadic case with Möbius syndrome, which can be classified into 
Group III (246) and demonstrated contiguous destruction of the entire brainstem including 
the traversing long tracts. 
 In hereditary congenital facial palsy, a primary disorder of the fourth rhombomere has 
been suggested since facial motoneurons arise in this rhombomere (319). Each 
rhombomere is characterized by a unique combination of Hox genes (17;320;321) The 
Hoxb1 gene is expressed only in the fourth rhombomere. Mice with targeted disruption of 
Hoxb1 fail to form the facial motor nucleus (322). In other mouse models, such as the 
Kreisler mouse (323) and Krox20-/- mice (87), rhombomeres 5 and 6, and 3 and 5 are 
absent, resulting in more extensive patterns of absence of brainstem motoneurons. In 
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Kreisler, the abducens nucleus and visceromotor, parasympathic motoneurons of the facial 
nerve, both formed in the fifth rhombomere, are absent but facial motoneurons are present. 
In Krox20-/- mutants, the abducens nucleus and the facial visceromotoneurons are absent, 
whereas the branchiomotor facial nucleus is hypoplastic. In the linkage intervals for 
hereditary congenital facial palsy on chromosomes 3 (221) and 10 (218), we investigated 
two human orthologs of genes that show involvement in Hox signaling; GATA2 at 
chromosome 3q21, and EGR2 at chromosome 10q21.3. GATA2 expression is restricted to 
rhombomere 4 during murine embryology, and its expression is directly regulated by 
Hoxb1 (324). Failure to express GATA2 during murine development abolishes the 
downstream expression of GATA3, and results in a phenotype similar to the Hoxb1 knock-
out mouse. EGR2 is the human ortholog for murine Krox20, a gene regulating the 
expression of several Hox genes involved in hindbrain development, including Hoxa2, 
Hoxb2 and Hoxb3 (91;325;326). EGR2 was, therefore, considered to be an excellent 
candidate gene for hereditary congenital facial palsy, even though it was positioned just 
outside the linkage interval. However, sequence analysis of the GATA2 and EGR2 genes 
in members from the corresponding families did not yield causative mutations (222), and 
so these genes are not causally involved in hereditary congenital facial palsy. 
 This report strengthens the brainstem pathogenetic mechanism in congenital facial 
palsy, one of the disorders recently defined as congenital cranial dysinnervation disorders 
(CCDD) (177). The CCDDSs encompass congenital, nonprogressive, sporadic or familial 
abnormalities of cranial musculature that result from developmental abnormalities of, or 
the complete absence of, one or more cranial nerves with primary or secondary muscle 
dysinnervation. Probably the same developmental mechanism is involved in cases of 
Möbius syndrome; however, in Möbius syndrome a developmental defect of the entire 
lower brainstem is implied with possibly different mechanisms leading to a similar 
phenotype.  
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Table 2.  Neuropathological findings of cranial nerve nuclei, according to the classification 
of Towfighi(246), in cases of cranial nerve palsies in which congenital facial weakness is 
the prime feature and are classified as having Möbius syndrome.   
 
 Author Affected cranial 
 nerve nuclei 
Other malformations 
I: Hypoplasia of cranial 
nerve nuclei 
Heubner(315) 
 
 
Spatz and Ullrich(327) 
Phillips et al.(328) 
Richter(312) 
Nardelli et al.(316) 
 
 
 
 
Sudarshan and Goldie(313) 
 
Harding and Copp(329) 
 
Tran et al.(330) 
Lengyel et al.(275) 
6,7,12 
 
 
3,4,6,7 
6 
7 
All* 
 
 
 
 
All* 
 
7,12  
 
3,7,10,12 
3,5,6,7,12 
Asymmetric hypoplastic brainstem, 
dysplastic inferior olivary nucleus 
and pyramid 
Hypoplastic brainstem 
- 
- 
Hypoplastic brainstem, absent 
olfactory bulbs, hippocampal 
abnormalities, hypoplastic corpus 
callosum, cerebellum, absent pyra-
mids 
Unremarkable gross brain 
examination 
Hypoplastic inferior olivary 
nucleus 
- 
Hypoplastic brainstem 
II: Atrophy and active 
neuronal degeneration of 
cranial nerve nuclei 
Marfan(309) 
 
Rainy and Fowlers(310) 
 
Saito et al.(331) 
7 
 
7 
 
Not examined, 
(6,7)x 
Malformed temporal bone, facial 
muscles not examined 
Degeneration of facial nerve, 
normal facial muscles 
Disappearance of facial nerve in 
fallopian canal, facial muscles not 
examined 
III: Atrophy and active 
neuronal degeneration in 
the tegmentum of pons 
en medulla in the region 
of cranial nerve nuclei 
with focal necrosis  
Balint(332) 
Fényes(333) 
Riggs(334) 
Riggs(335) 
Riggs(335) 
 
Thakkar et al.(336) 
Thakkar et al.(336) 
Towfighi et al.(246) 
Lipson et al.(261) 
Lipson et al.(261) 
Wilson et al.(337) 
Wilson et al.(337) 
Sudarshan and Goldie(313) 
 
Kuhn et al.(338) 
 
St.Charles et al.(243) 
D’Cruz et al.(339) 
(Jaradeh et al.(266)) 
 
 
D’Cruz et al.(339) 
D’Cruz et al.(339) 
 
 
6,7 
6,7,9,10,12 
6,7,12 
6,7 
6,7 
 
5,6,7,8,10,12 
6,7 
6,7,12 
6,7,9,12 
3,6,7,9,12 
3,5,8 (6,7,9)x 
5 (7-12)x 
-,(7)x 
 
3,4,6,7,9,12 
 
3,4,6,7,10,12 
4,5,6,7,10 
 
 
 
6,7,10 
6,(7)x,9,10,11,12 
 
 
- 
- 
- 
- 
Abnormal vascular pattern in the 
midline of the pontine tegmentum 
Ventricular dilatation 
- 
Not mentioned 
Not mentioned 
Not mentioned 
- 
- 
Hypoplastic brainstem, genu facial 
nerve involved in tegmental 
necrosis, ventricular dilatation  
Hypoplastic brainstem and 
cerebellum 
Hypoplastic brainstem 
Hypoplastic brainstem, ventricular 
dilatation, capillary telangiectasia, 
reduced number of anterior horn 
cells 
Hypoplastic brainstem 
Dysgenesis of brainstem architec-
ture, caudal displacement of 
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D’Cruz et al.(339) 
 
Cortez and Kinney(340) 
 
Cortez and Kinney(340) 
 
Yoon et al.(341) 
 
 
Lammens et al.(317) 
 
 
 
Lammens et al.(317) 
Tran et al.(330) 
Peleg et al.(342) 
 
 
 
Present case 
 
6,(7)x,9,12 
 
6,7,12 
 
6,7,9,10,11,12 
 
6,7,10,12 
 
 
6,7,9,10,12 
 
 
 
6,(7)x,10,12 
3,7,10,12 
3-12 
 
 
 
6,7,12 
colliculus inferior and olive inferior 
- 
 
Hypoplastic inferior olivary 
nucleus, tegmental necrosis 
Hypoplastic brainstem and inferior 
olivary nucleus, tegmental necrosis 
Hypoplastic brainstem and inferior 
olivary nucleus, capillary 
telangiectasia 
Hypoplastic brainstem and 
cerebellar hemisphere, atrophic 
tegmentum, dysplastic inferior 
olivary nucleus and dentate nucleus  
- 
- 
Gliosis and calcifications in medial 
inferior olive and dentate nucleus, 
thalamic nuclei, basal ganglia, 
anterior horns and lateral columns 
Aberrant, thick cochlear nerve, 
absent abducens nerves. 
Intramedullary, some facial fibers 
joining the cochlear nerves, normal 
3rd and 5th cranial nerve roots. Small 
abducens nuclei, small cell groups 
reminiscent of the facial motor 
nuclei. Asymmetric and 
hypoplastic brainstem, dysplastic, 
centrally situated inferior olivary 
nucleus and dysplastic 
asymmetrical pyramidal formations 
with absent decussating of 
pyramidal tracts, dysplastic medial 
lemnisci.. 
IV: Unremarkable 
cranial nerve nuclei 
Neurath(311) 
Wallis(343) 
Pitner et al.(344) 
-,(7)x 
-,(3,5,6,7)x 
-,(5,6,7,9,12)x 
- 
- 
Dysplastic muscles, absent inferior 
olivary nucleus, hypoplastic 
cerebellar hemisphere 
 
-: Not affected. *: All cranial nerve nuclei at the pontine and medullary level. x: Cranial 
nerve nuclei innervating the clinically affected muscles.  
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EDITORMöbius syndrome (MBS, MIM 157900) is a rare congenital disorder 
characterised by paralysis of the facial nerve. This paralysis may be complete or partial and 
unilateral or bilateral. Other cranial nerves are often implicated, most frequently the 
abducens and hypoglossal nerve. Limb malformations and facial dysmorfisms occur 
frequently. Features seen less often in MBS are structural anomalies of the ear, defective 
branchial musculature (Poland syndrome, MIM 173800) and mild mental retardation (218). 
Although Möbius syndrome usually occurs in isolated cases, familial recurrence has been 
reported. Patterns of inheritance observed in affected families suggest different modes of 
inheritance for the syndrome, ranging from autosomal recessive to autosomal dominant 
and X-linked.  
 To date, 4 genetic loci for MBS have been described. In 1977 a reciprocal 
translocation of 13q12.2-13 was identified, co-segregating with the disease in a three-
generation MBS family (232). Slee et al. reported a MBS patient with a deletion of 
chromosome 13q12.2 in 1991(233). Therefore chromosome 13q12.2-q13 is thought to 
harbour a gene for MBS (MBS1). We identified two additional loci for MBS, MBS2 at 
3q21-q22 (221), and MBS3 at 10q21 (218), in two large Dutch families with a mild 
Möbius phenotype, co-segregating in an autosomal dominant fashion with reduced 
penetrance. A fourth locus harbouring a gene for MBS on chromosome 1p22 was inferred 
on two reports. Donahue et al.(234) identified a t(1;11)(p22;p13) translocation in a patient 
with Möbius syndrome. The 1p22 locus was confirmed by a t(1;2)(p22.3;q21.1) 
translocation in a patient with Möbius-like syndrome, reported by Nishikawa and 
colleagues.(235) All these data combined prove genetic heterogeneity for MBS.  
 Although no conclusive evidence has been gathered so far, two modes of action have 
been postulated explaining the etiology of MBS. Firstly, a primary metameric defect in the 
brain stem nuclei in the region of the tegmentum could result in MBS. Secondly, an 
ischemic process resulting from an interruption of the vascular supply of the brainstem and 
other structures during early foetal development could be causative (218). In line with 
these hypotheses, different genetic defects in a broad range of processes underlying 
neurogenesis, axonal outgrowth or angiogenesis could result in the features observed in 
Möbius syndrome.  
 In order to identify candidate genes for Möbius syndrome we directed our efforts at 
genes included in the MBS2 and MBS3 loci, that could play a role in the development of 
the hindbrain, the guidance of axons, and angiogenesis. Linkage analysis on additional 
members of the MBS2 linked family (221) enabled us to reduce the MBS2 critical region 
to a 4.9 cM region between the markers D3S1589 and ACPP. Our mutation analysis 
included the human prostaglandin transporter (PGT) gene and the gene encoding the 
GATA-binding protein 2 (GATA2) transcription factor at the MBS2 locus, and the Early 
Growth Response 2 (EGR2) gene at the MBS3 locus. Mutation analysis comprised direct 
sequencing of individuals from the relevant families (either MBS2 or MBS3), on an ABI-
PRISM 377 (EGR2) or 3700 DNA analyzer (GATA2, PGT), using BigDye terminator 
chemistry (Applied Biosystems). 
 PGT (or SLC21A2) was analysed because a correlation was suggested between the 
maternal use of a synthetic prostaglandin, Misoprostol, illegally used as an abortificant, 
and an increased incidence of Möbius syndrome in new-borns following failed abortion 
attempts (282;345;346). Primers for the amplification and direct sequencing of PGT are 
listed in table 1. Mutation analysis of the PGT gene in patients from the MBS2 linked 
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family revealed only one nucleotide change, in exon 9. This A to G nucleotide change 
(basepair 1269) results in the substitution of Threonine 396 for Alanine (numbering 
according to sequence data from Genbank accession number NM_005630). The nucleotide 
change did not co-segregate with the disease, and several individuals related by marriage 
also carried the A to G nucleotide change. Therefore this change in exon 9 can be classified 
as a polymorphism. No other changes were encountered in the coding sequence (cds) and 
flanking intronic sequences of PGT. Therefore it is unlikely that the PGT gene is involved 
in MBS2. 
 The second gene analysed at the MBS2 locus at 3q21-q22 is GATA2, a member of the 
GATA-binding protein family of transcription factors (347). This gene is an interesting 
candidate for two reasons: (1) GATA2 expression in the developing hindbrain is limited to 
rhombomere 4, an important structure for the development of the facial nerve(153), and (2) 
GATA2 expression is regulated by Hoxb-1, a homeobox domain protein that functions in 
patterning of the hindbrain (324). The Hoxb-1 knockout mouse shows a defect in the 
formation of the motor nucleus of the facial nerve, and is considered an appropriate animal 
model for Bell's palsy and Möbius syndrome (322). Primers were designed flanking the 7 
exons of GATA2 (2 alternatively used exons of the 5’UTR and 5 coding exons), shown in 
table 1. No nucleotide changes were found in the cds or splice sites in patients from the 
MBS2 linked family. This lack of mutations in the GATA2 gene suggests that this gene is 
not the causative gene for MBS2. 
The Early Growth Response 2 gene, coding for the EGR2 transcription factor, is located at 
10q21.3 near the MBS3 critical region. The EGR2 gene was included in the mutation 
analysis based on the function of the mouse orthologue Krox-20. Krox-20 is preferentially 
expressed in rhombomeres 3 and 5 in the developing hindbrain (348), embracing 
rhombomere 4. During brain development, Krox-20 regulates the expression of several 
homeobox proteins in rhombomeres 3 and 5 that are important for patterning of the 
hindbrain. Genes regulated by Krox-20 include Hoxa-2, Hoxb-2 and Hoxb-3 (91;325;326). 
As rhombomeres 4 and 5 are the site of origin of the majority of the cells that eventually 
make up the facial nerve (153), failure to express functional EGR2 could give rise to a 
Möbius phenotype. Although mutations in the EGR2 gene have been described in patients 
with congenital hypomyelinating neuropathy (CHN), and Charcot-Marie-Tooth type 1 
(CMT1) (349), allelism with MBS3 cannot be excluded. Primers were designed for 
amplification and direct sequencing of the EGR2 coding sequence and splice sites (table 1). 
No mutations were found in the coding sequence and splice sites of the EGR2 gene in 
patients from the MBS3 linked family. This suggests that the EGR2 gene is not involved in 
MBS3. 
 In summary, the lack of pathogenic mutations in the coding sequences and splice sites 
of the three genes investigated justifies the exclusion of these genes as candidate genes in 
MBS2 (PGT and GATA2) or MBS3 (EGR2).  
 In a future positional candidate gene approach, new candidate genes need to be 
considered for mutation analysis in MBS2 or MBS3 patients. As Möbius syndrome is a 
rare disorder, familial cases are hard to find. Additional familial Möbius syndrome patient 
material would be very useful, as this increases the chances of identifying causative 
mutations.  
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Table 1. Oligonucleotide sequences flanking each of the exons of the PGT, GATA2, and 
EGR2 genes. GATA2 has 2 alternatively used, non-coding, exons 1, we named these exon 
1a and 1b. Exon 2 of the EGR2 gene was divided into 8 amplicons (a-h) to facilitate PCR 
and subsequent sequencing. Amplification conditions are available upon request. 
 
Gene 
 
 
Forward 5’→3’ Reverse 5’→3’ Product 
(bp) 
   
 PGT    
Exon 1 GAGGGAGAGCGCGTTTCATC CGGGTGCCCAGCCGAAGG 351 
Exon 2 GCTTGTCGTCCAGAAACTCACG GGATCTTGTGGTCAGGGTGGTG 240 
Exon 3 TTCTCTGTGGGTGGGTGAGGACAG CCATTCCTTACCCCTTGAGGC 267 
Exon 4 GTGGAGACCAGCAAGCACTCTC GCTACATCAGGACCTCACCCATC 310 
Exon 5 CCTTTTCCAGCCATCTTATTTGCC TTCTCTGTTCTGATTGGATGAGGG 192 
Exon 6 AAATCAGTAAACTCCCCCTGATC TCCCTTTCTTCAACTCCATCAGG 130 
Exon 7 CGTGAACACTCACCCCTTTATTG GTCACTGTGCCAGCCCACC 149 
Exon 8 GGGGTTCTGCCAGAGCTTGAC GGGTGGCTGGAGTGCCTG 268 
Exon 9 TAGCCCACATGCAGTCCCAG AGTTAAGGAAGCAGGAAGGAAGATG 337 
Exon 10 TGGTCTTGCTTTGTTTGATTCCC GCCTATCCTGGAGCCGAGAAAC 306 
Exon 11 AATTTCCCCCTTTTTCCCTCC AGAAGCCACGCCCCAGACTC 238 
Exon 12 CTGCTGATTTCCTGTCTGTCTTTTC TTCTTGGGAAGAGGGGTCTTAGAC 122 
Exon 13 GCAGTTCCACCTGACCAGGG  TGGGACACACATACATGATGGG 193 
Exon 14 AGAGCCCCCTCCCTCACCAG  CAAGGTCCACTCTCTGGAGCAG 201 
GATA2   
 
Exon1a CGAGGCGCACTCTACCCCCA CAGAGTCCCCTCAAAGCTAG 207 
Exon1b CAGGCGGCTGGACCTGGTAG GCAAACGGACCACAGCGATTCG 532 
Exon2 CACCTCGTGGTGGGACTTTG GATTCCTGCGGATCCTACATC 430 
Exon3 GAGTCGTGATCTCAATGTCTG GAAACCAACACTGCCACCTC 837 
Exon4 TCCTGCCCAGGCTGTTGCAG AAATCTGGCCCGAAAGAATCTG 383 
Exon5 GATTTAGCCCTCCTTGACTG CAAGCTGGATCTTGTGGCTG 314 
Exon6 CTCAGCTTGACCTGCCTCTG GTGTCGGCTTCGGGAAATGC 460 
EGR2    
Exon1 AAGTGTGGAGGGCAAAAGGA ACGCGGCTTACCTCCGGC 299 
Exon2a TCCCCTTCCCCAGATGGCATG TGACGCTGGATGAGGCTGTG 248 
Exon2b GCTACCCAGAAGGCATAATC CGGAAGGAGGTGGTGGGTAG 300 
Exon2c CCCTTCTGCGTTCCTGTCAG CAGGGTAAAGTTACGGATTG 273 
Exon2d ACCCAGGTGTCTTCCCAATG GCAGGTGGTGTGGGTTATAG 306 
Exon2e CAATCCGTAACTTTACCCTG GGATGTGCCGTGTCAGCTCG 286 
Exon2f CGAGCTGACACGGCACATCC CTCCGCCAAGACTGCTGCTG 326 
Exon2g CGCAAGTACCCCAACAGACC GGTGGTCACTGCGGCTGAAG 186 
Exon2h ATCGGTGCCAGCCCCCTCTA TAGGTGGAAAGGGGGCAGTG 287 
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Abstract 
 
Hereditary congenital facial paresis (HCFP) belongs to the family of congenital cranial 
dysinnervation disorders, and is characterized by an isolated dysfunction of the facial nerve 
(nVII). While genetic defects have been identified for several members of this disease 
family, genes underlying congenital facial paresis and Möbius syndrome remain to be 
discovered. Here we focus on HCFP linked to chromosome 3q21-q22 and identify new 
candidate genes using expression analysis by means of RNA in situ hybridization during 
mouse embryogenesis. We selected 28 positional candidates, and identified seventeen 
genes with either undetectable expression levels during mouse development, ubiquitous 
expression, or expression in tissues not affected in HCFP, respectively. Additionally, seven 
genes were excluded by direct sequence, or reverse transciption PCR analysis. The 
remaining four genes (Klf15, Flj40083, Kiaa0779, and Podxl2) were found to be expressed 
at spatial and temporal positions during mouse development that correlate to HCFP regions 
in human, defining these genes as primary candidates in HCFP. 
 
Introduction 
 
Hereditary congenital facial paresis (HCFP) is transmitted as an autosomal dominant trait, 
characterized by the almost exclusive dysfunction of the facial nerve (nVII). HCFP is a 
member of the congenital cranial dysinnervation disorders (CCDDs), a disease family 
containing syndromes with abnormal motility of the eye, the eyelid, and/or facial 
movement (177). Genome-wide linkage mapping using two large Dutch HCFP families 
has identified loci at chromosome 3q21-q22 (221) and 10q21-q22 (218). Although several 
positional candidate genes selected from both loci have already been analysed, no causal 
relations between these genes and HCFP could be shown to date (222;350). The selection 
criteria for HCFP candidate genes included information available from private and public 
genome databases (Celera discovery system, NCBI, UCSC, Ensemble), and the literature, 
and were chosen based on 1) localization to the HCFP mapping intervals, 2) their inferred 
function (or that of gene family members) in development of the facial nerve or nucleus, or 
a more general function in the development of the hindbrain, 3) information on gene 
knock-out or knock-down effects in animal models showing facial nerve defects, and 4) 
expression of the gene transcript in the tissues affected in HCFP. 
 In this report, we focus on the HCFP locus at chromosome 3q21-q22 defined by the 
markers D3S1589 and ACPP (221;222). The region spans about 4.9 cM, and contains a 
predicted 127 transcripts. In order to select new candidate genes associated with HCFP we 
performed a systematic RNA in situ hybridisation analysis during mouse embryogenesis of 
genes mapped to the 3q locus. We selected 23 candidate genes for involvement in HCFP 
based on the selection criteria mentioned above. In addition, five genes were selected 
following a recent high-throughput screen for human disease genes in yeast, identifying 
new human proteins associated with mitochondrial function (351). These five yeast related 
genes where excluded by direct genomic sequencing in members of the linkage family, and 
two more genes were eliminated after RT-PCR analysis. Our RNA in situ hybridisation 
analysis of the remaining 21 genes identified four genes with expression patterns 
characteristic for (hind-)brain development, representing new candidate genes underlying 
HCFP. 
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Results 
 
Selection of genes for RNA in situ hybridisation 
At the time of selection, 127 individual transcripts had been identified in the linkage region 
for for HCFP on chromosome 3q21-q22. All 127 transcripts were analysed by translating 
BLAST (http://www.ncbi.nlm.nih.gov, to identify conserved protein domains, and to find 
possible protein families to which these transcripts belong. On the basis of three criteria, 
we selected 28 genes for closer examination (table 1); these genes were located in or near 
the loci for HCFP,  have an inferred function in development of the facial nerve / 
hindbrain, or are expressed in tissues affected in HCFP. The criterion for functional 
implication in facial nerve or hindbrain development was used less stringently, as several 
of the chosen genes were predictions without homology to known proteins. Genes 
containing one or several domains known to be involved in cell-cell contact, regulated cell 
death, and cell motility, but without designation to a protein family were also considered 
possible candidates. Homologous mouse genes for these transcripts were identified. 
 Five of the 28 genes (MRPL3, ATP2C1, PIK3R4, RAB7, and SELB) were analysed for 
nucleotide variations by direct sequencing in members from our HCFP family linked to 
chromosome 3q21-q22. For the yeast othologs of these genes, a metabolic phenotype was 
observed in a deletion screen (351). As energy expendature of neural cells is relatively 
high, we felt these genes to be good candidates, even prior to expression analysis. 
Unfortunately, no causative mutations, amenable to PCR amplification, could be identified 
in the coding regions and intron-exon boundaries of these genes. These genes were 
considered unlikely to be involvement in HCFP, and, therefore excluded from the RNA in 
situ hybridisation analysis.  
 We then proceeded to generate transcript specific RT-PCR products for the remaining 
23 genes from total RNA that had been isolated from juvenile mouse brain. In general, one 
primer was chosen in the 3’ region of the coding sequence, and one primer in the 3’UTR, 
in regions showing low sequence homology with other genes (confirmed by BLAST 
analysis). By inclusion of a part of the 3’UTR, we aimed to introduce more specificity of 
the probes, when compared to possible family members. With mouse gene specific primers 
(sequences available on request), we were able to amplify products for 21 of the 23 genes. 
Two transcripts, Cidec (FSP27-like) and the predicted Mgc34728 (no significant 
homologies) could not be amplified, even after RT-PCR with 45 extension cycles. These 
genes were excluded from the remainder of the analysis as they could not be amplified 
from our mouse brain RNA pool. Additionally, CIDEC has recently been linked to another 
region of chromosome 3, outside the linkage interval for HCFP. To verify the integrity of 
the RT-PCR products, the 21 amplicons were sequenced, showing correct amplification of 
the sequences reported in the databases. 
 
RNA in situ hybridisation during mouse embryogenesis 
The PCR products obtained from the RT-PCR were used as templates to synthesize 
Digoxigenin-labelled cRNA probes for in situ hybridisation. Expression was considered 
genuine only when the sense probe hybridised to adjacent sections showed no staining, or 
only very low intensity background staining of the entire section. Based on the resulting 
expression patterns we divided the genes into 4 groups: genes with 1) no detectable 
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expression, 2) ubiquitous expression, 3) expression in tissues not affected in HCFP, and 4) 
genes with restricted expression in the (hind-)brain during mouse embryogenesis.  
 
Genes without detectable expression during embryogenesis 
For genes that did not show detectable expression during mouse embryogenesis (between 
12.5 dpc and 18.5 dpc), the in situ hybridisation was repeated with a second probe, 
preferentially non-overlapping with the first (primer sequences available on request). When 
this dual probe approach did not yield a detectable expression pattern, we concluded that 
these genes were not expressed at the stages we investigated. In total, eight genes were 
categorised to this group (table 1). Because these genes do not appear to be expressed 
during (mouse) embryogenesis, it is unlikely that they are involved in HCFP. 
 
Ubiquitously expressed genes 
The genes belonging to group 2 showed ubiquitous expression, or expression in a large 
number of tissues (see table 1, and figure 1). One of these ubiquitously expressed genes, 
Rps20, has recently been positioned at chromosome 8q12.1, excluding it as a candidate for 
HCFP. The genes from group 2 appear to function in basic cellular processes, and are 
therefore probably indispensable for viable development. Involvement in HCFP is unlikely 
because a broader phenotype would be expected when either of these genes is mutated. 
 
 
Figure 1. Ubiquitously expressed genes. A) In a 12.5-dpc mouse embryo, Znf9 is expressed the highest in liver, 
which shows the darkest staining. B) Expression of Mcm2 in a 12.5-dpc mouse embryo. Abbreviations (all 
figures):  fb: forebrain, he: heart, li: liver, med: medulla oblongata, mb: midbrain, ne: neuroepithelium, sc: 
spinal cord, 4th: fourth ventricle, hb: hindbrain, ie: inner ear, kd: kidney, lj: lower jaw, lv: lateral ventricle, nc: 
nasal cavity, noe: non-olfactory epithelium, ole: olfactory epithelium, ad: adrenal gland, mc: meckels cartilage, 
pa: palate, ul: upper lip, uj: upper jaw. 4th: fourth ventricle, co: cochlea, drg: dorsal root ganglion, fn: facial 
nerve nucleus, g7: facial nerve ganglion, he: heart,  mf: mesencephalic flexure, n7: facial nerve, neco: neocortex, 
ob: olfactory bulb, sp: soft palate, tri: trigeminal ganglion, hv: hepatic vein, in: intestine, pf: pontine flexure, to: 
tongue, tri: trigeminal ganglion. Magnification A-B: 12.5X. Color figure available in appendix. 
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Genes expressed in non-HCFP affected tissues 
Group 3 genes are expressed preferentially in one or a small number of tissues, that are not 
associated with HCFP (table1, figure 2), and involvement in HCFP is therefore unlikely.  
 Flj13861, a predicted gene with homology to the X-linked zinc-finger transcription 
factor ZXDA, showed expression in the seminiferous tubules of the testis from 16.5 dpc 
onward. No other sites of expression were detected (not shown).   
 The gene CHST13, encoding the C4ST3 protein, was investigated because family 
members of the chondroitin sulfotransferase proteoglycan family have been implicated in 
neurite outgrowth, neural cell adhesion, neuronal migration, and neuron survival 
(352;353). At 12.5 dpc Chst13 was expressed exclusively in the liver (not shown). From 
14.5 dpc onward, additional expression was seen in kidney (cortical region) and in a 
selection of developing bones (Figures 2A and 2B). The bones forming the upper and 
lower jaw, the eye socket, the base of the skull and the dorsal part of the ribs expressed 
Chst13. At 18.5 dpc the high level of expression in the liver had completely vanished. 
Expression of Chst13 in the bones of the jaws (including the odontoblasts of the incisor 
teeth), base of the skull, and cortex of the kidney was still present (data no shown). No 
Chst13 expression was detectable in the mouse embryonic brain, contrary to expression of 
CHST13 in adult brain (352). 
 ABTB1, a gene encoding a protein with an ankyrin repeat and two BTB/POZ domains 
implicated in protein-protein interactions, was shown to be expressed in human fetal heart, 
brain, liver, and kidney by semi-quantitative RT-PCR (354). During mouse embryogenesis 
we found a markedly different expression pattern for the gene. A very low level of Abtb1 
expression was detected in the liver from 12.5 to 16.5 dpc (not shown). Additionally, at 
16.5 dpc high levels of Abtb1 expression were visible in the forebrain, limited to the lateral 
borders of the cerebral hemispheres (figure 2C). The expression was located in the 
intermediate zone of the developing neocortex, and displayed a gradient with highest 
expression in the lateral regions of the cortex, and low expression near the midline. This 
forebrain expression pattern of Abtb1 is strikingly similar to the expression pattern of the 
homeobox gene Emx2, that is involved in patterning of the dorsal telencephalon 
(Theil2002). Surprisingly, at 18.5 dpc brain specific expression of Abtb1 was completely 
lost, indicating tight temporal and spatial regulation of expression. No hindbrain expression 
of Abtb1 was detected.  
 Kiaa1257, a predicted gene showing no homology to any known genes, was 
expressed at a very low level in the choroid plexus of the lateral ventricle from 12.5 dpc, 
and in the cells adjacent to the central canal of the spinal cord (not shown). From 16.5 dpc 
expression was visible in the non-olfactory epithelium of the nasal cavity and the nasal 
pharynx, up to the point were the nasal and buccal pharynx join (Figure 2D), this 
expression was maintained at 18.5 dpc.  
 
Expression patterns of four new HCFP candidate genes 
The remaining four genes, Klf15, FLJ40083, Kiaa0779 and Podxl2, make up group 4. 
These genes show a spatial and temporal expression pattern in the (hind-)brain that 
matches the origin of developmental defects observed in HCFP patients.  
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Figure 2. Expression of transcripts in non-HCFP affected tissues. A) Expression of Chst13 in a 14.5-dpc mouse 
embryo (lower half). Arrows indicate clusters of cells in the kidney expressing Chst13. B) Chst13 expression in a 
14.5-dpc mouse embryo (head). Arrows indicate Chst13 expression in bones from the upper and lower jaw, and 
the eye socket. C) Expression of Abtb1 in a 16.5-dpc mouse embryo head. Expression is localised to the 
intermediate zone of the neocortex. D) Kiaa1257 expression in a 16.5-dpc mouse embryo. Arrows indicate 
expression in the non-olfactory epithelium of the nasal cavity, and in the nasal pharynx, up to the epiglossis. 
Magnification A,D: 12.5X, B,C : 25X. Color figure available in appendix. 
 
 KLF15 is a member of the Krüppel like protein family of transcriptional regulators, 
implicated in a large number of processes, including the differentiation of neuronal 
precursors (355), and refs therein). Several reports have shed light on the expression of 
human KLF15, and its murine ortholog Klf15 (356;357), in adult tissues, including liver, 
kidney, adipose tissue, brain, and muscle. This is the first report on the embryonic 
expression of Klf15. Starting 12.5 dpc, we detected Klf15 expression in the 
neuroepithelium of distinct brain regions (figure 3). The anterior expression limit of Klf15 
coincided with the anterior border of the midbrain, and the expression extended more 
caudally into the hindbrain and the spinal cord (figure 3A, and 3B). The expression was 
located near the midline of the embryo, in the floorplate of the neural tube. A faint staining 
also indicated Klf15 expression in the liver (not shown). At 14.5 dpc, the expression of 
Klf15 expanded to the neuroepithelium of the entire central nervous system, and more 
lateral from the midline. Staining in the ventricular zone of the neocortex, and the Anlage 
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of the hippocampus was much lighter than staining of cells in the midbrain and spinal cord 
neuroepithelium, suggestive of lower levels of Klf15 expression (figure 3C). The 
expression of Klf15 in the liver was maintained (figure 3D). In addition, small clusters of 
cells in the kidney, and the nasal epithelium expressed Klf15 (figure 3D, and 3E). At 16.5 
and 18.5 dpc, respectively, the pattern of Klf15 expression was identical to that at 14.5 dpc, 
with increased staining in the kidney (figure 3F). These data show a partial overlap of 
embryonic and adult expression of Klf15, as expression was present in the brain, liver, and 
kidney at both stages. However, expression of Klf15 in muscle, described before in adult 
mice  (357;358), was not detected during embryogenesis. In addition, we have shown that 
Klf15 is expressed in the neuroepithelium of the developing mouse brain, from a time point 
at which neural precursors start terminal differentiation. 
 FLJ40083 is a predicted protein with no homology to other proteins. We included the 
corresponding mouse gene in the RNA in situ experiment, to decide on the basis of 
expression if it would make a candidate for HCFP. The expression pattern of Flj40083 
showed a large overlap with Klf15 expression, with exclusive expression in the nervous 
system at early stages. At 12.5 dpc, Flj40083 expression was detectable in the 
neuroepithelium around the midbrain mesencephalic flexure and in the anterior part of the 
hindbrain, near the midline of the embryo (figure 4A, and 4B). At 14.5 dpc the expression 
had extended caudally along the midline, and was now detectable in midbrain, hindbrain, 
and spinal cord (figure 4C). In contrast to Klf15, Flj40083 showed no expression in the 
neuroepithelium of the neocortex and the Anlage of the hippocampus (compare figure 4C 
to figure 3C). Flj40083 expression at 16.5 and 18.5 dpc was comparable to 14.5 dpc, with 
the addition of expression in the non-olfactory epithelium of the nasal cavity and 
nasopharynx from 16.5 dpc (figure 4D).  
 The third gene, KIAA0779, showed partial homology to the nucleic acid binding zinc-
ribbon domain (49% identity in a 100 amino acid stretch), which has been shown to be 
involved in RNA and DNA binding and transcription elongation  (359;360). At 12.5 dpc, 
Kiaa0779 was expressed throughout the nervous system at a low level. Kiaa0779 
expressing cells were seen in the brain, the spinal cord, and all ganglia (figure 5A, and 5B). 
In the spinal cord, cells located at the ventral side of the neural tube showed the highest 
levels of Kiaa0779 expression (figure 5A). At 14.5 dpc, the cranial nerve ganglia showed 
higher levels of Kiaa0779 expression, including the facial nerve ganglion (figure 5C). In 
the hindbrain, a group of cells at the position of the facial nerve nucleus expressed 
Kiaa0779 at a higher level than the surrounding tissues (figure 5D), which was still 
prominent at 16.5 dpc (figure 5E). Additionally, the olfactory epithelium expressed 
Kiaa0779 (figure 5F). At 18.5 dpc, the levels of Kiaa0779 expression in the brain dropped 
considerably, and the distinct group of cells in the hindbrain could no longer be identified 
(not shown). The outmost layer of the olfactory bulb and the neocortex expressed a slightly 
higher level of Kiaa0779 than before (figure 5F, and not shown). 
 Podocalyxin-like 2 (PODXL2) is the fourth gene of group four. PODXL2 codes for 
the endoglycan protein, a member of the CD34/podocalyxin family of sialomucins (361). 
PODXL2 expression was investigated by Northern analysis of adult tissues, and was shown 
to be expressed most prominently in brain, but also in kidney, liver, and all tested 
haematopoietic and lymphoid tissues (361). Only one fetal tissue, liver, was present in this 
Northern analysis. In our experiments we also identified Podxl2 expression in the central 
and peripheral nervous system at all developmental stages investigated (including the 
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retina), with a lower level of expression in other tissues. The highest levels of Podxl2 
expression were seen in dorsal cells of the cerebellar primordium, the hindbrain and 
anterior part of the medulla oblongata and spinal cord (figure 6A). The neuroepithelium of 
the medulla showed no Podxl2 expression, whereas hindbrain neuroepithelium showed 
Podxl2 expression levels comparable to the deeper zone (figure 6B, arrows). The midbrain 
neuroepithelial cells also expressed Podxl2, but in other regions of the central nervous 
system the neuroepithelium was void of Podxl2 expressing cells (figure 6B, arrowheads). 
Podxl2 was also clearly expressed in the peripheral nervous system, including the ganglia 
of the cranial nerves (figure 6C). Additionally, from 14.5 dpc Podxl2 expression was 
detected in smooth muscle of several organs, including stomach, intestine, tongue, and 
bronchi (figure 6D, and not shown). These results are comparable to immuno-
histochemical staining of smooth muscle described before (361). From 14.5 dpc, 
expression in the olfactory epithelium and cortical region of the kidney were detected 
(figure 6E, and 6F). During later stages of embryonic development the distribution of 
Podxl2 remained unchanged, except that the level of Podxl2 expression in the dorsal side 
of the hindbrain and medulla was no longer increased (figure 6G). At this stage higher 
levels of expression were present in the cerebellum, the olfactory bulb, and several layers 
of the neocortex (figure 6G). 
 
Discussion 
 
Pathological studies performed on hindbrain tissues from HCFP patients revealed an 
isolated defect of the facial nerve nuclei and the facial nerves, making an initial patterning 
defect of the hindbrain in these patients unlikely (220). More likely, the HCFP phenotype 
is due to defects that occur during the final phase of hindbrain segmentation or  later 
events. At least three possible etiologies for HCFP can be envisioned: 1) insufficient cells 
from R4/R5 have committed to a facial nerve fate; 2) cells are not maintained properly 
during or after differentiation; and/or 3) cells do not migrate correctly and are eventually 
eliminated from the hindbrain (possibly by apoptotic pathways). Each of these three 
hypotheses would affect the correct development of facial nuclei, and nerves, which is 
supported by observations in tissues from HCFP patients (362). 
 The critical region for HCFP at chromosome 3q21-q22 spans 4.9 cM, and contains 
well over 6 million basepairs (222). As familial patient material for this syndrome is very 
rare, a refinement of the critical region by additional recombinants is not expected. The 
region contains 127 individual transcripts. By a traditional candidate gene approach we 
have excluded several candidate genes that are known to function in brain development, 
among which were GATA2, EGR2 (Krox-20 ortholog), and PLEXIN-D1 (222;350).  
 We have now combined the traditional positional candidate gene approach with the 
use of RNA in situ hybridisation, to select new candidate genes from this locus. We chose 
28 of the 127 genes in the region as most lilely candidates based on selection criteria 
mentioned above. Seven of these genes were excluded by sequence and RT-PCR analysis 
before we performed RNA in situ hybridisations. Of these, CIDEC, has recently been 
linked to chromosome 3p25.3 (UCSC genome browser, May 2004 freeze), and is no longer 
in the critical interval for HCFP. Our analysis of the remaining 21 genes showed no 
detectable expression patterns for eight genes (table1), making these genes less likely 
candidates underlying the pathology of HCFP. A further eight genes showed a ubiquitous 
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expression pattern or expression restricted to tissues not associated with HCFP (table1). 
Defects in these genes would most likely lead to different phenotypes than the specific 
defect seen in HCFP. The ubiquitously expressed Rps20 gene was excluded because it had 
been assigned to chromosome 8 (UCSC genome browser, May 2004 freeze). For four 
genes we found an embryonic expression pattern compatible with the phenotype/etiology 
of HCFP.  
 
 
 
Figure 3. Expression of Klf15 during mouse embryogenesis. A,B) Arrows indicate expression of Klf15 in the 
neuroepithelium of the mid- and hindbrain of a 12.5-dpc mouse embryo, respectively. C) Expression of Klf15 at 
14.5 dpc in the neuroepithelium of the entire central nervous system of a mouse embryo, arrows indicate 
markedly lower expression levels in the neuroepithelium of the forebrain. D) Expression of Klf15 at 14.5 dpc in 
liver and kidney. E) Arrows indicate Klf15 expression in the nasal cavity, in olfactory and non-olfactory 
epithelium of a 14.5-dpc mouse embryo. F) At 16.5 dpc, the levels of Klf15 expression in the mouse liver and 
kidney have significantly increased, as shown by a more intense blue staining. Magnification A-D: 12.5X, E,F: 
25X. Color figure available in appendix. 
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Figure 4. Expression of Flj40083 during mouse embryogenesis. A,B) Mouse brain expression of Flj40083 at 12.5 
dpc: the boxes show magnified sections of  the mid- and the hindbrain regions, respectively, with arrows 
indicating expression of Flj40083 in the neuroepithelium. C) Expression of Flj40083 in the neuroepithelium of the 
midbrain, and posterior into the hindbrain and spinal cord of a 16.5-dpc mouse embryo. D) Expression of 
Flj40083 in the nasal cavity, and nasopharynx at 16.5 dpc. Magnification A-C: 12.5X, D: 25X.Color figure 
available in appendix. 
 
 KLF15 is a member of the Krüppel-like factor protein family, and its function is still 
largely unknown. KLF15 has been shown to influence expression of various genes, 
including the kidney specific CLC-K1/2 genes (356), the insulin-sensitive glucose 
transporter gene GLUT4 (358), and AceCS2, a mitochondrial acetyl-CoA synthase gene 
(363). The last two reports suggest a role for KLF15 in cellular energy metabolism. A non-
functional KLF15 could lead to cell death during development, as a consequence of 
metabolic shortage. Cells with a high energy metabolism and dependency on glucose, such 
as neuronal cells, could be particularly vulnerable. Additionally, KLF15 might have a 
function in regulation of cell differentiation. Several KLFs play a role in the decision to 
switch from cell proliferation to cell cycle arrest / differentiation (364-367).  KLF7 is 
particularly interesting, as expression in motor neurons in the ventral horn starts at the 
moment when neuronal cells exit the cell cycle, and start to differentiate, in a manner 
similar to NeuroD (367). KLF7 expression during early brain development is located in the 
mantle zone, whereas the expression of KLF15 is uniquely located in the adjacent 
ventricular neuroepithelium of the mid and hindbrain at this stage. It can be postulated that 
KLF15 and KLF7 serve opposite roles: KLF15 in keeping neuronal precursor cells in a 
proliferative state in the neuroepithelium, and KLF7 in arresting the cell cycle and starting 
differentiation in the mantle zone. A lack of KLF15 function could thereby lead to a 
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decrease in the number of differentiating cells brought about by a premature exit of the cell 
cycle, and underdevelopment of the facial nuclei.  
 The second new candidate for HCFP is the FLJ40083 gene. The embryonic 
expression of murine Flj40083 shows a large overlap with the expression of Klf15. As 
there is no homology with any other protein, it is not possible to assign a functional 
characteristic to the protein. However, the time and place of expression are such that a role 
in the etiology of HCFP is possible. 
 
 
 
Figure 5. Expression of Kiaa0779 during mouse embryogenesis. A) Expression of Kiaa0779 in a 12.5-dpc mouse 
embryo. Arrows indicate higher level of expression on the ventral side of the spinal cord. 3B) Arrows indicate 
expression of Kiaa0779 in dorsal root ganglia of a 12.5-dpc mouse embryo. C) Mouse brain expression of 
Kiaa0779 at 14.5 dpc. The arrow indicates Kiaa0779 expression in the facial nerve ganglion, arrowheads 
indicate expression in the facial nerve. D, E) Expression of Kiaa0779 in the presumptive facial nucleus at 14.5 
and 16.5 dpc, respectively. Arrow(s) indicate cells at the correct spatial position to represent the facial nucleus, 
expressing a higher level of Kiaa0779 than the surrounding tissue. Arrowheads show expression of Kiaa0779 in 
the dorsal root ganglia. F) Expression of Kiaa0779 at 18.5 dpc in the olfactory epithelium indicated by arrows, 
and in the olfactory bulb.  Magnification A,C-E: 12.5X, B,F: 25X. Color figure available in appendix. 
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Figure 6. Expression of Podxl2 during mouse embryogenesis. A) Podxl2 expression in the neural tube of a 12.5-
dpc mouse embryo. B) Partial magnification of figure 6A, arrows indicate Podxl2 expression in anterior 
hindbrain neuroepithelial cells, arrowheads show neuroepithelium in posterior hindbrain/medulla void of Podxl2 
expression. C) Arrows indicate expression of Podxl2 in the facial nerve ganglion (fac), and the facial nerve (n7) 
of a 14.5-dpc mouse embryo. D) Expression of Podxl2 in smooth muscle cells of the 14.5-dpc mouse gutwall. E) 
Arrows indicate expression of Podxl2 in the olfactory epithelium of a 14.5-dpc mouse embryo. F) Light staining of 
the cortical region of the kidney, 16.5-dpc mouse embryo. G) Expression of Podxl2 in the brain of a 18.5-dpc 
mouse embryo. Expression is most prominent in the olfactory bulb, several layers of the neocortex and the 
cerebellum. Magnification A,D,E,G: 12.5X, C,F: 25X, B: 50X. Color figure available in appendix 
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 KIAA0779 is the third new candidate that emerged from our analysis. Kiaa0799 was 
expressed at a low level throughout the murine nervous system. A higher level of 
expression was present in a small group of cells in the hindbrain, that are at the correct 
position to represent the developing facial nucleus, and in the facial nerve ganglia. The 
protein product of KIAA0779 shows partial homology to a zinc ribbon domain, a nucleic 
acid binding domain implicated in RNA and DNA binding, and in transcriptional control 
(360;368). A defective function of KIAA0779 in transcriptional control during facial nerve 
development could lead to the HCFP phenotype. 
 The fourth new candidate gene for HCFP is Podocalyxin-like 2 (PODXL2), coding 
for the endoglycan protein, a member of the CD34 family. Podocalyxin functions primarily 
as an anti-adhesin in the kidney, maintaining the open filtration pathway between foot 
processes by charge repulsion (369). Members of the CD34 family have also been 
implicated in lymphocyte homing and inflammatory trafficking by interactions of 
carbohydrate structures on endothelial cells and L-selectins on leukocytes (370). 
Endoglycan is expected to be highly glycosylated in its extra-cellular domain, containing a 
dense O-linked carbohydrate (in the mucin domain) and four potential N-linked 
carbohydrates in the extra-cellular domain (361). This glycosylation, combined with a very 
acidic amino terminal domain, leads to interference of cell adhesion, both by steric 
hindrance and charge repulsion (369). Tissue-specific glycosylation has been shown to 
play an important role in the function of CD34 and podocalyxin, where expression of the 
appropriate glycoforms enables these proteins to promote the adhesion between 
lymphocytes and endothelial cells. A similar glycosylation dependent mechanism of cell 
movement is very important for the migration of neuronal cells during the development of 
the brain, and impairment of glycosylation has been shown to lead to several congenital 
brain defects (371). We suggest that endoglycan with its charged and highly glycosylated 
extra-cellular domain could serve a similar role during brain development, with a non-
functional protein leading to the observed phenotype in HCFP.  
 In conclusion, our in situ hybridisation studies thus identified four new candidate 
genes for HCFP among the 21 genes analysed. In addition, the expression pattern of some 
of the remaining 17 genes may be instrumental to link these to other inherited human 
disorders mapped to chromosome 3q21-q22.  
 
Materials and Methods 
 
Transcript data mining and sequence analysis 
We used the Celera discovery system (www.Celeradiscoverysystem.com), and the publicly 
available databases on the world wide web (NCBI Map Viewer, Ensembl Genome 
Browser, and  UCSC Human Genome Browser) to obtain information on the transcripts in 
the HCFP interval on chromosome 3q21-q22. Protein domains and protein family members 
were identified by subjecting the transcripts to a translating BLAST search (372;373). We 
selected 28 genes in total for further analysis. Twenty-three genes were selected for having 
either an implied function in nervous system development (or family members functioning 
in brain development), harbouring conserved protein domains suggestive of a role in brain 
development, or showing expression in brain (mostly adult tissues). The murine 
counterparts of these genes were identified in the syntenic mouse chromosome regions 
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(human 3q21-q22 vs. mouse chromosome 6D1 and 9F1), and confirmed by homology 
analysis (NCBI BLAST and Homologene). In addition, five genes were selected from the 
linkage interval based on their homology to a protein in Saccharomyces cerevisea. The 
yeast orthologues had been identified recently in a high-throughput deletion screen 
selecting for proteins associated with mitochondrial function (351). Exon-intron structure 
of these candidate genes was predicted using the Ensembl Genome Browser (MartView), 
PCR amplicons covering all predicted exons and intron-splice-junctions were designed 
(374), and consequently genomic DNA from members of the 3q21-q22 linked HCFP 
family was analyzed by dideoxynucleotide Sanger sequencing.     
 
Reverse Transcriptase PCR 
Total RNA was extracted from a 6-day old juvenile mouse brain, using RNAzol B 
according to the manufacturers protocol (Campro Scientific). For 23 candidate genes, 
excluding those that had been identified by the yeast deletion screen, we designed Reverse 
Transcriptase (RT)-PCR primers (table 2). The forward / reverse oriented primers were 
complemented by a T7 or T3 promoter sequence respectively at the 5’ end (T7 : 
TAATACGACTCACTATAGGG, T3: TAACCCTCACTAAAGGGA ). These sequences 
were subsequently used to drive T7- or T3-dependent cRNA synthesis in the DIG labelling 
reaction (see below). The length of the RT-PCR products ranged from 500 to 900 
basepairs. RT-PCR was performed using 250 ng of total RNA in a reaction with 20 pmol 
of either primer, using the OneStep RT-PCR kit (Qiagen), according to the manufacturers 
protocol. For Flj20871 and MGC34728, the standard reaction did not yield a product. The 
number of cycles was increased (up to 45 cycles per PCR), and buffer compositions 
altered, without producing a gene specific product. No further attempts were made to 
amplify these genes. 
 
Digoxigenin labelling of cRNA in situ hybridisation probes 
DIG-cRNA probes were generated by incubating 400 ng of RT-PCR product with: 2 µl 
10*DIG RNA labelling mix (ENZO), 2 µl T3 (antisense) or T7 (sense) dependent RNA 
polymerase (Roche), 2 µl 10 X Transcription buffer (Roche) and RNAse free H2O added to 
a final volume of 20 µl, at 37ºC for 2 h. After incubation, 2 µl 0.2 M EDTA (pH 8.0), was 
added to stop the reaction. The cRNA probe was ethanol precipitated, and dissolved in 100 
µl RNAse free H2O. Probe DIG concentrations were determined by dot blot analysis on 
Hybond N+ nylon membranes (Amersham) by comparison to control DIG-cRNA probe 
(Roche), and stored at -80ºC. 
 
RNA in situ hybridisation 
Mouse embryos were collected at various embryonic stages (12.5 dpc to 18.5 dpc), frozen 
on crushed dry ice, and stored at –80ºC. The embryos were embedded in Tissue-Tek® 
O.C.T. compound (Sakura), and sagitally cut into 16 µm sections at temperatures of -16 to 
-20ºC. Sections were collected on SuperFrost® Plus microscope slides (Menzel-Gläser). 
After quickly drying the sections, they were stored at -80ºC until further use. The 
digoxigenin labelled cRNA probes were then hybridised to the mouse tissue sections as 
follows: Samples were rapidly defrosted using a hot air blower, and fixed in 4 % 
paraformaldehyde in phosphate-buffered saline (PBS, pH7.4) for 10 minutes. Slides were 
washed 3 times for 3 minutes each in PBS, pH 7.4, and acetylated for 10 minutes in a 
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solution containing 3.3 ml triethanolamine, 0.438 ml 37% fuming HCl, 0.625 ml acetic 
anhydride, in a final volume of 250 ml H20. Slides were washed 3 times 5 minutes in PBS, 
and prehybridised for 2 h at room temperature (RT) with hybridisation mix (50 % 
deionised formamide, 5 X SSC, 5 X Denhardt’s solution, 250 µg/ml brewer’s yeast tRNA 
(Roche), and 500 µg/ml sonicated salmon sperm DNA (Sigma)). Subsequently, 150 µl 
hybridisation mix containing 400 ng/ml DIG labelled probe was pipetted onto the slides, 
and covered with a strip of self-sealing NESCO film (Omnilabo). Slides were incubated 
overnight at 72ºC, washed briefly at 72ºC in 2 X SSC, and then washed for 2 hours at 72ºC 
in 0.2 X SSC. Slides were allowed to cool, transferred to 0.2 X SSC at RT for 5 minutes, 
and subsequently transferred to buffer 1 (100 mM TrisHCl, pH 7.4, 150 mM NaCl). Slides 
were incubated for 1 h at RT with 10% heat inactivated foetal calf serum (FCS) in buffer 1, 
followed by overnight incubation at 4 ºC with 0.7 ml 1% heat inactivated FCS in buffer 1 
with 1:5000 diluted anti-Digoxigenin-AP, fab fragment from sheep (Roche) per slide. 
Slides were washed 3 times 5 minutes each in buffer 1, and 5 minutes in buffer 2 (100 mM 
TrisHCl, pH 9.5, 100 mM NaCl, 50 mM MgCl2), at RT. 1 ml of staining solution (200 µl 
of NBT-BCIP stock solution (Roche), 1 ml Levamisole (Sigma, 2.4 mg/ml), and 8.8 ml 
buffer 2 per 10 ml) was placed on the slides, and staining was allowed to take place for 6 h 
to overnight in a dark environment, afterwards the slides were washed once in T10E5 (10 
mM Tris, pH 8.0, and 5 mM EDTA) to stop the reaction. Slides were dehydrated (30, 50, 
70, 96 and 100 % ethanol for 1 minute each, followed by 2 times 3 minutes xylol) , and 
sealed using Entellan rapid mounting media (ProSciTech). Images were recorded on a 
Zeiss Axioskop2 plus microscope with a Sony power HAD DXC-950P 3CCD color video 
camera, using Grabstore 1.1 software, and electronically stored. 
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Remarks 
Phenotype in yeast deletion screen; excluded by direct sequencing 
Phenotype in yeast deletion screen; excluded by direct sequencing 
Phenotype in yeast deletion screen; excluded by direct sequencing 
Phenotype in yeast deletion screen; excluded by direct sequencing 
Phenotype in yeast deletion screen; excluded by direct sequencing 
Cell death inducing; no RT-PCR product from brain RNA,  now 3p25.3 
No significant homology; no RT-PCR product from brain RNA 
G protein-coupled receptor; n.e.d. 
Energy metabolism related; n.e.d. 
Chaperone for protein folding, involved in cell viability; n.e.d. 
Homology to brain-specific N-copine; n.e.d. 
Hormone release, influence on embryonic rat neurons; n.e.d. 
hypothetical DNA binding, DNA repair; n.e.d. 
Homology to Syndesmos (cell spreading, actin organization; n.e.d. 
Kelch domains, protein-protein interaction; n.e.d. 
DNA binding, transcriptional control; ubiquitous expression 
Murine 
homolog 
NM_013762 
NM_175025 
XM_135116 
NM_009005 
NM_023060 
NM_178373 
NM_177738 
NM_011906 
NM_172678 
NM_019964 
XM_135115 
NM_009426 
NM_025651 
NM_029385                
-- 
NM_013493 
Human 
accession 
number 
NM_007208 
NM_014382 
NM_014602 
NM_004637 
NM_021937 
NM_022094 
NM_152533 
NM_016372 
NM_014049 
NM_153330 
NM_130808 
NM_007117 
NM_014065 
NM_152395 
NM_207335 
NM_003418 
Gene  name 
MRPL3 
ATP2C1 
PIK3R4 
RAB7 
SELB 
CIDEC 
MGC34728 
GPR175 
ACAD9 
DNAJB8 
Copine 4 
TRH 
HT001 
NUDT16 
FLJ46299 
ZNF9 
Group 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
1 
1 
1 
1 
1 
1 
1 
1 
2 
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Expression remarks 
DNA replication, cell division ; ubiquitous expression 
(Methylated) DNA binding, transcritptional control; ubiquitous expression 
Protein synthesis; ubiquitous expression 
Protein synthesis, ubiquitous, assigned to chromosome 8q12.1! 
Homology to zinc-finger transcription factor ZXDA; expression in the seminiferous 
tubules of the testis from 16.5 dpc 
Family members in neural development; expressed in liver, kidney, facial bones, and 
dorsal portion of the ribs 
Implicated in protein-protein interactions; expression in liver up to 16.5 dpc, and lateral 
forebrain (only at 16.5 dpc) 
No significant homology; expressed in choroid plexus of the lateral ventricle, spinal 
cord neuroepithelium, and non-olfactory epithelium in nose / nasal pharynx 
Family of transcriptional regulators; early expression in midline neuro epithelium 
caudal to the esencephalic flexure, more lateral at later stages.  Additional faint staining 
in forebrain neuroepithelium, liver, kidney, and nasal epithelium. 
No significant homology; expression in midline neuroepithelium of mesencephalic 
flexure, and anterior hindbrain. Additional expression in non-olf. epithelium of nasal 
cavity and nasopharynx 
Homology with DNA/RNA binding zinc-ribbon domain; expression throughout 
nervous system, elevated in cells of the facial nucleus (14.5 dpc and 16.5 dpc). Also 
expressed in facial nerve ganglia 
Sialomucin family mebmer (glycosylated?); highly expressed in adult brain; expression 
in hindbrain neuroepithelium, and facial nerve ganglia. Additional expression in 
smooth muscle, kidney and olf. epithelium 
Murine 
homolog 
NM_008564 
NM_010774 
-- 
NM_026147 
NM_030260 
XM_355798 
NM_030251 
XM_485802 
NM_023184 
NM_173775 
XM_132843 
NM_176973 
Human 
accession 
number 
NM_004526 
NM_003925 
AC073021 
NM_001023 
NM_025112 
NM_152889 
NM_172027 
XM_371664 
NM_014079 
NM_182628 
NM_015008 
NM_015720 
Gene name 
MCM2 
MBD4 
RPL7-like 
RPS20 
FLJ13861 
CHST13 
ABTB1 
KIAA1257 
KLF15 
FLJ40083 
KIAA0779 
PODXL2 
Group 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
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Table 2. RT-PCR primers for the amplification of gene specific products for the murine 
orthologs of HCFP candidate genes. All forward primers contain a T7 sequence 
(TAATACGACTCACTATAGGG), reverse primers a T3 sequence 
(TAACCCTCACTAAAGGGA), to allow for T7/T3 dependent RNA synthesis in the DIG 
labeling reactions. 
 
Gene name 
 
Orientation  Nucleotide sequence Product  
size (bp) 
Forward TAATACGACTCACTATAGGGCACAATCGTGGAGACAGAAG Cidec 
Reverse TAACCCTCACTAAAGGGATCCTCTAAGCTACCTGAGAG 
724 
Forward TAATACGACTCACTATAGGGGAAGCATCTGAGAGAAGACTG Mgc34728 
Reverse TAACCCTCACTAAAGGGAAAAGTTTATTGGTGCTGTATGG 
673 
Forward TAATACGACTCACTATAGGGCAGCTGAGGATTTCAACATC Gpr175 
Reverse TAACCCTCACTAAAGGGATCCCACACTAGAGCACAGG 
763 
Forward TAATACGACTCACTATAGGGCAGTGCCAACAAGCTTGAGG  Acad9 
Reverse TAACCCTCACTAAAGGGAGCTGGTACTTCCTTCCTTCC 
612 
Forward TAATACGACTCACTATAGGGTTTGCGTTGGCACCCTGAC Dnajb8 
Reverse TAACCCTCACTAAAGGGAGTCACTTGTCCACCCTCATG 
640 
Forward TAATACGACTCACTATAGGGTCCTTCGAGACATCGTCCAG Copine 4 
Reverse TAACCCTCACTAAAGGGAAAAATCTCTCATCCTATAGGAG 
633 
Forward TAATACGACTCACTATAGGGTCTTGGAAAGCTCTGCAGAG Trh 
Reverse TAACCCTCACTAAAGGGACCAGGATGCTGACGTTTCTC 
691 
Forward TAATACGACTCACTATAGGGGGTCAAACAGGTTGTCCTGG Ht001 
Reverse TAACCCTCACTAAAGGGAGCTTCAAGTGAGGTAAGAGAC 
782 
Forward TAATACGACTCACTATAGGGGCATCGGAAAGTGGAGCTC Nudt16 
Reverse TAACCCTCACTAAAGGGAGCAATAATGCCAGGATCCAG 
580 
Forward TAATACGACTCACTATAGGGCATTGGGAACAATTCTTCTGG Flj46299 
Reverse TAACCCTCACTAAAGGGAGTCAGCCATCATCTTTACTAC 
630 
Forward TAATACGACTCACTATAGGGTGTGGTGAGTCTGGTCATC Znf9 
Reverse TAACCCTCACTAAAGGGAACACTGCAAGTAAAGCTCAC 
531 
Forward TAATACGACTCACTATAGGGCCACATCGAGTCCATGATC Mcm2 
Reverse TAACCCTCACTAAAGGGAAAAGTCTGTCACCTGAACAC 
724 
Forward TAATACGACTCACTATAGGGCAGAGGAAATCAGATCGAAG Mbd4 
Reverse TAACCCTCACTAAAGGGAGCGACGCATGGGAAACTTC 
740 
Forward TAATACGACTCACTATAGGGGGAATTTCACAGAGTTGAAGG Rpl7-like 
Reverse TAACCCTCACTAAAGGGATGTTTATCTGGTCTTCCCTG 
695 
Forward TAATACGACTCACTATAGGGACGTGAAGTCGCTGGAGAAG Rps20 
Reverse TAACCCTCACTAAAGGGATCTGCTCTTTTCTAACCCAAC 
638 
Forward TAATACGACTCACTATAGGGCAGATGATTCACAGGCCATG Flj13861 
Reverse TAACCCTCACTAAAGGGAGCTCTTCTAGGACTTGTCAC 
756 
Forward TAATACGACTCACTATAGGGGCGACTACCTGACCTTTCTC Chst13 
Reverse TAACCCTCACTAAAGGGAGTCCTAGGAAGAAGCCTGAC 
823 
Forward TAATACGACTCACTATAGGGCTTGGACATCGGTGTAGAAC Abtb1 
Reverse TAACCCTCACTAAAGGGAATCTTGGCTATGCGCCAAAC 
678 
Forward TAATACGACTCACTATAGGGCGTCAATTCTACCACATTGAG Kiaa1257 
Reverse TAACCCTCACTAAAGGGAGTTAAGCTGCTCAACGATGG 
667 
Forward TAATACGACTCACTATAGGGTGCCTCAAGTGGTACCATCC Klf15 
Reverse TAACCCTCACTAAAGGGACAGCCATGGTGGCTCTGG 
650 
Forward TAATACGACTCACTATAGGGTGCTGGTGGATGCCAGAATG Flj40083 
Reverse TAACCCTCACTAAAGGGACCTTGGATGCATAGGTCATC 
566 
Forward TAATACGACTCACTATAGGGATGGAGCTGCAGCAGCAAC Kiaa0779 
Reverse TAACCCTCACTAAAGGGACTTCAGTGTGCTGCAGATTG 
604 
Forward TAATACGACTCACTATAGGGCTAACACCGTGGGACTCTAC Podlx2 
Reverse TAACCCTCACTAAAGGGACTGCATCTCCGACTGGCTG 
626 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
 
 
 
 
 
 
PLEXIN-D1, a novel plexin family member, is 
expressed in vascular endothelium and the central 
nervous system during mouse embryogenesis. 
 
 
 
van der Zwaag B, Hellemons AJ, Leenders WP, Burbach JP, Brunner HG, 
Padberg GW, van Bokhoven H. 
 
 
 
Dev Dyn. 2002 Nov;225(3):336-43. 
  
PLEXIN-D1 EXPRESSION DURING MOUSE EMBRYOGENESIS 
 101 
Abstract 
 
The genetic defect in Möbius syndrome 2 (MBS2, MIM 601471), a dominantly inherited 
disorder charaterised by paralysis of the facial nerve, is situated at chromosome 3q21-q22. 
We characterised the cDNA and predicted protein, and examined the expression pattern 
during mouse embryogenesis of a positional candidate gene, PLEXIN-D1 (PLXND1). The 
cDNA for PLXND1 is 7095 base pairs in length, coding for a predicted protein of 1925 
amino acids. The protein features all known domains of plexin family members, with the 
exception of the third Met related sequence (MRS). Northern analysis revealed a very low 
expression of PLXND1 in adult mouse and adult human tissues. To investigate the 
expression of PlxnD1 during embryogenesis, RNA in situ hybridisation was perfomed on 
mouse embryos from varying stages. This revealed expression of PlxnD1 in cells from the 
central nervous system (CNS) and in vascular endothelium. Early expression in the CNS is 
located in the ganglia, cortical plate of the cortex, and striatum. At later embryological 
stages, neural expression was also seen in the marginal zone of the cerebellum and several 
nerve nuclei. The expression in the vascular system resides solely in the endothelial cells of 
developing bloodvessels. Based on our results, we suggest that this unprecedented 
expression of a member of the plexin family in vascular endothelium could point towards a 
role in embyonic vasculogenesis.  
 
Introduction 
 
Accurate axonal guidance during embryogenesis is a crucial process for the correct 
formation and function of the nervous system. The path taken by developing axons is 
controlled by the concerted action of short and long range attractive and repulsive cues 
(375). A family of proteins with primarily repulsive action are the semaphorins (376;377). 
Over 30 semaphorins have been identified, and grouped into 8 subfamilies (317). The 
semaphorins are characterised by a conserved domain of about 500 amino acids, called the 
sema-domain (377). A special group of semaphorins are those comprising the class 3 
semaphorins. These secreted semaphorins posses potent growth cone collapse activity for a 
specific set of neurons (376;378;379).  
 Neuropilin-1 (NP1) and neuropilin-2 (NP2) have been shown to function as high 
affinity receptors for several class 3 semaphorins. Sema3A binds solely to NP1, whereas 
Sema3B, Sema3C, and Sema3F are capable of binding both to NP1 and NP2 (380). Several 
domains in neuropilins have been shown to be crucial for semaphorin binding and signal 
transduction. The complement binding (CUB) domain of neuropilins is essential for 
semaphorin binding, as was revealed by deletion studies of NP1 (381;382). Signal 
transduction following the binding of Sema3A is dependent on the presence of the 
juxtamembrane MAM (Meprin, A5, mu) domain of NP1 (382). The transmembrane region 
and the short cytoplasmatic tail of NP1 can be deleted without consequences for Sema3A 
signalling, indicating that it is not involved in Sema3A signalling (382). On their own, 
neuropilins are not capable of activating the intracellular pathways leading to growth cone 
collapse and redirection of axon growth. For this, an additional protein named plexin is 
necessary (383;384).  
 Plexins (PLXN) are large single pass transmembrane proteins with homology to the 
scatter factor receptors, encoded by the MET gene family (385). They are capable of 
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conveying axonal guidance cues from the outside of the cells into the cytoplasm (386). The 
family of plexins consists of 4 sub-families, classified PLXNA, -B, -C, -D (384). 
Drosophila melanogaster plexin A was shown to function as a receptor for Sema1A/B 
(386). PLXNC1, also named VESPR because of its viral origin, serves as a receptor for the 
virally encoded SemaVA (387). In vertebrates it was shown that PLXNB1 and PLXNC1 
are binding sites for Sema4D and Sema7A, respectively (384).  
 The dependency on plexins in semaphorin signalling was shown in several reports. 
Firstly, binding of Sema3A to a NP1/PLXNA1 complex was enhanced when compared to 
NP1 alone, and Sema3A-induced contraction of COS-7 cells was only seen when both NP-
1 and PLXNA1 were expressed in these cells (383). Secondly, over-expression of a mutant 
form of PLXNA1, with a deletion of its intracellular domain, was shown to inhibit the 
Sema3A induced response in dorsal root ganglion growth cones (383), and Xenopus laevis 
spinal axons (384). These experiments confirm that a Sema3-NP complex needs a 
functional plexin to operate as the signal transducing protein. 
 The intracellular cascade that follows the coupling of semaphorin and neuropilin to 
plexins is at present largely unknown. Efforts in this field of research point towards the 
involvement of small GTPases. In 1997 Jin et al. showed that a dominant negative form of 
Rac1 blocked the Sema3A-induced dorsal root ganglion and motorneuron growth cone 
collapse (388). It was also shown that the intracellular conserved domain of plexin-A1 has 
sequence homology to GTPase activating proteins (GAPs), and that mutation of two 
arginines, corresponding to conserved catalytic residues of Ras GAPs, results in an inactive 
plexin A1 (389). A mechanism for plexin B signalling to the actin cytoskeleton, dependent 
on two Rho family GTPases (Rac and Rho), was suggested by Driessens et al. (390). More 
recently, it has been shown that Drosophila plexin B mediates axonal guidance by the 
inhibition of activated Rac, and the simultaneous enhancement of RhoA signalling (391). 
Moreover, Drosophila plexin A associates with Off-track (Otk), a transmembrane protein 
with weak tyrosine kinase activity, to function downstream of Sema1A (392). The 
interaction of plexin A and Otk results in a repulsive signal, possibly by recruiting other, as 
yet unknown kinases in response to the Sema1A stimulus.  
 In our efforts to elucidate the molecular genetic cause of Möbius Syndrome (MBS, 
MIM 157900), a rare congenital disorder mainly characterised by paralysis of the 7th 
and/or 6th cranial nerve, we have investigated a novel plexin gene, PLEXIN D1 
(PLXND1), in the MBS2 critical region on chromosome 3q. We characterised the cDNA 
and predicted protein of PLXND1, and in addition we determined its expression pattern by 
Northern analysis in humans, and by Northern analysis and RNA in situ hybridisation in 
mice. Our data suggests a role for PLXND1 in the establishment of part of the neural as wel 
as the vascular systems during embryogenesis. This makes PLXND1 a good candidate gene 
for analysis in MBS, as this syndrome has been postulated to be caused by either a 
metameric defect in the tegmentum, or by an ischemic event leading to maldevelopment of 
the hindbrain (218). 
 
Results and Discussion 
 
PLXND1 in silico cloning and characterisation 
The mRNA for KIAA0620 (PLXND1) is listed in the GenBank database as an incomplete 
cDNA of 6754 bp (AB014520). In an effort to complete the cDNA sequence of PLXND1, 
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electronical 5' and 3' RACE experiments were performed. The analysis resulted in the 
addition of 341 basepairs to the 3'UTR,no additional basepairs were found at the 5’ end. 
The complete mRNA for PLXND1, 7095bp, has been submitted to Genbank, and is 
accessible as PLXND1 (accession number AY116661). PLXND1 is contained in BAC 
clone AC000380 (164 kb), and consists of 36 exons with the total intron/exon structure 
spanning just over 51 kb of genomic sequence. The genomic structure of PLXND1 can be 
viewed at the human genome draft sequence database (http://genome.cse.ucsc.edu), 
accession number AB014520.  
 The ATG codon at nucleotide position 181 qualifies as a translational starting point, 
as it matches the consensus sequence proposed by Kozak (393). The open reading frame 
(ORF) extends up to nucleotide 5958, where a TGA stop codon is encountered. A putative 
poly-adenylation signal is present at position 7032-7037 (AATAAA).  
 The 5775 nucleotide ORF codes for a predicted protein of 1925 amino-acids with a 
predicted molecular weight of 212 kDa (Figure 1). The first methionine is followed by a 
stretch of hydrophobic amino acids at position 30-46, comprising a cleavable membrane 
localisation signal sequence according to signalP prediction (394). Proteolitic cleavage at 
this site is predicted to generate a mature protein of 1879 amino acids, with a predicted 
molecular weight of 208 kDa. Hydropathy analysis of the amino acid sequence, according 
to the method of Kyte and Doolittle (395), suggests the presence of a single transmembrane 
region between residues 1273-1292. The transmembrane domain is directly followed by a 
set of hydrophilic residues (TKSRR, residues 1295-1299), possibly functioning as a 
cytoplasmic anchor. At position 1637-1643 the amino-acid sequence possesses a putative 
Rac binding site : NLTAHYK, almost identical to the sequence identified by Hu et al. 
(391). PLXND1 also posseses two highly conserved arginine residues at positions 1485 
and 1770. In PLXNA1 these two conserved arginine residues were positioned in a domain 
with homology to Ras GAPs, and were shown to be crucial for Sema3A induced collapse 
of COS-7 cells (389).  
 PLXND1 contains all the domains that are present in plexin family members: a sema-
domain, three Met-related sequences (MRS), three glycine/proline-rich motifs, a single 
transmembrane domain, and two highly conserved intracellular domains together known as 
the SEX-plexin (SP) domain (384). PLXND1 differs from other plexins in the third MRS 
motif, which contains only 6 of the 8 conserved cysteines normally encountered in a MRS. 
Figure 2 shows the protein domain structure of PLXND1 and the other plexin sub-families. 
 
Northern analysis of PLXND1 
To investigate the expression of PLXND1, Northern blot analysis was performed on adult 
human and mouse poly(A)+ RNA blots (Fig. 3), with PLXND1 probes. A single band of 
just over 7 Kb was seen on both blots. Expression of the mouse homologue of PLXND1 
(PlxnD1) in adult mouse tissues was highest in heart and liver, followed by intermediate 
levels of expression in lung, skeletal muscle and testis. Low levels of expression were seen 
in brain, and there was hardly any expression visible in kidney and spleen. The expression 
pattern in adult human tissues shows partial overlap with that in mice: highest levels of 
expression were seen in the heart and placenta, with moderate expression levels in skeletal 
muscle, thymus, liver and lung. PLXND1 showed low expression in kidney and small 
intestine, and very low expression levels were visible in brain, colon, spleen and peripheral 
blood leukocytes.  
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1
6 1
1 2 1
1 8 1
2 4 1
3 0 1
3 6 1
4 2 1
4 8 1
5 4 1
6 0 1
6 6 1
7 2 1
7 8 1
8 4 1
9 0 1
9 6 1
1 0 2 1
1 0 8 1
1 1 4 1
1 2 0 1
1 2 6 1
1 3 2 1
1 3 8 1
1 4 4 1
1 5 0 1
1 5 6 1
1 6 2 1
1 6 8 1
1 7 4 1
1 8 0 1
1 8 6 1
1 9 2 1
M A P R AA G G A P L S AR AA A A S P P PF Q T P P R C PV P LL L L L L L GA A R A G A LE I QR R F P S P T PT N
N F A L DG A A G T V Y LA AV N R L Y Q LS G A N L S L EA E AA V G P V P DS P L C H A PQ L PQ A S C E H P RR L
T D N Y NK I L Q L D P GQ GL V V V C G SI Y Q G F C Q LR R RG N I S A V AV R F P P A AP P AE P V T V F P SM L
N V A A NH P N A S T V GL VL P P A A G AG G S R L L V GA T YT G Y G S S FF P R N R S LE D HR F E N T P E IA I
R S L D TR G D L A K L FT FD L N P S D DN I L K I K Q GA K EQ H K L G F VS A F L H P SD P PP G A Q S Y A YL A
L N S E AR A G D K E S QA RS L L A R I CL P H G A G G DA K KL T E S Y I QL G L Q C A GG A GR G D L Y S R LV S
V F P A RE R L F A V F ER PQ G S P A A RA A P A A L C AF R FA D V R A A IR A A R T A CF V EP A P D V V A VL D
S V V Q GT G P A C E R KL NI Q L Q P E QL D C G A A H LQ H PL S I L Q P LK A T P V F RA P GL T S V A V A SV N
N Y T A VF L G T V N G RL LK I N L N E SM Q V V S R R VV T VA Y G E P V HH V M Q F D PA D SV Y L Y L M T SH Q
M A R V KV A A C N V H ST CG D C V G A AD A Y C G W C AL E TR C T L Q Q DC T N S S Q QH F WT S A S E G P SR C
P A M T VL P S E I D V RQ EY P G M I L QI S G S L P S LS G ME M A C D Y GN N I R T V AR V PG P A F G H Q IA Y
C N L L PR D Q F P P F PP NQ D H V T V EM S V R V N G RN I VK A N F T I YD C S R T A QV Y PH T A C T S C LS A
Q W P C FW C S Q Q H S CV SN Q S R C E AS P N P T S P QD C PR T L L S P LA P V P T G GS Q NI L V P L A N TA F
F Q G A AL E C S F G L EE IF E A V W V NE S V V R C D QV V LH T T R K S QV F P L S L QL K GR P A R F L D SP E
P M T V MV Y N C A M G SP DC S Q C L G RE D L G H L C MW S DG C R L R G PL Q P M A G TC P AP E I R A I E PL S
G P L D GG T L L T I R GR NL G R R L S DV A H G V W I GG V AC E P L P D RY T V S E E IV C VT G P A P G P LS G
V V T V NA S K E G K S RD RF S Y V L P LV H S L E P T MG P KA G G T R I TI H G N D L HV G SE L Q V L V N DT D
P C T E LM R T D T S I AC TM P E G A L PA P V P V C V RF E RR G C V H G NL T F W Y M QN P VI T A I S P R RS P
V S G G RT I T V A G E RF HM V Q N V S MA V H H I G R EP T LC K V L N S TL I T C P S PG A LS N A S A P V DF F
I N G R AY A D E V A V AE EL L D P E E AQ R G S R F R LD Y LP N P Q F S TA K R E K W IK H HP G E P L T L VI H
K E Q D SL G L Q S H E YR VK I G Q V S CD I Q I V S D RI I HC S V N E S LG A A V G Q LP I TI Q V G N F N QT I
A T L Q LG G S E T A I IV SI V I C S V LL L L S V V A LF V FC T K S R R AE R Y W Q K TL L QM E E M E S Q IR E
E I R K GF A E L Q T D MT DL T K E L N RS Q G I P F L EY K HF V T R T F FP K C S S L YE E RY V L P S Q T LN S
Q G S S QA Q E T H P L LG EW K I P E S CR P N M E E G IS L FS S L L N N KH F L I V F VH A LE Q Q K D F A VR D
R C S L AS L L T I A L HG KL E Y Y T S IM K E L L V D LI D AS A A K N P KL M L R R T ES V VE K M L T N W MS I
C M Y S CL R E T V G E PF FL L L C A I KQ Q I N K G S ID A IT G K A R Y TL N E E W L LR E NI E A K P R N LN V
S F Q G CG M D S L S V RA MD T D T L T QV K E K I L E AF C KN V P Y S Q WP R A E D V DL E WF A S S T Q S YI L
R D L D DT S V V E D G RK KL N T L A H YK I P E G A S LA M SL I D K K D NT L G R V K DL D TE K Y F H L V LP T
D E L A EP K K S H R Q SH RK K V L P E IY L T R L L S TK G TL Q K F L D DL F K A I L SI R ED K P P L A V KY F
F D F L EE Q A E K R G IS DP D T L H I WK T N S L P L RF W VN I L K N P QF V F D I D KT D HI D A C L S V IA Q
A F I D AC S I S D L Q LG KD S P T N K LL Y A K E I P EY R KI V Q R Y Y KQ I Q D M T PL S EQ E M N A H L AE E
S R K Y QN E F N T N V AM AE I Y K Y A KR Y R P Q I M AA L EA N P T A R RT Q L Q H K FE Q VV A L M E D N IY E
C Y S E A
 
Figure 1. Predicted amino acid sequence of PLXND1 protein : The cysteine rich Met-related-sequences are 
boxed, solid circles indicate the cysteines at conserved positions of the MRS. The 3rd MRS contains 6 instead of 8 
conserved cysteines. Open diamonds indicate potential N-Glycosylation sites (N−X−S/T, X ≠ P). The N-terminal 
putative cleavable signal sequence (30-46) is underlined ; the putative transmembrane region (1273-1292) and 
cytoplasmic anchor sequence (1295-1299) are underlined with bars. The 2 intracellular conserved regions of the 
Sex-Plexin (SP) domain are underlined, and shown in bold. At positions 1637-1643 Plexin D1 contains a putative 
Rac binding domain, NLTAHYK (thick bar). 
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Figure 2. Structural domains of plexin 
family members: Four sub-families have 
been identified, named plexin A-D (384). 
Horizontaly hatched boxes indicate 
"Sema" domains, MRS motifs are 
indicated by diagonally hatched boxes, 
the clear box indicates the atypical MRS 
motif of PLXND1. Plexin B subfamily 
members have a potential furin-like 
proteolityc site, marked by a grey 
ribbon. The transmembrane region is 
marked by a shaded box, and is followed 
by 2 conserved intracellular domains, 
together comprising the SP-domain, 
marked by 2 ovals. 
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Figure 3. Northern blot analysis of PLXND1 expression. The upper left panel shows that expression of PlxnD1 in 
adult mice is highest in heart and liver, followed by intermediate expression in lung, skeletal muscle and testis, 
expression in whole brain is very low. There seems to be almost no expression in kidney and spleen. The upper 
right panel shows expression of PLXND1 in adult human tissues. Expression levels are highest in heart and 
placenta, followed by moderate expression in lung, skeletal muscle, kidney, thymus and liver. Brain, colon, 
spleen, small intestine, and peripheral blood leukocytes show very low levels of PLXND1 expression. Lower two 
panels: control   -actin probe hybridisation of the corresponding upper blots. 
 
RNA in situ Hybridisation of PlxnD1 
To investigate the cellular expression of PlxnD1 during mouse embryogenesis, we 
performed RNA in situ hybridisation experiments with digoxigenin (DIG) labelled sense 
and antisense PlxnD1 probes on mouse embryo sections. We detected expression of 
PlxnD1 as early as 9.5 days post coitum (dpc, earliest stage examined). However, 
expression could not be assigned to a specific cell type, as the positive cells were scattered 
throughout the embryo (data not shown). 
PlexinBPlexinA PlexinC PlexinD
Cell membrane
in
out
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 During embryogenesis (12.5, 14.5, 16.5, and 18.5 dpc) expression of PlxnD1 was 
observed in the endothelial cells of the vascular system. At 12.5 dpc the expression was 
localised in distinct structures typical for the developing vascular endothelium (Fig. 4). A 
representative result is shown in figure 4B, where the olfactory epithelium and the 
arachnoid showed staining of the capillaries. Another example of this expression is 
demonstrated in figure 4D, where expression in the capillaries in the tail was seen. To 
verify that the expression seen was truly located in the developing vascular system, we 
performed immunological staining on adjacent sections, using an antibody against the 
CD31 antigen, specific for vascular endothelial cells (396). Figure 4C, and 4E show that 
the expression of the CD31 antigen in adjacent sections co-localised with the expression of 
PlxnD1 in the olfactory epithelium, arachnoid and tail. In addition to this expression in 
vascular endothelium, there was expression of PlxnD1 in the CNS. The cranial as well as 
the spinal ganglia showed expression of PlxnD1 in cells that were negative for CD31 in the 
adjacent sections. A good example of this was seen in the 5th (trigeminal) ganglion. When 
comparing the RNA in situ sections to the CD31 stained sections, the 5th-ganglion clearly 
had more cells expressing the PlxnD1 transcript, than merely the vascular endothelial cells 
(Fig. 4F and 4G). However, the expression level appeared to be lower in these neural cells 
than in the endothelial cells. As a control, sections were hybridised with a sense PlxnD1 
probe, which revealed virtually no background (Fig. 4H). 
 The latest embyonic stage examined was 18.5 dpc. The expression pattern did not 
change drastically, but the levels of expression in several tissues were markedly reduced. 
Most striking was the change in expression level in lung and adipose tissue. The dark blue 
staining that was present in the endothelial cells in prior stages (see Fig. 5F) dropped 
almost to background levels (Fig. 5K). The expression of PlxnD1 was still relatively high 
in the CNS: the cranial and spinal ganglia, the cerebral cortical plate, the striatum, and the 
marginal zone of the cerebellum showed expression of PlxnD1. In addition, cells in the 
hypothalamic region, and several nerve nuclei in the medulla showed expression of PlxnD1 
(Fig. 5L). The hypothalamic signal originated in the subthalamic nucleus.  
 In summary, the expression of PlxnD1 in the mouse suggests a dual role for this more 
distant plexin family member: Firstly, unlike other plexins that are predominantly 
expressed in the CNS (386;397;398), the most prominent expression of PlxnD1 during 
early embryogenesis was seen in the vascular endothelium. The disappearance of vascular 
expression at later stages suggests an involvement of PlxnD1 in the developing vascular 
system. This action could be directed at branching of the microvessels and/or guidance of 
capillaries to their target sites. Secondly, PlxnD1 expression was also seen in restricted 
regions of the CNS such as the cranial and spinal ganglia, the cortical plate, the marginal 
zone of the cerebellum and striatum. This CNS specific expression pattern may reflect a 
role in the development and outgrowth of specific neuronal cell populations.The 
expression pattern of PlxnD1 during mouse embryogenesis thus suggests that this member 
of the plexin family could not only function as a signal transducer in axonal guidance, but 
could also play a role in embyonic vasculogenesis. Interestingly, neuropilin, which is 
capable of binding several plexins, also functions as a co-receptor for VEGF165, a factor 
that is crucial in embryonic vasculogenesis (399). Perhaps, a PLXND1-NP complex is 
involved in angiogenic signalling via VEGF. Recent evidence indicates that other plexins 
are also expressed outside the central nervous system (400), strengthening the suggestion 
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that plexins are involved in more processes than the development of neural structures 
alone. 
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Figure 4. RNA in situ hybridisation with an antisense PlxnD1 cRNA probe (A, B, D, F), and CD31 
immunohistochemical stained adjacent sections (C, E, G): (A) 12.5 dpc embryo, (B, C) magnification of nasal 
cavity and forebrain, arrows/arrowheads indicate overlapping expression pattern, (D, E) magnification of tail 
sections, co-localised expression patterns are indicated (arrows/arrow-heads), (F,G) 5th/trigeminal ganglion; 
additional staining is visible in PlxnD1 in situ sections, when compared to the CD31 signal, (H) 12.5 dpc embryo, 
control in situ hybridisation with a sense PlxnD1 probe. bv : bloodvessel, oe: olfactory epithelium, 5th : 
trigeminal (5th) ganglion. Scalebars in A and H : 1 mm, in B–G : 200   m. Color figure available in appendix 
 
 The expression pattern of PlxnD1, together with the chromosomal location of human 
PLXND1, make this gene an excellent candidate for mutation analysis in Möbius 
Syndrome 2, linked to chromosome 3q21-q22 (221). As during early mouse embryogenesis  
PlxnD1 shows expression in the vascular endothelium, and CNS, and thus in tissues 
affected in Möbius syndrome, it could well play a part in the etiology of Möbius syndrome.  
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Fig. 5. RNA in situ hybridisation with an antisense PlxnD1 cRNA probe (A,B,D,F,G,I,K,L), and CD31 
immunohistochemically stained adjacent sections (C,E,H,J). A: A 14.5 days postcoitus (dpc) embryo (lower 
body). B,C: Magnification of kidney. Arrows and arrowheads indicate colocalisation of in situ hybridisation and 
CD31 immunohistochemical staining in glomeruli. D,E: PlxnD1 in situ hybridisation sections show additional 
staining in the neocortex, compared with CD31 immunohistochemical stained sections. F: A 16.5 dpc embryo. 
G,H: Magnification of the cerebellum. Arrows in G show broader zone of expression, compared with CD31 
stained adjacent section (H, arrowheads). I,J: PlxnD1 expression is nearly invisible in midbrain/hindbrain 
region, CD31 immunohistochemistry still shows presence of capillaries (arrows in J). K: PLXND1 expression in 
an 18.5 dpc embryo: mid-body section, compare lung and adipose expression with F. L: An 18.5 dpc embryo 
forebrain. ad, adipose tissue; ag, adrenal gland; ar, arachnoid; bv, blood vessel; cap, capillaries; co, cochlea; 
cp, cortical plate; drg, dorsal root ganglion; egl, external granular layer; fb, forebrain; glom, glomeruli; ht, 
heart; int, intestine; kd, kidney; lu, lung; li, liver; mb, midbrain; nc, neocortex; pc, plexus choroideus of the 4th 
ventricle; str, striatum; sn, subthalamic nucleus; to, tongue. Scalebars: 1 mm in F, I-L, 500   m in in A,D,E, and 
200   m in B,C,G,H.Color figure available in appendix 
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Experimental procedure 
 
Electronic database information 
The instant RACE (IRACE) data for the 5' and 3'RACE experiments were obtained at 
Compugen Ltd. LabOnWeb Server, http://www.labonweb.com. Cleavable signal 
predictions were performed using SignalP V1.1, http://www.cbs.dtu.dk. The Kyte and 
Doolitle hydropathy analysis was performed at the CMBI server of the Center for 
Molecular and Biomolecur informatics (http://www.cmbi.nl). 
 
Northern analysis 
Filters containing 1 Τg human or 2 Τg mouse poly (A)+ RNA per lane were purchased 
from Clontech. A 587 basepair PCR fragment containing exon 36 and a part of the 3’ UTR 
of PLXND1 was generated with primers: 36F(T7) : 5’-
TAATACGACTCACTATAGGGGCTTTGATGGAGGACAACATC-3’, and 36R(T3) : 
5’-TAACCCTCACTAAAGGGATACTTGAAACTGTC TGTGGC-3’). The cDNA insert 
of IMAGE clone 1195364, a murine cDNA clone with over 86 % identity to human 
PLXND1, was isolated by PCR with standard T7 and T3 primers (Roche). 32P d-CTP probe 
labelling was performed with the Decalabel™ DNA labelling kit (MBI Fermentas), and 
probes were hybridised to the corresponding blot according to the manufacturers protocol. 
Autoradiographs were recorded on X-OMAT UV film (Kodak), with exposure times 
ranging from 9 to 17 days, with two X-omatic intensifying screens (Kodak). As a control 
for loading a 32P labelled ∃-actin probe was hybridised to the blots in the same manner, 
exposure times for autoradiographs were 2 days. 
 
cRNA probe labelling 
The mouse PlxnD1 cDNA insert of IMAGE clone 1195364 was isolated by PCR, using 
standard T7 and T3 primers (Roche). The PCR product was digoxigenin labelled by 
incubating 2 Τg of PCR product with: 2 Τl 10*DIG RNA labelling mix (ENZO), 2 Τl T3- 
or T7-dependent RNA polymerase (Roche), 2 Τl 10*Transcription buffer (Roche) and H2O 
added to a final volume of 20 Τl, at 37ºC for 2 hrs. After incubation, 2 units of RNAse free 
DNAseI (Roche, 10U/Τl) was added to the mix, and incubated at 37ºC for 15 minutes, after 
which 2 Τl 0.2 M EDTA, pH 8.0 was added to stop the nuclease treatment. The cRNA 
probe was ethanol precipitated, and dissolved in 100 Τl RNAse free H2O. Probe 
concentrations were determined on Hybond N+ nylon membranes (Amersham) by 
comparison to control DIG-RNA probe (Roche) and stored at -80ºC. 
 
RNA in situ hybridisation 
Mouse embryos were collected at various embyonic stages, frozen on crushed dry ice, and 
stored at –80 °C. The embryos were embedded in Tissue-Tek® O.C.T. compound (Sakura), 
cut sagitally into 16 Τm sections at temperatures of -16 to –20 °C, and mounted on 
SuperFrost® Plus microscope slides (Menzel-gläser). After quickly drying the slides with a 
hot-air gun, they were stored at –80 °C until further use. The digoxigenin labelled cRNA 
probe was hybridised to the mouse tissue sections according to the RNA in situ 
hybridisation protocol used by the Jessell Laboratory (401). Images were recorded on a 
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Zeiss Axioskop2 plus microscope with a Sony power HAD DXC-950P 3CCD color 
videocamera, using Grabstore 1.1, and electronically stored.  
 
Immunohistochemistry 
Frozen 16 µm sagital embryo sections were dried, and fixed in acetone. Sections were pre-
incubated for 10 minutes with normal rabbit serum and subsequently incubated overnight 
with a rat-anti-mouse CD31 antibody (HyCult Biotechnology), 1:200 diluted in PBS/1% 
BSA. Bound antibodies were visualized using a biotinylated anti-rat IgG followed by 
standard ABC development. Images were recorded in the same manner as for the RNA in 
situ hybridisation. 
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Abstract 
 
Möbius syndrome is a rare congenital disease characterised by the paralysis of the facial 
nerve, accompanied by impaired ocular abduction. We have performed an extensive 
mutation analysis on a recently identified positional candidate gene, PLEXIN-D1, for 
Möbius syndrome 2 mapping to chromosome 3q21-q22. Southern analysis of patients from 
the Möbius syndrome 2 family and 41 isolated Möbius syndrome patients did not reveal 
chromosomal abnormalities in the PLEXIN-D1 gene. Direct sequencing of DNA from  
familial patients, and Single Strand Conformational Polymorphism analysis of PLEXIN-D1 
in 41 isolated patients identified 18 nucleotide changes. 17 of these 18 changes could be 
dismissed as polymorphisms, as they did not co-segregate with the disease, or were present 
in a control population. A single nucleotide change identified in intron 29 of an isolated 
Möbius syndrome patient could not be identified in a control population. However, the 
position of this nucleotide change makes it highly unlikely that it could be causative for 
Möbius syndrome in this patient, as it does not affect known splicing sequences. Likewise, 
Reverse Transcriptase PCR analysis in patients from the Möbius syndrome 2 family did 
not reveal splicing aberrations, and showed bi-allelic expression, ruling out the possibility 
of promoter disrupting mutations. Taken together these results lead us to the exclusion of 
the PLEXIN-D1 gene as the causative gene in Möbius syndrome 2, and in isolated Möbius 
syndrome. 
 
Introduction 
 
Möbius syndrome (MBS) is a rare congenital disorder, mainly characterised by the 
paralysis or paresis of the facial or  7th cranial nerve. This paralysis can be uni- or bi-
lateral, and incomplete. As a consequence, MBS patients are unable to show appropriate 
facial expression, or have only limited motility of the muscles that are innervated by the 
facial nerve. In addition to paralysis of the 7th cranial nerve, paralysis of the abducens (6th), 
and often the hypoglossal (12th) nerve is seen in MBS patients (230). The oculomotor, 
trochlear, trigeminal, vestibulocochlear and glossopharyngeal nerves can also show 
deficiencies, but these are less frequently observed. Congenital abnormalities of the 
extremities are not infrequently seen in MBS, these can range from syndactyly, 
brachydactyly or ectrodactyly of the hands, to talipes equinovarus (clubfeet). Less 
frequently observed features are Poland anomaly (MIM173800), characterised by 
unilateral symbrachydactyly and ipsilateral aplasia of the sternal head of the pectoralis 
major muscle, and orofacial malformations such as cleft palate (230). In MBS varying 
incidences of mental retardation and autistic spectrum disorders have been reported 
(230;270). The aetiology of MBS is still unclear, but two different theories have been 
postulated. First, a patterning defect of the brainstem during early embryonic development 
has been proposed to result in malformation of the brainstem. Secondly, it has been 
proposed that an ischemic process during early embryonic development could lead to a 
localised hypoxic state, resulting in the malformation of the brainstem in MBS patients 
(218;230).  
 Most MBS patients are isolated, and familial recurrence is rare. In the past, 
indications for a genetic cause for MBS were first shown in a three generation MBS 
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pedigree with co-segregation of a reciprocal translocation between chromosome 1p34 and 
13q13 (232). Subsequent identification of a deletion of chromosome 13q12.2 in an isolated 
MBS patient (233) suggests that a gene for MBS is situated at chromosome 13q12.2-q13 
(MBS1, MIM157900). We have identified two additional loci for MBS in two large 
unrelated Dutch MBS pedigrees showing autosomal dominant inheritance. MBS2 
(MIM601471) is situated at chromosome 3q21-q22 (221), and MBS3 (MIM604185) at 
chromosome 10q21.3-q22 (218). Based on two reports in isolated MBS patients, a fourth 
locus for MBS is inferred on chromosome 1p22. The first report shows a reciprocal 
translocation between chromosome 1 and 11: t(1;11)(p22;p13) in a MBS patient (234), the 
other shows a reciprocal translocation between chromosome 1 and 2: t(1;2)(p22.3;q21.1) in 
a boy with MBS (235).  
 In the past two years we have analysed several positional candidate genes from the 
MBS2 and MBS3 loci, but no causative gene was identified in either locus so far 
(219;221;222). Recently we have examined the expression pattern of a new candidate gene 
for MBS2: PLEXIN-D1 (AY116661) (402). PLEXIN-D1 is a member of the plexin family 
of transmembrane receptors, which are implicated in axonal guidance and cell-cell contact 
(384;403). We have shown that during mouse embryogenesis Plexin-D1 is expressed in the 
central and peripheral nervous system, and in the vascular endothelium of developing 
blood vessels. This could mean that PLEXIN-D1 may not only be involved in neural 
differentiation and axonal outgrowth, but that it could also play an important role in the 
development of the vascular system during early mouse embryogenesis. Thus the 
expression pattern, the possible function of PLEXIN-D1 in neural and vascular 
development, and the functional implication of its family members in neural development 
make this gene an excellent candidate gene in MBS2. 
 Here we report the mutation analysis of PLEXIN-D1 in the MBS2 family, and in 41 
isolated MBS patients. Except for 2 isolated patients sent to us by physicians from abroad, 
all patients were examined and diagnosed with Möbius syndrome at the department of 
Neurology, by H.T.F.M. Verzijl (230), and blood was obtained there for DNA extraction. 
DNA analysis included Southern analysis to identify relatively large gene deletions, direct 
sequencing of the coding sequence and intron-exon boundaries of PLEXIN-D1 , and 
Reverse Transcriptase PCR analysis of the PLEXIN-D1 transcript to identify splicing 
aberrations.  
 
Results and Discussion 
 
Southern Analysis 
To asses the possibility of  (partial) deletion or duplication of the PLEXIN-D1 gene in the 
MBS2 family, we performed Southern analysis. We also subjected a cohort of 41 isolated 
MBS patients to this analysis to address the question if micro-deletions or duplications of 
PLEXIN-D1 play a role in isolated MBS. From the genomic nucleotide sequence of the 
MBS2 region on chromosome 3q21-q22 we constructed restriction maps of the PLEXIN-
D1 gene and its flanking region for EcoRI, PstI, and HindIII restriction enzyme. From the 
map we selected HindIII as a suitable restriction enzyme, giving restriction fragment 
lengths between 0.9 Kb and 17.1 Kb. HindIII restricted DNA was resolved by 
electrophoresis on 0.8% TAE agarose gels, and subsequently transferred to Genescreen 
nylon membranes. Blots were probed with 32P radio-actively labelled exonic DNA probes 
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representing the different restriction fragments based on the HindIII restriction map. Auto 
radiographs were recorded and the banding patterns of the DNA was compared to a DNA 
size marker. No differences in fragment length between the MBS2 and isolated MBS 
patients could be identified, and the fragment lengths corresponded to the calculated sizes. 
When comparing the DNA loading of the gel to the intensities of the signals on the auto 
radiographs, also no difference could be seen, ruling out a complete absence of a restriction 
fragment from one or both of the alleles.  
 
Sequence analysis 
As we could not identify relatively large deletions or duplications in the PLEXIN-D1 gene 
by Southern analysis, we started mutation analysis by direct sequencing of the coding 
sequence and intron-exon boundaries in the MBS2 family. A total of 15 nucleotide changes 
were identified (table1). The majority (10/15) did not co segregate with the disease and 
were therefore excluded. Five nucleotide changes were found to co-segregate with the 
disease in the MBS2 family, located in exon 3, exon 5, exon 8, exon 15, and exon 19. The 
changes in exon 3 and exon 5 could be analysed by restriction fragment length 
polymorphism, as they affected consensus sites for the restriction enzymes MspI (exon3), 
and ScaI (exon5). Amplification of PCR products from 66 control DNA’s, followed by 
restriction with the appropriate restriction enzyme and electrophoresis on agarose gels 
revealed the presence of both these nucleotide changes in a control population, respectively 
in 4/132 alleles (3%) and 3/132 alleles (2.3 %). The changes in exons 8, exon 15, and exon 
19 could not be investigated by restriction fragment length polymorphism analysis (RFLP), 
and were subsequently analysed by single strand conformational polymorphism (SSCP) 
analysis. The SSCP analysis respectively showed the presence of these changes in the 
tested control population in 4/90 alleles (4.4 %), 5/96 alleles (5.2%), and 5/96 alleles 
(5.2%). These results indicated that neither of these five changes are causative for MBS 
and they should therefore be considered polymorphisms. However, it can be envisaged that 
the co-occurrence of these five rare polymorphisms is causative for the disease. Analysis of 
the SSCP gels for the 41 isolated MBS patients revealed a further four subjects sharing 
these five changes. Careful analysis of the RFLP and SSCP gels for the control population 
also identified the five mentioned nucleotide changes in three members of the control 
population. It is therefore very likely that these subjects all share the same ancestral allele, 
unrelated to the occurrence of MBS.  
 The SSCP analysis in isolated MBS patients further revealed 3 nucleotide changes 
not identified in the MBS2 family (table1). These mutations were located in exon 2, exon 
18, and intron 29. The nucleotide change in exon 2 did not result in an amino-acid 
substitution, and was present in control DNA (1/80 alleles, 1.3 %). The nucleotide change 
in intron 29 does not seem to alter an existing splice site, or create a new splice possibility 
(404). We could not study this change in detail by Reverse Transcriptase PCR analysis, 
because no RNA material from this patient is available. SSCP analysis in 160 control 
alleles did not show this nucleotide change in a control population. The nucleotide change 
in exon 18 (C3685T) results in the substitution of an Arginine for a Cysteine at position 
1169 of the PLEXIN-D1 protein. SSCP analysis revealed the presence of this nucleotide 
change in 4/88 control alleles (4.5 %) , and it is therefore regarded as a polymorphism.  
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Reverse Transcriptase PCR analysis 
As several intronic nucleotide changes in or near the splice sites of PLEXIN-D1 were 
encountered in the MBS2 patients, we performed Reverse Transcriptase PCR analysis of 
PLEXIN-D1 to asses the possibility of splicing errors as the cause of MBS in the MBS2 
family. Overlapping PCR products covering all splice sites were amplified, and sequenced. 
No aberrant splice products were identified, ruling out the possibility that splicing errors in 
PLEXIN-D1 could cause MBS in the MBS2 family.  In addition, sequencing of the Reverse 
Transcriptase PCR products allowed us to detect transcripts derived both from the wild 
type allele and from the allele carrying the above mentioned five polymorphisms.  This 
result demonstrates bi-allelic expression of the PLEXIN-D1 gene in the MBS2 family, and 
therefore excludes the involvement of promoter mutations. 
 
Discussion 
 
We have investigated the possible causative role of PLEXIN-D1 in Möbius syndrome. 
Based on our results we exclude PLEXIN-D1 as the causative gene for MBS2. First, 
Southern analysis showed no micro-deletions or duplications of PLEXIN-D1 in patients 
from the MBS2 family. Second, in the MBS2 family, all of the nucleotide changes in the 
PLEXIN-D1 gene that co-segregated with the syndrome were present in members from the 
ethnically matched  control population. These nucleotide changes should therefore be seen 
as harmless polymorphisms. Third, no abnormal PLEXIN-D1 transcripts were identified 
upon Reverse Transcriptase PCR analysis of the PLEXIN-D1 transcript in the MBS2 
family. Moreover, the Reverse Transcriptase PCR analysis revealed that both copies of the 
PLEXIN-D1 gene were expressed, as the previously identified co-segregating nucleotide 
changes were heterozygously present in Reverse Transcriptase PCR products. We also 
conclude that PLEXIN-D1 mutations are not causative for isolated MBS as no micro-
deletions or duplications where identified by Southern analysis, and no causative mutations 
could be identified by SSCP analysis and sequencing of 41 isolated MBS patients. A single 
nucleotide change in intron 29 (5174–4A > G) in one isolated MBS patient was not 
detected in a control panel of 160 alleles, from an ethnically matched population. 
Nonetheless this nucleotide substitution is unlikely to be causative as there is no effect on 
the protein amino acid sequence, and it does not drastically alter an existing or create a 
novel splice site (404). Formally we can not exclude this change as being causative for 
MBS in this patient, but RNA material for Reverse Transcriptase PCR verification is not 
available from this patient. From the combination of our data we therefore conclude that 
PLEXIN-D1 is not causally involved in inherited Möbius syndrome 2, nor in isolated 
Möbius syndrome. 
 
Materials and Methods 
 
Southern Blotting 
10   g genomic DNA was digested with HindIII restriction enzyme (Roche). Digested 
DNA was resolved by electrophoresis in a 0.8% TAE agarose gel, and transferred to a 
nylon membrane (Genescreen plus). Exonic probe DNA was randomly labelled with 32P-
dCTP, using the Decalabel™ DNA labelling kit (MBI fermentas). Probes were hybridised 
to the respective blots in hybridisation buffer ( 7% SDS , 50 mM phosphate and 0.5 % 
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bovine serum albumin), at 65 °C. Blots were washed at 65 °C to a final stringency of 40 
mM phosphate, and auto radiographs were recorded on X-OMAT UV film (Kodak), with 1 
intensifying screen, after 2 days exposure. 
 
Sequencing 
Polymerase Chain Reaction (PCR) products for the coding region and intron-exon 
boundaries of Plexin-D1 were generated by use of exon specific primers (primer sequences 
available on request), and were purified on PCR purification spin columns (Qiagen). Direct 
sequencing was performed at our DNA sequencing facility, using BigDye terminator 
chemistry (Applied Biosystems) on a 3700 DNA analyzer (ABI-PRISM). 
 
Restriction Fragment Length Polymorphism (RFLP) analysis 
PCR products of the relevant exons were digested with the appropriate restriction enzyme 
(MspI or Sca I, Roche), and resolved  by electrophoresis on TAE agarose gels. The 
restriction patterns from members of the MBS2 family, and the normal population were 
analysed. 
 
Single Strand Conformational Polymorphism (SSCP) analysis 
PCR products ranging in size from 160 to 280 base pairs were amplified from patient 
DNA, covering the coding sequence and intron-exon boundaries of Plexin-D1 (primer 
sequences available on request). The fragments were resolved by polyacrylamide gel 
electroforesis (PAGE) on 8% Acrylamide gels (Acrylamide:bis-acrylamide, 49:1). Gels 
were run overnight at 10 Watts using 1* TBE running buffer (Roche). The DNA patterns 
were visualised by silver staining, as described by Budowle (405), using a custom build 
staining frame for large PAGE gels (BTS GmbH, Germany). Bands showing a shift were 
re-PCR’ed and submitted to our sequencing facility for nucleotide analysis. 
 
Reverse Transcriptase PCR 
Total RNA was isolated from cultured fibroblast cell-lines from the relevant patients, using 
RNAzol B (Campro Scientific) according to the manufacturers protocol. Copy DNA was 
generated using 250 ng of total RNA, in a reaction with Molony Murine Leukemia Virus 
Reverse Transcriptase (Invitrogen), according to the manufacturers protocol. PCR products 
covering all splice sites were generated using exonic primers (primer sequences available 
on request). The PCR products were resolved on 2% TAE agarose gels, isolated on gel 
extraction spin columns (Qiagen), and sequenced as described above. 
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Table 1: Nucleotide changes in PLEXIN-D1 identified in MBS patients. Nucleotide 
positions are numbered according to the sequence of AY116661. * : nucleotide changes 
solely identified by SSCP analysis in isolated MBS patients. n : number of alleles tested, 
n.c. : not co-segregating. 
 
Location Nucleotide 
 position 
Amino acid  
position 
Frequency in control 
 population 
Exon 2* 1653C > T N490N 1.3 % (n= 80) 
Exon 3 1831G > A G551S 3.0 % (n= 132) 
Exon 5 2029C > T P617S 2.3 % (n= 132) 
Intron 5  2032–31C > A -- n.c. 
Exon 7 2214C > T H678H n.c. 
Exon 8 2376C > T S732S 4.4 % (n= 90) 
Exon 9 2475C > G T765T n.c. 
Exon 12 2788A > G M870V n.c. 
Exon 14 3051A > G P957P n.c. 
Exon 15 3210C > T S1010S 5.2 % (n = 96) 
Intron 17  3517–41G > A -- n.c. 
Exon 18* 3685C > T R1169C 4.5 % (n= 88) 
Exon 19 3807G > A Q1209Q 5.2 % (n= 96) 
Exon 21 4059C > T F1293F n.c. 
Exon 24 4414T > G L1412V n.c. 
Intron 29* 5174–4A > G -- 0.0 % (n= 160) 
Intron 30 5208+8G > A -- n.c. 
Exon 36 5907G > A Q1909Q n.c. 
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Abstract 
 
Hereditary congenital facial paresis is a rare autosomal dominantly inherited disorder, in 
which pathological changes in the brainstem affect the paired facial nuclei and nerves. 
Previously, the neuropilin-1 protein has been shown to control axon guidance and cell 
body position of facial motor neurons, and mice with a targeted disruption of neuropilin-1 
present with developmental defects of the facial nerve nuclei. Plexin-A1 can function as a 
signal transducing subunit for the neuronal neuropilin receptor, and its gene is located in 
the linkage interval for hereditary congenital facial paresis at chromosome 3q21-q22 
(MIM601471), making it an excellent candidate gene for this disorder. During mouse 
embryogenesis the murine ortholog of plexin-A1 gene showed restricted spatial and 
temporal expression in the hindbrain, consistent with a role in cell body movement, or 
axonal guidance during facial nerve development. Sequence analysis of the plexin-A1 gene 
in patients from the 3q21-q22 linked hereditary congenital facial paresis family revealed 
several nucleotide changes. However, non of the nucleotide changes led to an amino acid 
substitution, and Reverse Transcription polymerase chain reaction analysis did not detect 
aberrant RNA processing. We therefore conclude that it is highly unlikely that Plexin-A1 is 
involved in the pathogenicity of hereditary congenital facial paresis. 
 
Introduction 
 
Hereditary congenital facial paresis (HCFP) is a rare autosomal dominant syndrome 
characterized by the inability to properly innervate the muscles of the face, as a 
consequence of isolated complete or partial absence of the facial nerve (nVII), either uni- 
or bi-lateral. In the past we have identified two loci for HCFP, one on chromosome 3q21-
q22 (MIM601471) (221), and a second on chromosome 10q21-q22 (MIM604185) (218). 
HCFP belongs to the group of congenital cranial dysinnervation disorders (CCDD) 
(177).The family of CCDDs includes syndromes with congenital, non-progressive, 
sporadic or familial abnormalities of cranial musculature, that are caused by developmental 
abnormalities of one or more cranial nerves, with primary or secondary muscle 
dysinnervation. Möbius syndrome (MBS, MIM157900), minimally defined by the 
dysfunction of the facial (nVII) and the abducens nerve (nVI) (230), also belongs to this 
group, and is phenotypically related to HCFP, suggesting a common pathogenic 
mechanism underlying the etiology of both syndromes. However, HCFP and MBS should 
be treated as separate entities. Whereas several cranial nerves are involved in MBS, due to 
maldevelopment of possibly the entire brainstem (230), HCFP is restricted to the facial 
nerve, and is likely due to a more restricted developmental hypoplasia of the facial motor 
nuclei (220).  
 The processes governing neuronal cell migration and axonal guidance during 
development are very complex, but several important players have been identified. The 
transmembrane proteins neuropilin-1 and neuropilin-2 have both been implicated in axon 
guidance and neuronal migration (406;407). Moreover, loss of neuropilin-1 affects both 
axon guidance and cell body positioning of facial branchiomotor neurons (156;169), not 
unlike the histo-pathological changes observed in HCFP patients (220). Neuropilins serve 
as ligand binding receptors for class 3 Semaphorins, well known neuronal guidance cues, 
but they have to recruit a member of the plexin family of transmembrane proteins to 
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transduce semaphorin signals (168). In addition, neuropilins also bind isoforms of vascular 
endothelial growth factor (VEGF) (408). Plexins show homology to the scatter factor 
receptors, can mediate attractive as well as repulsive cues, and the plexin family contains 
four subfamilies, A-D (384;385). Whilst semaphorins are required for axon guidance of the 
facial nerve, the VEGF isoform VEGF164 controls cell body positioning of the facial 
motor neurons in the brainstem (156). 
 In our efforts to elucidate the genetic defects leading to HCFP and MBS we have 
performed mutation analysis on several candidate genes, from the loci on 3q and 10q 
(222). Recently we analysed plexin-D1, located at chromosome 3q21, for involvement in 
HCFP (350;402). Plexin-D1 contains an atypical domain (third Met related sequence), 
setting it apart from the rest of the plexin family members, and is expressed in vascular 
endothelium and the nervous system during mouse embryogenesis. On the basis of its 
expression, and the role that plexins play in neural development, we hypothesised that 
plexin-D1 could be involved in the etiology of HCFP, but sequence analysis failed to 
identify causal changes. However, the locus for HCFP on chromosome 3q21 harbours 
another plexin family member, plexin-A1, that belongs to the plexin A subfamily, shown to 
play a keyrole in class 3 semaphorin signalling during brain development (409).  
 In this report we determine the expression pattern of plexin-A1 in the brainstem by 
RNA in situ hybridisation during mouse embryogenesis. In addition, we performed 
mutation analysis of plexin-A1 in patients from the HCFP family linked to chromosome 3q.  
 
Results 
 
Expression of plexin-A1 during hindbrain development 
At 10.5 dpc, plexin-A1 was already widely expressed in the forebrain, midbrain, hindbrain, 
spinal cord and dorsal root ganglia. The specificity of the signal was confirmed by in situ 
hybridisation with a sense plexin-A1 probe, that produced negligible background staining. 
Intense staining was observed in the dorsal root ganglia, and the ventral rim of the spinal 
cord (figure 1A). At 12.5 dpc a population of cells in the hindbrain showed more intense 
staining of plexin-A1 transcripts. The cells formed a medially positioned line in the lateral 
hindbrain, extending more caudally into the medulla oblongata (figure 1B). When sections 
approached the midline, the signal was shifted towards the ventral part of the hindbrain, 
near the region of the floorplate (figure 1C). At 14.5 dpc the plexin-A1 expressing cells 
along the ventral side of the hindbrain showed intense staining, suggesting a high level of 
plexin-A1 expression (figure 1D). The streak of cells expressing an enhanced plexin-A1 
signal terminated at a position abutting the region of the facial nucleus. The levels of 
expression in the more lateral positions of the hindbrain had dropped to the level of 
surrounding cells (not shown). The elevated level of plexin-A1 expression in the ventral 
position of the hindbrain was maintained at 16.5 dpc. Additionally, plexin-A1 expressing 
cells of the facial nucleus could be seen as a distinct structure (figure 1E). 
 
Mutation analysis of plexin-A1 in the HCFP family linked to 3q21 
PCR amplicons were generated to cover the entire coding sequence and the intron-exon 
boundaries of plexin-A1 (31 exons, Primer sequences available on request). Sequence 
analysis revealed three nucleotide changes in the coding region of the gene, and eight 
intronic sequence changes (table 1). Two of the three nucleotide changes in the coding 
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sequence were heterozygous, cosegregated with the disease in the family, and where not 
present in unaffected family members and unrelated control samples (exon 1: T948C and 
exon 11: C2370T). The remaining coding nucleotide change and the eight intronic changes 
did not cosegregate with the disorder. None of the changes in the open reading frame lead 
to an amino acid substitution: T316T (exon 1), R790R (exon 11), and L1241L (exon 19).  
 
 
Figure 1. Plexin-A1 expression in the mouse embryonic nervous system. A) 10.5 dpc mouse embryo. Arrows 
indicate intense staining of plexin-A1 expression in the dorsal root ganglia, arrowheads indicate higher levels of 
expression in the ventral neural tube. B) 12.5 dpc mouse embryo. Arrows indicate cells with elevated level of 
plexin-A1 expression, medially positioned in the hindbrain/medulla region. C) 12.5 dpc mouse embryo. Arrows 
indicate ventrally positioned cells in the hindbrain with higher levels of plexin-A1 expression, near the floorplate. 
D) 14.5 dpc mouse embryo brain. Arrows indicate cells with intenser staining, suggestive of higher plexin-A1 
expression levels, abutting the position of the facial nucleus (7n). E) 16.5 dpc mouse embryo brain. Arrows 
indicate sustained elevated levels of plexin-A1 expression in some ventrally positioned cells in the hindbrain, the 
facial nerve nucleus is indicated by an oval. The inlay shows a magnification of the region of the facial nerve 
nucleus. 7n: facial nerve nucleus, v3: third ventricle, v4: fourth ventricle, cb: cerebellum, cpu: caudate putamen, 
drg: dorsal root ganglia, fb: forebrain, he: heart, hyp: hypothalamus, lv: lateral ventricle, mb: midbrain, med: 
medulla oblongata, nc: neocortex, sc: spinal cord, tha: thalamus. Scalebars: A-E : 50   m, E inlay: 25   m.Color 
figure available in appendix  
 
 To address the possibility that the cosegregating sequence variations in the open 
reading frame of plexin-A1 could influence exonic splice enhancer (ESE) sequences (410), 
or that one of the cosegregating intronic nucleotide changes affected splicing of the 
transcript, we performed Reverse Transcription (RT) PCR analysis. Total RNA was 
isolated from cultured lymphoblast cell-lines from the corresponding patients, and primers 
CHAPTER 8 
 124 
were designed to generate overlapping amplicons covering all splice sites, and the 
sequence variations in the coding sequence (Primer sequences available on request). No 
products of an aberrant size were identified, and sequencing of the RT-PCR products 
revealed correct splicesite usage. The two cosegregating exonic sequence variations 
(T948C and C2370T) were heterozygously re-confirmed in plexin-A1 transcripts obtained 
from patient cells. This latter result indicated that both plexin-A1 alleles were transcribed in 
EBV-transformed lymphoblastoid cells from our patients.  
 Finally, a Southern analysis of the Plexin-A1 gene was performed, to investigate 
(partial) gene deletions/duplications. Genomic DNA was digested with either BglII 
restriction enzyme alone, or double digested with BglII and XhoI restriction enzyme. Equal 
amounts of genomic DNA from affected patients, unaffected family members, and an 
unrelated control were resolved on agarose gel, and blotted to nitrocellulose membranes. 
Radioactively labelled exonic probes identifying all plexin-A1 containing restriction 
fragments were used to screen for size, and quantitative differences. On examination of the 
autoradiographs, no differences in restriction fragment size or signal intensity were 
identified between the affected and (non-affected) control DNA’s (not shown). Thus, 
partial or complete deletions or duplications of the plexin-A1 gene were not present in our 
HCFP family (Figure 2). 
 
 
 
Figure 2. Partial pedigree of HCFP family showing the 
affected patients, obligate carrier, and unaffected 
individuals used for the plexin-A1 nucleotide analysis. 
Generations and patients are numbered according to the 
extended pedigree reported with the initial linkage 
analysis in 1996 (221). 
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Discussion 
 
Candidate genes for HCFP at chromosome 3q21-q22 involved in neuropilin-
dependent signalling 
The normal patterning of facial branchiomotor neuron migration is dependent on 
neuropilin-1, and its ligands, sema3A and VEGF164 isoform (156;408). Members of the 
plexin protein family, have been implicated in transducing sema3A/neuropilin signals 
(168), and may also be involved in mediating VEGF164/neuropilin signals (156). Plexins, 
neuropilin ligands, and other proteins involved in plexin signal transduction are therefore 
likely candidates for HCFP. Three such candidate genes are situated at chromosome 3q21-
q22: plexin-A1, plexin-D1 and sema5B.  
 Sema5B could be discarded for involvement in HCFP as it is located outside the 4.9 
cM linkage region on chromosome 3q (222). The plexin-D1 gene was analysed by RNA in 
situ hybridisation during mouse embryogenesis in a similar way to the data described in 
this report. Expression was shown in vascular endothelium, and cranial nerve ganglia 
during hindbrain development (402). However, mutation analysis of the plexin-D1 gene 
did not show a causal involvement of plexin-D1 in HCFP (350). We now show that plexin-
A1 is expressed in a spatiotemporal manner consistent with a role in facial nerve 
development, but exclude it as a candidate gene for HCFP. 
 
Plexin-A1 expression during hindbrain development 
 The expression patterns of murine plexin-A subfamily members, including plexin-A1, 
have been described in mice 13.5 days post coitum (dpc) to 5 day old neonate mice 
(397;411). However, the expression of plexin-A1 during (early) hindbrain development has 
not been examined. Therefore we have performed an extensive analysis of Plexin-A1 
expression in the developing hindbrain during mouse embryogenesis. By RNA in situ 
hybridisation during mouse embryogenesis we show that plexin-A1 was expressed in the 
developing hindbrain at the correct spatial and temporal position to be involved in facial 
nerve development. Migration of facial branchiomotor neurons occurs between 11 and 14.5 
dpc, and starts with a tangential movement of the cell bodies along the body axis, on the 
ventricular side of the hindbrain (82;153). In rhombomere 6 the migration path makes a 
turn, and facial branchiomotor neurons crossover to the pial side of the brainstem, where 
the facial nucleus is formed (153;408). At 12.5 and 14.5 dpc plexin-A1 expression was seen 
in the hindbrain in a specific streak of cells (see figure 1). This streak of plexin-A1 
expressing cells could form a cell guiding barrier in the hindbrain, assuring caudal 
migration of motor neurons from rhombomere 4 to rhombomere 6 at the ventricular side. 
In line with this suggestion, elevated levels of plexin-A1 expression in the lateral caudal 
hindbrain ceased at a position in the hindbrain just anterior to the definitive site of the 
facial nucleus, possibly generating a permissive environment for migration to the pial side 
posterior to this position. At 16.5 dpc, when migration of facial branchiomotor neurons is 
completed, the elevated levels of plexin-A1 expression in the hindbrain dropped to the 
levels seen in surrounding cells, in all but a few cells, again making it likely that plexin-A1 
plays a role in early development of the facial nerve nucleus, or nerve. Additionally, in the 
neuropilin-1 knock-out mouse ectopic nuclei are formed along the migration path of the 
facial nerve nucleus, showing premature migration towards the pial hindbrain side (156), a 
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phenotype that may also be elicited by a defect in cell guidance along the streak of plexin-
A1 expressing cells. 
 
Sequence analysis of plexin-A1 in HCFP patients 
Our extensive analysis of the plexin-A1 gene in the 3q21 linked HCFP family did not 
suggest a causal connection between sequence variations in this gene and HCFP as; 1) Two 
cosegregating nucleotide changes were identified in the open reading frame that do not 
lead to amino acid substitutions, these changes most liklely represent single nucleotide 
polymorphisms (SNPs), and as such are listed in the NCBI SNP database 
(www.ncbi.nlm.nih.gov/projects/SNP). The remaining nucleotide changes did not 
cosegregate with the disorder, and therefore cannot be causaly related to the disorder. 2) 
Possible disruptive effects by identified or unidentified sequence variants on the plexin-A1 
transcript was refuted by RT-PCR analysis. No aberrant splice products were identified in 
the analysis, and bi-allelic expression of plexin-A1 could be proven as sequence analysis 
identified of the two cosegregating heterozygous exon changes  (exon1 and exon11) in the 
RNA pool. Quantative effects of nucleotide changes in the promoter on the expression of 
plexin-A1 were not investigated, but are highly unlikely, as both alleles apeared equally 
represented in the RNA, based on surface area beneath the sequence peaks. 3) Finally, no 
(partial) deletions or duplications of the plexin-A1 gene could be identified by Southern 
analysis. We therefore think it is unlikely that plexin-A1 is involved in the etiology of 
HCFP in our family. However, it is too soon to definitely exclude plexin-A1 as the 
causative gene in HFCP, simply because we are unable to screen for all possible sequence 
variations. For example, mutations that give rise to disrupted expression of plexin-A1 at 
specific developmental stages, or in specific tissues would not have been detected in our 
analysis. The striking resemblance in pathological defects of HCFP patients (220) and the 
Nrp1-/- mice (156) hinted towards a role for plexin-A1 in HCFP. Therefore, we believe that 
analysis of the plexin-A1 gene is still worthwhile in additional HCFP families linked to 
chromosome 3q21-q22, should they become available in the future. Alternatively, plexin 
and/or neuropilin dependent signalling could be involved in the etiology of some of the 
other syndromes included in the family of CCDDs. 
 
Materials and Methods 
 
RNA in situ hybridisation 
 C57Bl6 mouse embryos were collected at various embryonic stages, frozen on crushed dry 
ice, and stored at –80ºC. The embryos were embedded in Tissue-Tek® O.C.T. compound 
(Sakura), serially cut into 16   m slices at temperatures of -16 to -20ºC, mounted on 
SuperFrost® Plus microscope slides (Menzel-gläser), and stored at -80ºC. A mouse plexin-
1 (mouse homologue of plexin-A1) specific product was generated by RT-PCR on mouse 
brain RNA, using transcript specific primers containing T7 and T3 sequences for 
Digoxigenin (DIG) labelling (T7mPlex1for: TAATACGACTCACTATAGGGGCTGCA 
TCTCAGCCA GTTC, T3mPlex1rev: TAACCCTCACTAAAGGGACTAGCCTTGGGTA 
TCTCACC, product size 656 basepairs). For DIG labelling 400 ng of RT-PCR product was 
incubated with: 2   l 10*DIG RNA labelling mix (ENZO), 2   l T7 (Sense) or T3 
(Antisense) dependent RNA polymerase (Roche), 2   l 10*Transcription buffer (Roche), 
and H2O added to a final volume of 20   l, at 37 ºC for 2 hrs. After incubation 2   l 0.2 M 
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EDTA, pH 8.0 was added to stop the reaction. The cRNA probe was ethanol precipitated, 
dissolved in 100   l RNase free H2O, and stored at –80 ºC. Probe DIG concentrations were 
determined on Hybond N+ nylon membranes (Amersham) by comparison to control DIG-
RNA probe (Roche). The labelled cRNA probes were hybridised to the mouse tissue 
sections according to the RNA in situ protocol used by the Jessell Laboratory (401), at a 
concentration of 400 ng/ml hybridisation mix. Images were recorded on a Zeiss Axioskop2 
plus microscope with a Sony power HAD DXC-950P 3CCD color video camera. 
 
Sequence analysis 
 To obtain the full coding sequence for human plexin-A1, we aligned the sequences of 
X87832 and AL162013. The open reading frame is 5610 basepairs, and is terminated at a 
TGA stop codon. Alignment of the coding sequence to the genomic sequence of 
chromosome 3q identified 31 exons. PCR products for the coding region and intron-exon 
boundaries of plexin-A1 were generated by use of gene specific primers (primer sequences 
available on request), and were purified on PCR purification spin columns (Qiagen). Direct 
sequencing was performed using BigDye terminator chemistry (Applied Biosystems) on a 
3730 DNA analyzer (ABI-PRISM). 
 
Reverse Transcriptase-PCR analysis 
 Total RNA was isolated from cultured EBV-transformed lymphoblastoid cell-lines from 
the relevant patients, using RNAzol B (Campro scientific) according to the manufacturer’s 
protocol. 200-400 ng RNA was used to generate cDNA products with the One Step RT-
PCR kit (Qiagen) , according to the manufacturer’s protocol. RT-PCR products covering 
all plexin-A1 splice sites were generated using exonic primers (primer sequences available 
on request). RT-PCR products were resolved on 2% TAE agarose gels, isolated on gel 
extraction spin columns (Qiagen), and sequenced as described above. 
 
Southern analysis 
 10   g genomic DNA from 4 affected patients, 2 unaffected family members, and 1 
unrelated control was digested with BglII restriction enzyme (Roche), or double digested 
with BglII and XhoI restriction enzyme (Roche). Resulting plexin-A1 restriction fragments 
ranged from 16.3 to 1.9 kilobases. Digested DNA was resolved by electrophoresis in a 
0.8% TAE agarose gel, and transferred to nylon membrane (Genescreen plus). Exonic 
plexin-A1 probe DNA was randomly labelled with 32P-dCTP, using the Decalabel™ DNA 
labelling kit (MBI Fermentas). Probes were hybridised to the respective blots in 
Expresshyb hybridisation solution (BD biosciences), for 2 hours at 65 °C. Blots were 
washed at a maximum temperature of 65 °C, according to the Expresshyb hybridisation 
solution protocol (BD biosciences) supplied by the manufacturer. Autoradiographs were 
recorded on X-OMAT UV film (Kodak), with 2 intensifying screens, and 2 to 4 days 
exposure at –80 ºC. 
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Table 1. Nucleotide variations of plexin-A1 in HCFP patients. Nucleotide positions and 
changes, numbered from the ATG start codon, A = 1, are shown. When available, entry 
numbers for the corresponding nucleotide changes in dbSNP (www.ncbi.nlm.nih.gov 
/projects/SNP) are listed. For nucleotide changes in the open reading frame, the effect on 
amino acid composition of the plexin-A1 protein were determined. Both cosegregating 
nucleotide changes were exclusively present in the affected patients, and in the obligate 
carrier. The remaining nucleotide changes were either identified in a portion of the 
affected, or in the unaffected family members.  * : homozygous sequence variant, n.a.: not 
available, +: cosegregating, -: non cosegregating. 
 
Gene  
position 
Nucleotide  
position 
dbSNP Amino acid  
position 
Segregation 
Exon 1 T948C rs6773789 T316T + 
Intron 6 1828 A+64G n.a. -- - 
Intron 6 1829 G-40C rs1248934 -- - 
Exon 11 C2370T rs1171948 R790R + 
Intron 18 3592 A–30G n.a. -- - 
Exon 19 C3723A * rs4679323 L1241L - 
Intron 22 4294 A-93G rs9851451 -- - 
Intron 22 4294 T–51G rs9833827 -- - 
Intron 26 4802 A–29G rs2241676 -- - 
Intron 29  5275 C+36T rs9840115 -- - 
Intron 30 5526 G+10A * rs6439031 -- - 
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The aim of this thesis was to unravel the genetic defects that underly hereditary congenital 
facial paresis (HCFP), and Möbius syndrome (MBS), both belonging to the group of 
congenital cranial dysinnervation disorders (CCDDs, (177)). At the onset of the project, 
January 2000, the common view was that congenital facial paresis and Möbius syndrome 
belonged to one and the same entity, sharing a common pathology. The hallmark 
diagnostic criterion for MBS was the presence of congenital facial palsy, with or without 
abducens palsy (239). Therefore, using this diagnostic approach, isolated congenital facial 
paresis was classified as being a mild expression of the “Möbius spectrum”, that gradually 
expands as patients present with additional clinical features. However, on the basis of 
recent clinical, and neuropathological findings we believe that HCFP and MBS should be 
considered two seperate entities, with differing pathogenesis.  
 
9.1 Möbius syndrome vs. hereditary congenital facial paresis 
 
We have redefined Möbius syndrome as a syndrome of rhombencephalic maldevelopment, 
in which the diagnostic criterion is congenital facial palsy with impairment of ocular 
abduction (Chapter 2). The clinical picture of MBS that emerged from our studies points 
towards a pathogenesis that involves predominantly the motor nuclei and axons, as well as 
traversing long tracts of the lower brainstem. The facial diplegia and ocular abduction 
impairment in MBS point to the involvement of more than one cranial nerve, and/or 
nucleus. Additionally, all cases described show clumsiness, poor coordination, and poor 
balance performance, to a degree greater than could be explained by hand and foot 
deformities. This probably results from hypoplasia of either the corticospinal or 
corticopontocerebellar tracts, or of hypoplasia of the cerebellum. In HCFP patients the 
phenotype is confined to facial weakness. In some cases hearing impairment was observed. 
However, this does not comprise a major recurring event. Thus only a defect in the facial 
nerves, or their nuclei appears to be consistently present in this disorder.  
 Neuropathological investigations in MBS and HCFP patients confirm the clinical 
observations (this thesis, and (315-317). In MBS the architecture of the entire brainstem, 
including parts of the traversing long tracts, were affected by dysgenesis, degeneration, and 
necrosis. Contrary to MBS, in HCFP the only defect seen in the brainstem was in the facial 
nerve nuclei and the facial nerves. The remainder of the cranial nerves was unaffected, and 
no deformities of the overall architecture of the brainstem was observed. As a consequence 
of these observations we envision that the genetic defects that underly the disorders will 
differ, and that individual approaches to investigate HCFP and MBS genetically should be 
made in the future.  
 In MBS a primary genetic defect that disturbs the patterning of the early hindbrain 
could result in the pathological and clinical phenotypes seen. A possible explanation is that 
a genetic factor that functions in early pre-patterning events of the hindbrain (see Chapter 
1, figure 9A) is defective in MBS. This would lead to a maldevelopment of the hindbrain 
itself, and indirectly, of the structures that have to traverse it to reach their targets in other 
parts of the brain. Alternatively, a vascular hypothesis for MBS has been postulated, in 
which hypoperfusion or occlusion of the primitive subclavian artery is deemed causal 
(242-244). When this hypothesis is approached from a genetic point of view, one could 
think of mutations in genes essential for the development of the arterial bed in the 
hindbrain, that lead to a localised ischemic hindbrain environmment in which overal 
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development is hampered. These genes then must have additional functions in the 
development of the upper and lower limbs. 
 For HCFP, a primary defect of the fourth rhombomere is more likely the cause of the 
disorder. The facial motoneurons arise almost exclusively in this rhombomere (319), and 
interference with its development has been shown to lead to a failure to form the facial 
motor nucleus (e.g. Hoxb1-/- mice (322)). The causal gene for HCFP will therefore likely 
be functionally restricted to development of this rhombomere, and the facial nucleus/nerve 
that forms from its cells. 
 
9.2 Genetic analysis in HCFP pedigrees, the positional candidate gene 
approach 
 
Prior to the human genome project, functional and positional cloning was the way to go to 
identify genes involved in heritable disorders (412-414). However, these processes were 
very labourious and time consuming. With the onset of the human genome sequencing, the 
positional candidate gene approach gradually gained more weight, and has become the 
standard for genetic analysis of human disease. With this in mind, classical linkage 
analysis was performed on two large Dutch pedigrees that presented with hereditary 
congenital facial paresis (initially termed Möbius syndrome). First in 1996, linkage with 
HCFP was reported to the long arm of chromosome 3, at 3q21-q22 (221). The critical 
interval extended over 10 centiMorgan (cM), and covered more than 10 Mb. In an effort to 
reduce the region, linkage analysis was performed on additional family members. A new 
demarcating recombination was identified, reducing the critical interval to 4.9 cM, and 
approximately 6 Mb (Chapter 4). In a second, unrelated, HCFP pedigree linkage was 
found to the long arm of chromosome 10, at 10q21-q22. The interval encompassed 3.7 cM, 
and approximately 2.6 Mb (218). 
 From the HCFP interval on chromosome 3, the CRBP1 gene was analysed by single 
strand conformation polymorphism (SSCP) analysis, but there were no indications for 
mutations (221). Additionally, we analysed several positional candidate genes (this thesis). 
GATA2 was considered a candidate as it is a transcription factor with expression in the 
hindbrain limited to rhombomere 4, under control of Hoxb1, a gene involved in 
segmentation and development of the rhombencephalon (153;324). The PGT gene codes 
for a prostaglandin transporter, and was considered a candidate gene as maternal misuse of 
the synthetic prostaglandin Misoprostol during early pregnancy increased the incidence of 
Möbius syndrome in new-borns (282;345;346).   
 From the interval on chromosome 10, EGR2, the human ortholog of Krox-20, was 
analysed. EGR2 is situated near the critical interval, and was analysed as its mouse 
ortholog is expressed selectively in rhombomeres 3 and 5 (348), and Krox-20 mouse 
mutants have hypoplastic branchiomotor facial nuclei (87).  Additionally, CTNNA3, coding 
for alphaT-catenin , a member of the alpha-catenin family (415-417), and LRRTM3, 
expressed in fetal brain, and coding for a protein containing leucine-rich repeats implicated 
in protein-protein interactions (e.g. in Slit-Robo signalling) (418;419), were analysed by 
direct sequencing (unpublished results).  
 However, none of the genes analysed showed nucleotide changes that could account 
for the facial paresis phenotype. On the basis of these analyses it seems unlikely that these 
genes are involved in the pathology of HCFP, but they need to be kept in mind for future 
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researchers as with the present techniques (PCR, RT-PCR and Southern analysis) 
mutations in non-coding regions of the genes could be missed. One could think of point 
mutations or micro-deletions in regulatory regions up- or downstream of the gene. 
Examples of such long range effects have been described for several genes, including 
Sonic hedgehog (420;421), Pou3F4 (422), and Sox9 (423-425). When new techniques 
become available to reliably analyse for these types of changes, the already analysed genes 
should be reconsidered. Second, at the moment we only had access to 2 large HCFP 
pedigrees, that each link to a separate region of the human genome. Should the genes in 
patients of these pedigrees carry the type of obscure mutations mentioned above, not 
amenable to the techniques we used, a gene could be wrongfully excluded. Additional 
HCFP pedigrees will be most welcome, as they will minimise the chances of overlooking a 
causal mutation, and unjustified exclusion of a candidate gene. 
 
9.3 Expression analysis to identify new candidates for HCFP 
 
At this point in the project, the most promising candidates for HCFP from either locus had 
been analysed, and a search for new candidate genes was called for. However, both loci 
presented with their own difficulties. The locus on chromosome 3, reduced from 10 cM to 
4.9 cM by the additional linkage analysis performed, was still spanning an enormous 
region of more than 6 Million bases, in which over a 120 different transcripts were 
identified. As additional family members from the linkage family, or new families with 
HCFP where unavailable, a further reduction of the interval was not to be expected in the 
near future. The locus on chromosome 10 was considerably smaller, but the genetic 
information was sparse, and the region appeared to be very gene poor. Two genes were 
identified in the region (CTNNA3 and LRRTM3), both of which we analysed. Several small 
human mRNA’s, and predictions have been added recently, but no new full lenght genes 
have been reported. We therefore decided to focus our attention to the chromosome 3 locus 
for now, as this had the biggest potential for finding a gene for HCFP. 
 The positional candidate gene strategy followed up to this point was eliminating 
candidates one by one, and in this fashion we had now exluded 3 of the 127 genes (2%) in 
the region for involvement in HCFP. With this large amount of genes in the region left, we 
adopted a different strategy to select new candidates: Expression analysis of gene 
transcripts during mouse embryogenesis, focussing on expression in the hindbrain. We 
selected a total of 30 genes (24% of genes in region) that fulfilled our selection criteria. 
Two of these 30 genes immediately caught our eye: PLEXIN-D1 and PLEXIN-A1. Both 
genes are members of a relatively new family of axon guidance molecules, that function in 
the development of the central and peripheral nervous system (384;386). Plexins were 
known to influence axonal guidance in response to cues from the semaphorin protein 
family (406). Elsewhere, it had already been shown that neuropilin-1, a co-receptor for 
plexins, plays a role in both axon guidance and cell body positioning of facial 
branchiomotor neurons (156;169). The hindbrain pathology of the neuropilin-1 knock-out 
mouse showed a striking overlap with the observed neuropathological changes in the 
brainstems of patients from the chromosome 3 linkage family (Chapter 3). The mutation 
analysis of PLXND1 and PLXNA1 in HCFP patients did not identify causal mutations in 
these genes. 
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 With the two Plexin genes excluded, we were left with 28 potential new candidate 
genes (table1, Chapter 5). Five of these genes (MRPL3, ATP2C1, PIK3R4, RAB7, and 
SELB), selected in collaboration with the Stanford Genome technology center, were 
directly analysed for sequence variations in the linkage family. The yeast orthologs of 
these genes had been identified in a large scale yeast deletion screen. Coding sequences 
and intron-exon boundaries of these genes were analysed by direct sequencing, and no 
causative mutations, amenable to PCR amplification, could be identified. Therefore it was 
highly unlikely that these genes play a role in the etiology of HCFP, and we eliminated 
them from the list of candidates. By RT-PCR we were able to amplify 21 of the 23 
remaining genes from a mouse brain RNA pool. Chapter 5 summarizes the results of the 
RNA in situ hybridisation analysis of the remaining 21 genes. The analysis identified four 
genes (Klf15, Flj40083, Kiaa0779, and Podxl2), for which we considered the spatio-
temporal expression pattern compatible with a role in the etiology of HCFP. The human 
counterparts of these genes should, and will, therefore be analysed for sequence variations 
in HCFP. By using RNA in situ hybridisation based expression profiling we have thus 
eliminated 17 of 21 (80 %) of the candidates we selected, considerably more than had been 
eliminated by direct sequencing in the years prior. 
 
9.4 Future directions 
 
When nucleotide analysis of the four candidate genes is completed, and nucleotide 
variations are identified, the results will show whether the expression profiling was a 
usefull and powerfull new tool in the selection of candidate genes from a very large, and 
gene-rich disease linkage region. If succesfull, more disorders that have been linked to 
gene-rich or large intervals could be analysed in a similar fashion to expedite the 
elucidation of their genetic defects. An additional bonus of the expression analysis is the 
wealth of information obtained. This information may not be usefull for HCFP,  but it may 
point to genes involved in other disorders linked to the same region. At the same time, this 
bonus is also one of the downsides of this approach, as a lot of time and effort is spent on 
genes that are not involved in the pathology of the disorder of interest. There is another 
downside to the positional candidate gene approach, and the expression analysis described 
in this thesis: The selection of any candidate gene is based on a set of criteria that we think 
the HCFP causal gene should meet. This approach is always biased by the personal ideas 
of the researcher, and the current opinions in the research community. Therefore, it could 
be that the wrong candidate genes were selected for analysis, and the actual causal gene is 
regarded as non-interesting. The high throughput sequence analysis devices available today 
make it acceptable, time and finance wise, to analyse all genes in the region for changes 
that could cause HCFP,  without selection bias. Direct sequence analysis of all remaining 
genes in the HCFP linkage region may therefore be a future approach to identifying the 
gene that is defective in the disorder. 
 One of the main concerns during this project has been the lack of new, large 
pedigrees with HCFP. Having only one pedigree for each locus has, for one, limited the 
possibility of reducing the size of the linkage regions. The high prevelance of non-
penetrance and the tendency in the western world to have smaller nuclear families reduces 
the chances for identifying new large families. Genetic heterogeneity might hamper the 
analysis of small families, and phenocopies (e.g. due to birth trauma) interfere with 
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analysis of individual cases. Additionally, with the analysis techniques of today, we are not 
able to identify all nucleotide variations that could lead to a phenotype. Having just one 
pedigree to analyse creates the risk that the true cause of the disorder is missed, and genes 
are excluded wrongfully. As we have been reporting our genetic research over the past 
years, new HCFP pedigrees have been brought to our attention, of which several are large 
enough to perform classical linkage analysis. Some of these will be subjected to linkage 
analysis in the near future. Hopefully they will lead to new disease loci, or reduce the 
known regions. This will undoubtedly boost the chances of quickly identifying the genetic 
defects that cause HCFP. 
 As mentioned in the beginning of this chapter, next to HCFP, we were also interested 
in unraveling the genetic defects that underlie MBS. Most of the cases of this disorder are 
sporadic, and there is still debate whether MBS has a genetic cause at all. A very recent 
technique that we have now implemented in our lab may bring relief. Microarray-based 
comparative genomic hybridisation (ArrayCGH) is a procedure that can screen the entire 
human genome for the presence of (micro-) deletions or duplications (426). In literature, 
several cases of MBS or MBS-like disorders have been shown to harbour chromosomal 
abnormalities (232-235;427). These aberrations (reciprocal and “balanced” translocations 
and deletions) have all been identified by traditional methods of karyotyping and 
fluorescence in situ hybridisation (FISH). The resolution of these techniques is limited to a 
maximum of 5 Mb, micro-deletions or duplications (<5 Mb) will therefore be overlooked. 
With the arrayCGH technique a resolution of approximately 100 kb can be reached, 
increasing the chances of identifying new chromosomal aberrations considerably. 
Recently, assisted by arrayCGH, the causal gene for CHARGE syndrome was identified 
(428). As with MBS, it had long been debated whether CHARGE was caused by a genetic 
defect. In a project funded by the Prinses Beatrix Fonds, we have used CGH microarray 
analysis to identify micro-deletions or duplications in isolated MBS patients. This will be 
followed by zooming in on these areas, and the already known loci (chromosome 1, 3, 10, 
and 13), by even more sensitive techniques like multiplex ligation-dependent probe 
amplification (MLPA)(429). Results are still preliminary, but very encouraging, as a 
number of possible small aberrations have been observed. These results await further 
validation, and in the future may lead us to new genomic regions, and candidate genes 
involved in MBS.  
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Summary 
 
Hereditary congenital facial paresis (HCFP) and Möbius syndrome (MBS) are members of 
the family of congenital cranial dysinnervation disorders (CCDD’s). Patients of both 
disorders present with limited or absent motility of the facial musculature, and in addition, 
Mobius syndrome patients display defects in eye motility and often have dysmorphic 
features. The complete spectrum of clinical features present in MBS was analyzed in a 
large cohort of isolated patients, and showed large variation (Chapter2). Untill recently, 
HCFP and MBS where thought to be syndromes with a similar pathogenesis, as they show 
overlap in the clinical features. However, neuropathological examination, and comparison 
of HCFP and MBS patients led us to conclude that these syndromes should be treated as 
separate entities, with differing pathogenesis (Chapter 3). Autosomal dominant 
inheritance of HCFP and recurring cytogenetic aberrations in isolated MBS patients point 
towards a genetic cause for these disorders, and indeed, for some other CCDD’s a genetic 
cause has already been identified. CFEOM 1 and 2, syndromes characterized by eye and 
eyelid motility defects, have been shown to arise from mutations in respectively the 
KIF21A and PHOX2A genes. Similarly, DRRS and HGPPS, syndromes with horizontal 
ocular motility defects, were shown to be caused by mutations in the SALL4 and ROBO3 
genes, respectively.  
 To identify the genetic causes for HCFP and MBS, we have adopted several 
strategies. First, we have performed a classical positional candidate gene approach for 
HCFP, in which we analyzed several genes from the linkage regions on chromosome 3 and 
chromosome 10 for their involvement in HCFP. Prior to this analysis we had reduced the 
linkage interval for HCFP on chromosome 3q by the identification of a novel demarcating 
recombination in additional family members. The genes we excluded by nucleotide 
analysis were: PGT, GATA2, and EGR2 (Chapter 4). Second, we have analyzed the 
expression patterns during mouse embryogenesis of a large number of putative HCFP 
candidate genes from the locus on chromosome 3q21-q22. From the locus, covering over 6 
Million bases and containing an estimated 127 unique transcripts, a total of 30 genes were 
selected and analyzed. Two members of the plexin family of axon guidance proteins were 
located in the linkage region, and we considered them top candidates. Expression of plexin-
D1 was shown in vascular endothelial cells, and throughout the central nervous system 
(Chapter 6). Nucleotide analysis of PLEXIN-D1 in the HCFP pedigree failed to identify 
causal mutations in the gene, and therefore it was excluded as a candidate (Chapter 7). 
The hindbrain expression during mouse embryogenesis of a second plexin gene in the 
region, plexin-A1, was also analyzed. The pattern of Plexin-A1 expression in the hindbrain 
led us to believe that this gene could be involved in regulation of cellbody movement and 
guidance during the formation of the facial nerve nuclei (Chapter 8). Correspondingly, the 
knock-out mouse of one of the plexin-A1 co-receptors (neuropilin-1) produced a phenotype 
in embryonic mice, resembling the observed neuropathological changes we found in HCFP 
patients. Nucleotide variation analysis of the PLEXIN-A1 gene in the corresponding 
pedigree did not lead to the identification of a causal mutation, and it is therefore highly 
unlikely that this gene plays a role in the pathogenesis of HCFP. The expression analysis of 
the remaining 28 candidate genes is described in Chapter 5. 17 of these were considered 
less likely candidates on the basis of their expression patterns, 5 on the basis of sequence 
analysis in HCFP patients, and for 2 genes no transcript could be generated from brain 
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RNA. The four remaining genes: KLF15, FLJ40083, KIAA0779, and PODXL2, showed 
(preferential) expression in the hindbrain or cranial nerve ganglia during development, and 
were therefore considered the best candidates for sequence analysis. Hopefully, nucleotide 
analysis in the 4 new candidate genes will lead to the identification of causal changes in 
one of them, and thereby give us a first insight in the mechanisms that underly the 
pathogenesis of facial paresis disorders. 
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Samenvatting 
 
Eerfelijke aangeboren verlamming van de aangezichtszenuw (in het engels afgekort als 
HCFP) en Möbius syndroom (MBS) maken als ziektebeelden beide onderdeel uit van de 
aangeboren craniale dysinnervatie syndromen (CCDD’s). Patiënten van beide syndromen 
vertonen beperkingen in de beweegelijkheid van de spieren in het aangezicht, of hebben 
een totale verlamming van de aangezichtsspieren. Bij MBS patiënten komen naast de 
verlamming van de aangezichtsspieren ook verlamming van de spieren rond het oog, en 
vaak ook nog afwijkingen aan de ledematen en skeletspieren voor (bijv. ontbreken van 
(delen van) vingers, en klompvoetjes). Om alle aspecten van MBS aan het licht te brengen 
hebben we in een grote groep geïsoleerde MBS patiënten (de patiënten zijn geen familie 
van elkaar) het complete ziektebeeld van MBS in kaart gebracht, waarbij we een grote 
variabiliteit in het ziektebeeld konden vaststellen. Tot voor kort werd aangenomen dat 
HCFP en MBS werden veroorzaakt door een en het zelfde pathologiche defekt, omdat er 
klinische overlap bestaat tussen beide ziektebeelden. Echter, na neuropathologische 
analyse en vergelijking van post-mortem materiaal van HCFP en MBS patiënten, komen 
wij tot de conclusie dat deze ziektebeelden moeten worden gezien als afzonderlijke 
entiteiten, die door verschillende pathologische defekten worden veroorzaakt.  
 Voor enkele ziektebeelden die behoren tot de familie van CCDD’s zijn 
veranderingen in het DNA (het erfelijke materiaal) geïdentificeerd die het ziektebeeld 
veroorzaken. Zo is aangetoond dat CFEOM1 en 2, syndromen die worden gekarakteriseerd 
door  oog en ooglid bewegingsstoornissen, worden veroorzaakt door mutaties in 
respectievelijk het KIF21A en het PHOX2A gen. Op  vergelijkbare wijze is aangetoond dat 
DRRS en HGPPS, ziektebeelden gekarakteriseerd door horizontale 
oogbewegingsstoornissen, worden veroorzaakt door mutaties in respectievelijk het SALL4 
en het ROBO3 gen. De autosomaal dominante overerving van HCFP en het herhaaldelijk 
voorkomen van dezelfde cytogenetische afwijkingen in geïsoleerde MBS patiënten duiden 
erop dat genetische defekten ook aan de basis van het onstaan van deze syndromen liggen. 
Om de genetische defecten die een rol spelen bij het ontstaan van HCFP en MBS te vinden 
hebben we een aantal onderzoeksmethoden gebruikt. 
 Ten eerste is er een klassieke positionele kandidaatgen analyse uitgevoerd om het 
gen dat HCFP veroorzaakt te identificeren. Daarvoor zijn kandidaatgenen uit de aan dit 
syndroom gekoppelde gebieden (locus) op chromosoom 3 en 10 geanalyseerd op het 
voorkomen van genetische veranderingen, het HCFP locus op chromosoom 3 is door de 
analyse van nieuw patiënten DNA eerst gehalveerd. De genetische analyse leide ertoe dat 
het PGT, GATA2, en EGR2 gen konden worden uitgesloten van betrokkenheid bij HCFP, 
omdat zij geen genetische veranderingen bevatten die tot de ziekte kunnen leiden.   
 Daarna is, om een meer gefundeerde keuze van nieuwe kandidaatgenen te kunnen 
maken, besloten om eerst de expressie van genen uit het locus op chromosoom 3 te 
analyseren tijdens de ontwikkeling van het muizen embryo. De embryonale ontwikkeling 
en het DNA van de muis en de mens vertonen grote overeenkomsten, en vaak spelen 
vergelijkbare genen in muis en mens een rol bij dezelfde processen. Van het locus op 
chromosoom 3, die meer dan 6 miljoen nucleotiden (de bouwstenen van het erfelijk 
materiaal) en meer dan 120 genen bevat, zijn in totaal 30 genen geselecteerd om aan deze 
analyse te onderwerpen. Twee van de genen in het gebied behoren tot de Plexine familie. 
Voor een aantal genen van deze familie is aangetoond dat ze betrokken zijn bij de groei 
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van zenuwen, en dus kunnen ze worden gezien als goede kandidaten voor betrokkenheid 
bij HCFP. Voor Plexine-D1, één van de twee genen, hebben we aangetoond dat het tijdens 
de ontwikkeling van het muizen embryo tot expressie komt in groeiende bloedvaten en in 
het centrale zenuwstelsel. Onderzoek naar veranderingen in de nucleotiden volgorde en 
samenstelling van dit gen in patiënten leverde echter geen bewijs op voor een rol bij het 
ontstaan van HCFP. Het tweede lid van de Plexine familie in het locus, Plexine-A1, komt 
tot expressie in de hersenstam van het ontwikkelende muizenembryo. De hersenstam is de 
plaats waar de kernen van de aangezichtszenuw zich bevinden, en een plaats waar 
verstoring van de embryonale ontwikkeling zou kunnen leiden tot het HCFP ziektebeeld. 
Naast de expressie van Plexine-A1 in de hersenstam, is door andere wetenschappers 
aangetoond dat het uitschakelen van een gen dat samenwerkt met Plexine-A1 leidt tot een 
afwijking in muizen die veel overeenkomsten vertoont met het HCFP ziektebeeld in 
mensen. Analyse van het erfelijke materiaal van patiënten leverde wel veranderingen op, 
echter deze konden allemaal worden ontmaskerd als polymorfismen, veranderingen in het 
erfelijke materiaal die geen invloed hebben op het functioneren van het uiteindelijke eiwit, 
het functionele product van een gen. Op basis van hun expressie patroon tijdens muizen 
ontwikkeling zijn 17 van de overgebleven 28 genen geoormerkt als minder waarschijnlijke 
kandidaten voor HCFP, en 5 genen, waarvan de nucleotide sequentie in het DNA van 
patienten is geanalyseerd zijn zeer waarschijnlijk niet betrokken bij het ziektebeeld. Van 
twee genen kon helemaal geen expressie in de hersenen worden aangetoond, ook niet met 
zeer gevoelige technieken; het is dus zeer onwaarschijnlijk dat deze genen betrokken zijn 
bij erfeklijke aangeboren verlamming van de aangezichtszenuw. Van de resterende 4 genen 
(KLF15, FLJ40083, KIAA0779, and PODXL2) is aangetoond dat ze in het ontwikkelende 
zenuwstelsel tot expressie komen, en dus goede nieuwe kandidaatgenen zijn om te 
analyseren in DNA van patiënten. Hopelijk zal de analyse van deze genen leiden tot de 
identificatie van de genetsiche defekten die ten grondslag liggen aan het HCFP ziektebeeld, 
en zullen ze ons meer inzicht geven in de processen die tijdens de ontwikkeling van de 
aangezichtszenuw een belangrijke rol spelen. 
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Tja, het is zover, verhaalde het voorgaande uitsluitend over de wetenschappelijke inhoud 
van mijn werk, hier mijn persoonlijke dankwoorden voor de belangrijke wetenschappelijke 
en evenzo belangrijke sociale input van een hoop mensen. 
 
Om te beginnen mijn promotores: Prof. Dr. George Padberg, en Prof. Dr. Han Brunner en 
mijn co-promotor: Dr. Hans van Bokhoven. Prof. Padberg, George, toen ik in December 
1998 mijn zinnen had gezet op een avontuur in de wetenschappelijke wereld had ik geen 
idee dat het allemaal zo snel zou beginnen. Enthousiast als ik was gesolliciteerd op het 
PTEN project, niet gedacht te worden aangenomen, maar nog geen drie maanden later zat 
ik al in Nijmegen. Vanaf dat moment heeft uw niet aflatende enthousiasme mij enorm 
gesterkt in mijn vastberadenheid om alles tot een goed einde te brengen, en ik heb geen 
moment getwijfeld dat het wel goed zou komen. Geen brug te hoog en geen dal te diep, of 
er was wel een mogelijkheid om erdoor te komen. Ik geloof niet dat ik ooit Nee heb 
gehoord als ik om iets kwam vragen of dat er ooit een gestelde vraag onbeantwoord is 
gebleven, daarvoor mijn diepste respect en veel dank. Ook Prof. Brunner, Han, bedankt. 
Nagenoeg altijd was je bereikbaar en bereid om problemen direct uit de wereld te helpen, 
en een ware lopende bibliotheek wat betreft de genetische wetenschap. En natuurlijk Hans, 
als directe begeleider was jij het meest betrokken bij de dagelijkse uitvoering van mijn 
project. Altijd tot over je oren in de aanvragen en manuscripten, maar toch ook de tijd om 
mij van raad en daad te voorzien. Zoals je eens zei:” Dat verrekte Möbius syndroom moet 
toch ook op te lossen zijn!” Helaas is het mij in mijn tijd niet gelukt, maar ik weet zeker 
dat het in de toekomst onder jouw leiding gaat gebeuren, eerder vroeg dan laat. 
 
Dan zijn er uiteraard een heleboel mensen op het lab zonder wie het nooit was gelukt. In 
mijn eerste jaren bij de Neurologie heb ik veel steun gehad van de mensen van het terziele 
gegane “Neurolabje”: Judith, Sandra, nogeens Judith (nee ik val niet in herhaling, het 
waren er wel degelijk 2 en soms zelfs 3), Rudi, Marcel, Hannie, Lisenka, Riko, Barbara, 
Mascha, Angelien, Frans, en natuurlijk ook Henk, Anneke, Hans en Lilian. Op het lab 
altijd bereid om voor elkaar iets te doen, maar ook bij elkaar eten of helemaal Limburg in 
karren om het beste ijs van Nederland eens te proberen (en lekker was het zeker). Harriëtte, 
ook jij was zeker niet onbelangrijk voor mijn werk. Door jou klinische werk konden we de 
definitie voor Möbius syndroom herschrijven, en daarmee een heleboel onnodig werk 
voorkomen. 
 
Ook Karin bedankt, je kwam je stage bij mij lopen, en hebt een hele berg werk verzet 
waarvoor dank. Helaas heb ik je niet kunnen overtuigen om in het onderzoek te blijven, 
maar jij komt zeker wel op je pootjes terecht. 
 
De mensen van moleculaire genetica, bij wie ik de laatse jaren van mijn project heb 
doorgebracht. Ik ben door jullie met open armen ontvangen, en heb altijd met veel plezier 
met en bij jullie gewerkt. In het bijzonder de dysmorfologiegroep, met Ellen, Pascal, Ernie,  
Tjitske, Jacopo, en later ook Jeroen en Tuula, een gezellige groep waar een goeie grap op 
zijn tijd zeker welkom was. Maar natuurlijk ook de andere aanwezigen, jullie zijn met te 
veel om me allemaal nog te kunnen herinneren, dus vergeef mij bij voorbaat als ik jullie 
niet allemaal bij naam noem, maar niet genoemd betekent niet niet gewaardeerd. 
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Een groot deel van mijn proefschrift is opgebouwd uit resultaten die ik bij elkaar heb 
gepipetteerd in Utrecht, op het Rudolf Magnus Instituut bij de groep van Prof. Burbach. 
Ook daar heb ik me altijd thuis gevoeld. Anita, je hebt mij wegwijs gemaakt in de wondere 
wereld van de in situ, en de dunne plakjes muis. En Peter, jij was steevast de eerste die een 
gecorrigeerd manuscript terugstuurde, iets wat uitermate prettig werkte. Ook de contacten 
met de andere mensen van de vierde verdieping: Patrick, Simone, Marten, Marco, Lars, 
Cornelle, Annemarie (nou ja eigenlijk een verdieping hoger), Ineke, Raymond, Koen (X2), 
Leo, Henk, en M&M waren gezellig en vaak constructief. Het is me zo goed bevallen, dat 
ik nu de komende jaren bij jullie door breng als Post-Doc. 
 
Uiteraard moet een belangrijke groep mensen niet vergeten worden, de patienten die geheel 
vrijwillig hun medewerking hebben verleend aan alle aspecten van dit onderzoek. Of het 
nu ging om de gesprekken en vragenformulieren, of om de donatie van bloed voor DNA 
isolatie, alles was bespreekbaar. Ik vondt het uitermate fijn om bij de patiëntenvereniging 
een praatje te geven, en eindelijk eens direct contact te hebben, in plaats van altijd maar die 
buisjes. Mede dankzij jullie inzet is mijn project mogelijk geweest. 
 
Een speciaal bedankje ook voor mijn paranimfen, die mij bij mijn promotie zullen 
assisteren. Erwin, ik heb heel wat sportieve momenten met je gedeeld op de squash en 
tennisbaan (dat met dat wandelen natuurlijk ook), en ook in het avondcircuit was jij altijd 
van de partij. Met jou erbij zal het feest dus vast en zeker een knaller worden. Je komt in je 
leven niet vaak een persoon tegen die ten alle tijde overal iets positiefs in ziet; jij bent zo 
iemand. En Monica, mijn zus, vanaf de eerste dag dat ik AIO was heb je aangegeven 
paranimf te willen zijn op de grote dag. En dat ben je dus nu ook, want je weet als jij iets 
wil dan.... Vroeger boterde het niet zo, maar we zijn nu zelfs al twee maal met elkaar op 
vakantie geweest. Daar zal het door de drukke levens nu wel niet meer van komen, maar 
door een huis aan het water te kopen heb je natuurlijk een goed alternatief geboden (Eens 
een visser altijd een visser, toch). 
 
Daarmee zijn we aanbeland bij de mensen zonder wie ik nooit zou hebben bestaan, Pap en 
Mam. Als ik aan jullie denk komt er altijd een zin uit een liedje van Froger bij mij op: 
dankzij hen heb ik een fijne jeugd gehad. Eindeloos rondsjeesen met Carmato om alle 
concoursen te bezoeken, tennissen en vissen natuurlijk, want dat is er als jongen al met de 
paplepel ingegoten. Ook in mijn beslissing om het onderzoek in te gaan hebben jullie me 
altijd gesteund, ook al ging ik daarvoor wel even 200 km verderop wonen (en dat was toch 
wel effe wennen). Ontelbaar vele malen heb je mij van het station in Assen gehaald pap, en 
evenzovele tassen vol was heb je er door gedraaid mam (ook al had ik zelf een 
wasmachine). Ook als ik krap bij kas zat in de begin jaren was er altijd nog wel iets over 
voor mij. Ik hoop dat ik nu en in de toekomst hetzelfde voor jullie kan betekenen, en dat de 
band alleen maar hechter wordt. 
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Curriculum Vitae. 
 
Albertus van der Zwaag (Bert) werd op 12 Mei 1974 geboren te Stadskanaal. In 1991 en 
1993 behaalde hij respectievelijk het HAVO en het V.W.O. diploma aan het Ubbo Emmius 
Lyceum te Stadskanaal. In 1993 werd een begin gemaakt met de studie Scheikunde, aan de 
Rijks Universiteit van Groningen, waarbij in 1995 gekozen werd voor de specialisatie 
richting Biochemie. In het kader van deze specialisatie werd een onderzoeksstage verricht 
onder supervisie van Prof. dr. P.J. van Haastert, gericht op de ontrafeling van 
signaaltransductie cascades die een rol spelen bij chemotaxis in de amoebe Dictyostelium 
Discoideum. In 1998 werd de doctoraal opleiding met goed gevolg afgesloten. In Maart 
1999 begon hij, onder supervisie van Prof. dr. G.W.A.M. Padberg, aan een promotie 
project van de Katholieke Universiteit Nijmegen in het Universitair Medisch Centrum St. 
Radboud, bij de afdeling Neurologie. Het eerste jaar van deze promotie was gewijd aan het 
PTEN eiwit, en de rol die dit eiwit speelt bij het erfelijke Cowden syndrome. In Januari 
2000 werd een andere wending gegeven aan het promotie project, en de resterende tijd 
werd besteed aan onderzoek met betrekking tot erfelijke aangeboren nervus facialis 
verlamming en Möbius syndroom, waarvan de resultaten zijn gebundeld in dit proefschrift. 
Sinds Oktober 2004 is hij als onderzoeker werkzaam op het Rudolf Magnus Instituut voor 
Neurowetenschappen van het Universitair Medisch Centrum Utrecht in de groep van Prof. 
dr. J.P.H. Burbach.  
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Chapter 1  
 
 
Figure 1. a. A schematic diagram, showing a ventral view of the adult mouse brainstem, and the overal 
organization of the cranial nerves. b. Schematic diagram of the position of afferent fibres of cranial sensory 
ganglia (left) and the positions of the nuclei of the different motor nerves (right). Reprinted with permission from 
Nature Reviews Neuroscience, (17)). 
 
Figure 3. Gene expression patterns at the murine MHB, from E7.5 to E9.5. At E9.5 the final Isthmic expression 
pattern has matured, and the Isthmus functions as a regional organizer for midbrain and anterior hindbrain 
development.  Mes: mesenchephalon, Met: Metencheplalon, D: Diencephalon, T: Telenchepalon, r2-4 : 
rhombomeres 2-4. Reprinted with permission from Current Opinion in Cell Biology, from (31)). Color figure  
available in Appendix.. 
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Chapter 3 
 
 Figure 1. Sporadic patient with 
Möbius syndrome. (A) At the 
level of the upper medulla 
oblongata malformations in the 
long tracts and in other nuclei 
than the facial nuclei are 
present (LFB-HE-stain). The 
inferior olives (IO) on both 
sides meet each other in the 
midline, above the dysplastic 
pyramids with on the left side 
one large pyramid and on the 
right side several bundles. 
Several areas of destruction of 
tegmental nuclei with 
calcifications are present 
(arrows). (B) Detail in box with 
microcalcifications, gliosis and 
encrusted neurons (arrows; 
hematoxylin-eosinstain).  
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Figure 2. (A) Patient 1 with asymmetric, bilateral facial palsy (Luxol fast blue-hematoxylin-eosin stain; LFB-HE). 
(B, C) Detail in boxes with a marked decrease in number of neurons bilaterally in motor facial nucleus, with a 
few normal neurons preserved, the left side (B) being more affected than the right side (cresyl violet stain). Color 
figure  available in Appendix. 
 
 
 
 
 
Figure 3. (A) Patient 2 with asymmetric, bilateral facial palsy (LFB-HE). (B, C) Detail facial nucleus in boxes 
with a marked decrease in number of neurons in both facial motor nuclei, the right side (C) being more affected 
than the left side (cresyl violet stain). Color figure  available in Appendix. 
 
 
 
 
 
Figure 4. (A) Patient 3 with right-sided facial palsy (LFB-HE). (B, C) Detail in boxes: on the left side (B) normal 
facial neurons, on the right side (C) a decrease in number of neurons in the facial motor nucleus (cresyl violet 
stain). Color figure available in Appendix. 
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Chapter 5 
 
 
Figure 1. Ubiquitously expressed genes. A) In a 12.5-dpc mouse embryo, Znf9 is expressed the highest in liver, 
which shows the darkest staining. B) Expression of Mcm2 in a 12.5-dpc mouse embryo. Abbreviations (all 
figures):  fb: forebrain, he: heart, li: liver, med: medulla oblongata, mb: midbrain, ne: neuroepithelium, sc: 
spinal cord, 4th: fourth ventricle, hb: hindbrain, ie: inner ear, kd: kidney, lj: lower jaw, lv: lateral ventricle, nc: 
nasal cavity, noe: non-olfactory epithelium, ole: olfactory epithelium, ad: adrenal gland, mc: meckels cartilage, 
pa: palate, ul: upper lip, uj: upper jaw. 4th: fourth ventricle, co: cochlea, drg: dorsal root ganglion, fn: facial 
nerve nucleus, g7: facial nerve ganglion, he: heart,  mf: mesencephalic flexure, n7: facial nerve, neco: neocortex, 
ob: olfactory bulb, sp: soft palate, tri: trigeminal ganglion, hv: hepatic vein, in: intestine, pf: pontine flexure, to: 
tongue, tri: trigeminal ganglion. Magnification A-B: 12.5X. Color figure available in appendix. 
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Figure 2. Expression of transcripts in non-HCFP affected tissues. A) Expression of Chst13 in a 14.5-dpc mouse 
embryo (lower half). Arrows indicate clusters of cells in the kidney expressing Chst13. B) Chst13 expression in a 
14.5-dpc mouse embryo (head). Arrows indicate Chst13 expression in bones from the upper and lower jaw, and 
the eye socket. C) Expression of Abtb1 in a 16.5-dpc mouse embryo head. Expression is localised to the 
intermediate zone of the neocortex. D) Kiaa1257 expression in a 16.5-dpc mouse embryo. Arrows indicate 
expression in the non-olfactory epithelium of the nasal cavity, and in the nasal pharynx, up to the epiglossis. 
Magnification A,D: 12.5X, B,C : 25X. Color figure available in appendix. 
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Figure 3. Expression of Klf15 during mouse embryogenesis. A,B) Arrows indicate expression of Klf15 in the 
neuroepithelium of the mid- and hindbrain of a 12.5-dpc mouse embryo, respectively. C) Expression of Klf15 at 
14.5 dpc in the neuroepithelium of the entire central nervous system of a mouse embryo, arrows indicate 
markedly lower expression levels in the neuroepithelium of the forebrain. D) Expression of Klf15 at 14.5 dpc in 
liver and kidney. E) Arrows indicate Klf15 expression in the nasal cavity, in olfactory and non-olfactory 
epithelium of a 14.5-dpc mouse embryo. F) At 16.5 dpc, the levels of Klf15 expression in the mouse liver and 
kidney have significantly increased, as shown by a more intense blue staining. Magnification A-D: 12.5X, E,F: 
25X. Color figure available in appendix. 
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Figure 4. Expression of Flj40083 during mouse embryogenesis. A,B) Mouse brain expression of Flj40083 at 12.5 
dpc: the boxes show magnified sections of  the mid- and the hindbrain regions, respectively, with arrows 
indicating expression of Flj40083 in the neuroepithelium. C) Expression of Flj40083 in the neuroepithelium of the 
midbrain, and posterior into the hindbrain and spinal cord of a 16.5-dpc mouse embryo. D) Expression of 
Flj40083 in the nasal cavity, and nasopharynx at 16.5 dpc. Magnification A-C: 12.5X, D: 25X.Color figure 
available in appendix. 
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Figure 5. Expression of Kiaa0779 during mouse embryogenesis. A) Expression of Kiaa0779 in a 12.5-dpc mouse 
embryo. Arrows indicate higher level of expression on the ventral side of the spinal cord. 3B) Arrows indicate 
expression of Kiaa0779 in dorsal root ganglia of a 12.5-dpc mouse embryo. C) Mouse brain expression of 
Kiaa0779 at 14.5 dpc. The arrow indicates Kiaa0779 expression in the facial nerve ganglion, arrowheads 
indicate expression in the facial nerve. D, E) Expression of Kiaa0779 in the presumptive facial nucleus at 14.5 
and 16.5 dpc, respectively. Arrow(s) indicate cells at the correct spatial position to represent the facial nucleus, 
expressing a higher level of Kiaa0779 than the surrounding tissue. Arrowheads show expression of Kiaa0779 in 
the dorsal root ganglia. F) Expression of Kiaa0779 at 18.5 dpc in the olfactory epithelium indicated by arrows, 
and in the olfactory bulb.  Magnification A,C-E: 12.5X, B,F: 25X. Color figure available in appendix. 
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Figure 6. Expression of Podxl2 during mouse embryogenesis. A) Podxl2 expression in the neural tube of a 12.5-
dpc mouse embryo. B) Partial magnification of figure 6A, arrows indicate Podxl2 expression in anterior 
hindbrain neuroepithelial cells, arrowheads show neuroepithelium in posterior hindbrain/medulla void of Podxl2 
expression. C) Arrows indicate expression of Podxl2 in the facial nerve ganglion (fac), and the facial nerve (n7) 
of a 14.5-dpc mouse embryo. D) Expression of Podxl2 in smooth muscle cells of the 14.5-dpc mouse gutwall. E) 
Arrows indicate expression of Podxl2 in the olfactory epithelium of a 14.5-dpc mouse embryo. F) Light staining of 
the cortical region of the kidney, 16.5-dpc mouse embryo. G) Expression of Podxl2 in the brain of a 18.5-dpc 
mouse embryo. Expression is most prominent in the olfactory bulb, several layers of the neocortex and the 
cerebellum. Magnification A,D,E,G: 12.5X, C,F: 25X, B: 50X. Color figure available in appendix 
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Figure 4. RNA in situ hybridisation with an antisense PlxnD1 cRNA probe (A, B, D, F), and CD31 
immunohistochemical stained adjacent sections (C, E, G): (A) 12.5 dpc embryo, (B, C) magnification of nasal 
cavity and forebrain, arrows/arrowheads indicate overlapping expression pattern, (D, E) magnification of tail 
sections, co-localised expression patterns are indicated (arrows/arrow-heads), (F,G) 5th/trigeminal ganglion; 
additional staining is visible in PlxnD1 in situ sections, when compared to the CD31 signal, (H) 12.5 dpc embryo, 
control in situ hybridisation with a sense PlxnD1 probe. bv : bloodvessel, oe: olfactory epithelium, 5th : 
trigeminal (5th) ganglion. Scalebars in A and H : 1 mm, in B–G : 200   m. Color figure available in appendix 
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Fig. 5. RNA in situ hybridisation with an antisense PlxnD1 cRNA probe (A,B,D,F,G,I,K,L), and CD31 
immunohistochemically stained adjacent sections (C,E,H,J). A: A 14.5 days postcoitus (dpc) embryo (lower 
body). B,C: Magnification of kidney. Arrows and arrowheads indicate colocalisation of in situ hybridisation and 
CD31 immunohistochemical staining in glomeruli. D,E: PlxnD1 in situ hybridisation sections show additional 
staining in the neocortex, compared with CD31 immunohistochemical stained sections. F: A 16.5 dpc embryo. 
G,H: Magnification of the cerebellum. Arrows in G show broader zone of expression, compared with CD31 
stained adjacent section (H, arrowheads). I,J: PlxnD1 expression is nearly invisible in midbrain/hindbrain 
region, CD31 immunohistochemistry still shows presence of capillaries (arrows in J). K: PLXND1 expression in 
an 18.5 dpc embryo: mid-body section, compare lung and adipose expression with F. L: An 18.5 dpc embryo 
forebrain. ad, adipose tissue; ag, adrenal gland; ar, arachnoid; bv, blood vessel; cap, capillaries; co, cochlea; 
cp, cortical plate; drg, dorsal root ganglion; egl, external granular layer; fb, forebrain; glom, glomeruli; ht, 
heart; int, intestine; kd, kidney; lu, lung; li, liver; mb, midbrain; nc, neocortex; pc, plexus choroideus of the 4th 
ventricle; str, striatum; sn, subthalamic nucleus; to, tongue. Scalebars: 1 mm in F, I-L, 500   m in in A,D,E, and 
200   m in B,C,G,H.Color figure available in appendix 
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Figure 1. Plexin-A1 expression in the mouse embryonic nervous system. A) 10.5 dpc mouse embryo. Arrows 
indicate intense staining of plexin-A1 expression in the dorsal root ganglia, arrowheads indicate higher levels of 
expression in the ventral neural tube. B) 12.5 dpc mouse embryo. Arrows indicate cells with elevated level of 
plexin-A1 expression, medially positioned in the hindbrain/medulla region. C) 12.5 dpc mouse embryo. Arrows 
indicate ventrally positioned cells in the hindbrain with higher levels of plexin-A1 expression, near the floorplate. 
D) 14.5 dpc mouse embryo brain. Arrows indicate cells with intenser staining, suggestive of higher plexin-A1 
expression levels, abutting the position of the facial nucleus (7n). E) 16.5 dpc mouse embryo brain. Arrows 
indicate sustained elevated levels of plexin-A1 expression in some ventrally positioned cells in the hindbrain, the 
facial nerve nucleus is indicated by an oval. The inlay shows a magnification of the region of the facial nerve 
nucleus. 7n: facial nerve nucleus, v3: third ventricle, v4: fourth ventricle, cb: cerebellum, cpu: caudate putamen, 
drg: dorsal root ganglia, fb: forebrain, he: heart, hyp: hypothalamus, lv: lateral ventricle, mb: midbrain, med: 
medulla oblongata, nc: neocortex, sc: spinal cord, tha: thalamus. Scalebars: A-E : 50   m, E inlay: 25   m.Color 
figure available in appendix  
 
